US20240008514A1 - Cannabinoid Lipid Premixture - Google Patents
Cannabinoid Lipid Premixture Download PDFInfo
- Publication number
- US20240008514A1 US20240008514A1 US17/857,937 US202217857937A US2024008514A1 US 20240008514 A1 US20240008514 A1 US 20240008514A1 US 202217857937 A US202217857937 A US 202217857937A US 2024008514 A1 US2024008514 A1 US 2024008514A1
- Authority
- US
- United States
- Prior art keywords
- powder
- premixture
- triglycerides
- cannabinoids
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 214
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 212
- 150000002632 lipids Chemical class 0.000 title claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 249
- 239000000203 mixture Substances 0.000 claims abstract description 200
- 229940065144 cannabinoids Drugs 0.000 claims abstract description 171
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 128
- 239000003765 sweetening agent Substances 0.000 claims abstract description 128
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 127
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 160
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 158
- 229950011318 cannabidiol Drugs 0.000 claims description 158
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 158
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 152
- 239000003826 tablet Substances 0.000 claims description 111
- 239000007909 solid dosage form Substances 0.000 claims description 90
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 67
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 49
- 229930195725 Mannitol Natural products 0.000 claims description 49
- 235000010355 mannitol Nutrition 0.000 claims description 49
- 239000000594 mannitol Substances 0.000 claims description 49
- 239000004615 ingredient Substances 0.000 claims description 46
- 150000005846 sugar alcohols Chemical class 0.000 claims description 45
- 239000007937 lozenge Substances 0.000 claims description 41
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 40
- 229960004242 dronabinol Drugs 0.000 claims description 40
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 39
- 235000015218 chewing gum Nutrition 0.000 claims description 38
- -1 C12 triglycerides Chemical class 0.000 claims description 29
- 229940112822 chewing gum Drugs 0.000 claims description 28
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 24
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 24
- 239000000811 xylitol Substances 0.000 claims description 24
- 235000010447 xylitol Nutrition 0.000 claims description 24
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 24
- 229960002675 xylitol Drugs 0.000 claims description 24
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 claims description 21
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 claims description 21
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 21
- UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 claims description 16
- 239000000845 maltitol Substances 0.000 claims description 14
- 235000010449 maltitol Nutrition 0.000 claims description 14
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 14
- 229940035436 maltitol Drugs 0.000 claims description 14
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 11
- 239000000905 isomalt Substances 0.000 claims description 11
- 235000010439 isomalt Nutrition 0.000 claims description 11
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 10
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 10
- 239000000600 sorbitol Substances 0.000 claims description 10
- 229960002920 sorbitol Drugs 0.000 claims description 10
- 235000010356 sorbitol Nutrition 0.000 claims description 10
- 239000004386 Erythritol Substances 0.000 claims description 9
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 9
- 235000019414 erythritol Nutrition 0.000 claims description 9
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 9
- 229940009714 erythritol Drugs 0.000 claims description 9
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 claims description 8
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 8
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 claims description 8
- 229960002446 octanoic acid Drugs 0.000 claims description 8
- 239000000832 lactitol Substances 0.000 claims description 6
- 235000010448 lactitol Nutrition 0.000 claims description 6
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 6
- 229960003451 lactitol Drugs 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 229960001855 mannitol Drugs 0.000 claims description 3
- 239000002245 particle Substances 0.000 description 87
- 239000010410 layer Substances 0.000 description 65
- 238000000034 method Methods 0.000 description 57
- 238000012360 testing method Methods 0.000 description 46
- 240000004308 marijuana Species 0.000 description 33
- 239000002994 raw material Substances 0.000 description 32
- 239000000796 flavoring agent Substances 0.000 description 30
- 235000019634 flavors Nutrition 0.000 description 28
- 239000003995 emulsifying agent Substances 0.000 description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 24
- 239000004480 active ingredient Substances 0.000 description 23
- 238000009472 formulation Methods 0.000 description 23
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 22
- 239000008123 high-intensity sweetener Substances 0.000 description 22
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 22
- 210000003296 saliva Anatomy 0.000 description 19
- 238000007906 compression Methods 0.000 description 18
- 230000006835 compression Effects 0.000 description 18
- 229920001971 elastomer Polymers 0.000 description 18
- 239000000806 elastomer Substances 0.000 description 18
- 239000000835 fiber Substances 0.000 description 17
- 238000000576 coating method Methods 0.000 description 14
- 210000000214 mouth Anatomy 0.000 description 14
- 229940088679 drug related substance Drugs 0.000 description 13
- 238000002156 mixing Methods 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 239000008186 active pharmaceutical agent Substances 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 239000003623 enhancer Substances 0.000 description 12
- 150000004676 glycans Chemical class 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 229920001282 polysaccharide Polymers 0.000 description 12
- 239000005017 polysaccharide Substances 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 239000000377 silicon dioxide Substances 0.000 description 12
- 238000010998 test method Methods 0.000 description 12
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 229920003048 styrene butadiene rubber Polymers 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 239000002621 endocannabinoid Substances 0.000 description 10
- 229960001031 glucose Drugs 0.000 description 10
- 239000000314 lubricant Substances 0.000 description 10
- 239000011164 primary particle Substances 0.000 description 10
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 9
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 9
- 239000008121 dextrose Substances 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- AAXZFUQLLRMVOG-UHFFFAOYSA-N 2-methyl-2-(4-methylpent-3-enyl)-7-propylchromen-5-ol Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCC)=CC(O)=C21 AAXZFUQLLRMVOG-UHFFFAOYSA-N 0.000 description 8
- ZLYNXDIDWUWASO-UHFFFAOYSA-N 6,6,9-trimethyl-3-pentyl-8,10-dihydro-7h-benzo[c]chromene-1,9,10-triol Chemical compound CC1(C)OC2=CC(CCCCC)=CC(O)=C2C2=C1CCC(C)(O)C2O ZLYNXDIDWUWASO-UHFFFAOYSA-N 0.000 description 8
- 239000002174 Styrene-butadiene Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 235000009120 camo Nutrition 0.000 description 8
- 235000005607 chanvre indien Nutrition 0.000 description 8
- 239000003086 colorant Substances 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 229920002367 Polyisobutene Polymers 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 6
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 6
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 6
- 239000001692 EU approved anti-caking agent Substances 0.000 description 6
- 235000014755 Eruca sativa Nutrition 0.000 description 6
- 244000024675 Eruca sativa Species 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000002706 dry binder Substances 0.000 description 6
- 239000011487 hemp Substances 0.000 description 6
- 230000003232 mucoadhesive effect Effects 0.000 description 6
- 235000012239 silicon dioxide Nutrition 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 5
- 108050007331 Cannabinoid receptor Proteins 0.000 description 5
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 125000005456 glyceride group Chemical group 0.000 description 5
- 150000002314 glycerols Chemical class 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 230000008447 perception Effects 0.000 description 5
- 239000004014 plasticizer Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- YJYIDZLGVYOPGU-XNTDXEJSSA-N 2-[(2e)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-XNTDXEJSSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 4
- 235000008697 Cannabis sativa Nutrition 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 4
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 239000004067 bulking agent Substances 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- HRHJHXJQMNWQTF-UHFFFAOYSA-N cannabichromenic acid Chemical compound O1C(C)(CCC=C(C)C)C=CC2=C1C=C(CCCCC)C(C(O)=O)=C2O HRHJHXJQMNWQTF-UHFFFAOYSA-N 0.000 description 4
- YJYIDZLGVYOPGU-UHFFFAOYSA-N cannabigeroldivarin Natural products CCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000004927 clay Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 229960002737 fructose Drugs 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000000873 masking effect Effects 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 239000006191 orally-disintegrating tablet Substances 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000009475 tablet pressing Methods 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 150000003505 terpenes Chemical class 0.000 description 4
- 235000007586 terpenes Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 206010021750 Infantile Spasms Diseases 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- IGHTZQUIFGUJTG-QSMXQIJUSA-N O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 Chemical compound O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 IGHTZQUIFGUJTG-QSMXQIJUSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 201000006791 West syndrome Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229960003563 calcium carbonate Drugs 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
- 235000015111 chews Nutrition 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 230000001427 coherent effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 3
- 229940038472 dicalcium phosphate Drugs 0.000 description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000005489 elastic deformation Effects 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 3
- 239000001095 magnesium carbonate Substances 0.000 description 3
- 235000014380 magnesium carbonate Nutrition 0.000 description 3
- 229960001708 magnesium carbonate Drugs 0.000 description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 3
- 229920003052 natural elastomer Polymers 0.000 description 3
- 239000000025 natural resin Substances 0.000 description 3
- 229920001194 natural rubber Polymers 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000009495 sugar coating Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- RBEAVAMWZAJWOI-MTOHEIAKSA-N (5as,6s,9r,9ar)-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5ah-dibenzofuran-1,6-diol Chemical compound C1=2C(O)=CC(CCCCC)=CC=2O[C@H]2[C@@H]1[C@H](C(C)=C)CC[C@]2(C)O RBEAVAMWZAJWOI-MTOHEIAKSA-N 0.000 description 2
- IQSYWEWTWDEVNO-ZIAGYGMSSA-N (6ar,10ar)-1-hydroxy-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCC)C(C(O)=O)=C1O IQSYWEWTWDEVNO-ZIAGYGMSSA-N 0.000 description 2
- IXJXRDCCQRZSDV-GCKMJXCFSA-N (6ar,9r,10as)-6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydro-6h-1,9-epoxybenzo[c]chromene Chemical compound C1C[C@@H](C(O2)(C)C)[C@@H]3C[C@]1(C)OC1=C3C2=CC(CCCCC)=C1 IXJXRDCCQRZSDV-GCKMJXCFSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 2
- RCRCTBLIHCHWDZ-UHFFFAOYSA-N 2-Arachidonoyl Glycerol Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-UHFFFAOYSA-N 0.000 description 2
- 244000099147 Ananas comosus Species 0.000 description 2
- 235000007119 Ananas comosus Nutrition 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- KASVLYINZPAMNS-UHFFFAOYSA-N Cannabigerol monomethylether Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(OC)=C1 KASVLYINZPAMNS-UHFFFAOYSA-N 0.000 description 2
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 2
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 244000004281 Eucalyptus maculata Species 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 235000011430 Malus pumila Nutrition 0.000 description 2
- 235000015103 Malus silvestris Nutrition 0.000 description 2
- 235000014749 Mentha crispa Nutrition 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 244000078639 Mentha spicata Species 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000005062 Polybutadiene Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 240000007651 Rubus glaucus Species 0.000 description 2
- 235000011034 Rubus glaucus Nutrition 0.000 description 2
- 235000009122 Rubus idaeus Nutrition 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229920005549 butyl rubber Polymers 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 244000213578 camo Species 0.000 description 2
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 description 2
- 229960003453 cannabinol Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 210000003254 palate Anatomy 0.000 description 2
- 229950007031 palmidrol Drugs 0.000 description 2
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical class OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 239000000057 synthetic resin Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000002759 woven fabric Substances 0.000 description 2
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- YTKBWWKAVMSYHE-OALUTQOASA-N (3s)-3-[3-(3-hydroxy-4-methoxyphenyl)propylamino]-4-[[(2s)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid Chemical compound C([C@@H](C(=O)OC)NC(=O)[C@H](CC(O)=O)NCCCC=1C=C(O)C(OC)=CC=1)C1=CC=CC=C1 YTKBWWKAVMSYHE-OALUTQOASA-N 0.000 description 1
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical class O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- LOVYCUYJRWLTSU-UHFFFAOYSA-N 2-(3,4-dichlorophenoxy)-n,n-diethylethanamine Chemical compound CCN(CC)CCOC1=CC=C(Cl)C(Cl)=C1 LOVYCUYJRWLTSU-UHFFFAOYSA-N 0.000 description 1
- CUJUUWXZAQHCNC-DOFZRALJSA-N 2-arachidonyl glyceryl ether Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CO)CO CUJUUWXZAQHCNC-DOFZRALJSA-N 0.000 description 1
- WITKSCOBOCOGSC-UHFFFAOYSA-N 2-dodecanoyloxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCCCC WITKSCOBOCOGSC-UHFFFAOYSA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 239000004394 Advantame Substances 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004377 Alitame Chemical class 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 244000226021 Anacardium occidentale Species 0.000 description 1
- MVVPIAAVGAWJNQ-DOFZRALJSA-N Arachidonoyl dopamine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCC1=CC=C(O)C(O)=C1 MVVPIAAVGAWJNQ-DOFZRALJSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 1
- KJQMOGOKAYDMOR-UHFFFAOYSA-N CC(=C)C=C.CC(=C)C=C Chemical compound CC(=C)C=C.CC(=C)C=C KJQMOGOKAYDMOR-UHFFFAOYSA-N 0.000 description 1
- 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 229920001412 Chicle Polymers 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 240000009226 Corylus americana Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- 201000007547 Dravet syndrome Diseases 0.000 description 1
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
- 240000000896 Dyera costulata Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 239000004378 Glycyrrhizin Chemical class 0.000 description 1
- 239000000899 Gutta-Percha Substances 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000035899 Infantile spasms syndrome Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- VHOQXEIFYTTXJU-UHFFFAOYSA-N Isobutylene-isoprene copolymer Chemical compound CC(C)=C.CC(=C)C=C VHOQXEIFYTTXJU-UHFFFAOYSA-N 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 206010071082 Juvenile myoclonic epilepsy Diseases 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 240000002636 Manilkara bidentata Species 0.000 description 1
- 240000001794 Manilkara zapota Species 0.000 description 1
- 235000011339 Manilkara zapota Nutrition 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 108050004114 Monellin Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 108010093901 N-(N-(3-(3-hydroxy-4-methoxyphenyl) propyl)-alpha-aspartyl)-L-phenylalanine 1-methyl ester Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004384 Neotame Chemical class 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000000342 Palaquium gutta Species 0.000 description 1
- 241001495453 Parthenium argentatum Species 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241001409321 Siraitia grosvenorii Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- GANNOFFDYMSBSZ-UHFFFAOYSA-N [AlH3].[Mg] Chemical compound [AlH3].[Mg] GANNOFFDYMSBSZ-UHFFFAOYSA-N 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical class CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 235000019453 advantame Nutrition 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 235000019409 alitame Nutrition 0.000 description 1
- 108010009985 alitame Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000016302 balata Nutrition 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 239000010620 bay oil Substances 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 150000001579 beta-carotenes Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- HHSPVTKDOHQBKF-UHFFFAOYSA-J calcium;magnesium;dicarbonate Chemical compound [Mg+2].[Ca+2].[O-]C([O-])=O.[O-]C([O-])=O HHSPVTKDOHQBKF-UHFFFAOYSA-J 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003375 cannabimimetic effect Effects 0.000 description 1
- 239000003554 cannabinoid 1 receptor agonist Substances 0.000 description 1
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 description 1
- 229940121376 cannabinoid receptor agonist Drugs 0.000 description 1
- 239000003537 cannabinoid receptor agonist Substances 0.000 description 1
- SVTKBAIRFMXQQF-UHFFFAOYSA-N cannabivarin Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCC)C=C3OC(C)(C)C2=C1 SVTKBAIRFMXQQF-UHFFFAOYSA-N 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000020226 cashew nut Nutrition 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 229940119201 cedar leaf oil Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- PWEOPMBMTXREGV-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC(O)=O.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O PWEOPMBMTXREGV-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 125000000373 fatty alcohol group Chemical group 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960003082 galactose Drugs 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Chemical class C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Chemical class CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 229920000588 gutta-percha Polymers 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000034287 idiopathic generalized susceptibility to 7 epilepsy Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000005184 irreversible process Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229920003008 liquid latex Polymers 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical class CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Chemical class 0.000 description 1
- 230000003227 neuromodulating effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 235000019895 oat fiber Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 150000003097 polyterpenes Chemical class 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 1
- 229960003015 rimonabant Drugs 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical class C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000011115 styrene butadiene Substances 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000003784 tall oil Substances 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000001789 thuja occidentalis l. leaf oil Substances 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- LGUDZTGJDWUGDV-HXUWFJFHSA-N win 55212 Chemical compound C([C@H]1CC(=O)C=2C=CC=C3C(C(=O)C=4C5=CC=CC=C5C=CC=4)=C(N1C3=2)C)N1CCOCC1 LGUDZTGJDWUGDV-HXUWFJFHSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
- A23L27/34—Sugar alcohols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/37—Sugar alcohols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
Definitions
- the invention relates to the field of cannabinoids.
- the invention relates to a powder premixture for oral administration of cannabinoids.
- Cannabinoids are a group of chemicals found in Cannabis sativa, Cannabis indica, Cannabis ruderalis , Marijuana plant and related plant species. They are known to activate cannabinoid receptors (CB1 and CB2). These chemicals are also produced endogenously in humans and other animals. Cannabinoids are cyclic molecules exhibiting particular properties such as being lipophilic, have the ability to easily cross the blood-brain barrier, and having low toxicity.
- Cannabis sativa contains more than 400 chemicals and approximately 120 cannabinoids, the active constituents of cannabis , including tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), tetrahydrocannabivarin (THCV) and cannabigerol (CBG).
- THC tetrahydrocannabinol
- CBD cannabidiol
- CBN cannabinol
- THCV tetrahydrocannabivarin
- CBG cannabigerol
- THC tetrahydrocannabinol
- THC tetrahydrocannabinol
- THC is also effective in the treatment of allergies, inflammation, infection, depression, migraine, bipolar disorders, anxiety disorder, drug dependency and drug withdrawal syndromes.
- Cannabinoids are highly lipophilic, meaning that they are soluble in lipids and some organic solvents while being substantially insoluble or only sparsely soluble in water. Cannabinoids are soluble in highly non-polar solvents. Some of these solvents are pharmaceutically unacceptable, and the pharmaceutically acceptable solvents need to be used in high concentrations to produce solutions.
- cannabinoids such as CBD or THC
- cannabinoids such as CBD or THC
- a formulation is provided that may also help in obtaining improved sensorics properties of oral cannabinoid delivery.
- important sensorics properties include friability, texture, flavor perception, sweetness perception and off-notes associated with cannabinoids. These properties are both relevant from a convenience perspective in solid dosage forms, but certainly also in order to support an appropriate delivery of cannabinoids from the tablets and avoid adverse side effects of cannabinoids.
- cannabinoids tend to be associated with off-notes during administration due to the specific physiochemical properties of the compounds.
- the taste masking challenge is more profound when a higher release of cannabinoids are delivered. If off-notes are the predominant sensation during administration, convenience may be affected and even more critically, the delivery of cannabinoids may also be affected.
- a powder premixture for oral administration of cannabinoids comprising a cannabinoid powder composition comprising one or more isolated cannabinoids in an amount of at least 2% by weight of the powder premixture; a lipid composition comprising one or more triglycerides in an amount of at least 1.0% by weight of the powder premixture; and a sweetener powder composition comprising one or more sweeteners, wherein the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:4.
- oral administration forms where this powder is incorporated, such as partly or completely.
- One of the advantages of the present invention is that accurate dosing of cannabinoids and reliability of formulating cannabinoids, such as CBD or THC, in oral formulations may be provided. For instance, homogeneous products would be beneficial but to some degree have been counteracted by the nature of the cannabinoids being highly lipophilic and thereby potentially interacting with remaining components of the oral formulations.
- cannabinoids being highly lipophilic may not be properly formulated with other components in a powder or solid dosage form without compromising the other components and the interacting in the system.
- the formulation according to the invention may also help in obtaining improved sensorics properties of oral cannabinoid delivery.
- important sensorics properties include friability, texture, flavor perception, sweetness perception and off-notes associated with cannabinoids. These properties are both relevant from a convenience perspective in solid dosage forms, but certainly also in order to support an appropriate delivery of cannabinoids from the solid dosage forms and avoid adverse side effects of cannabinoids.
- the invention may help addressing off-notes during administration.
- the taste masking challenge is more profound when a higher release of cannabinoids are delivered by such solid dosage forms. If off-notes are the predominant sensation during administration, convenience may be affected and even more critically, the delivery of cannabinoids may also be affected.
- the method used for content uniformity of samples is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units.
- the acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance.
- An appropriate analytical method is selected for content uniformity, e.g. employing standard HPLC techniques.
- a series of at least 5 samples each having the same fixed weight in the range of 0.25-2 g and taken from the powder mixture to be analyzed varies with a relative standard deviation (RSD) below 10% with respect to the content of the one or more cannabinoids.
- RSS relative standard deviation
- a series of at least 5 samples each having the same fixed weight in the range of 0.25-2 g and taken from the powder mixture to be analyzed varies with a relative standard deviation (RSD) below 5% with respect to the content of the one or more cannabinoids.
- RSS relative standard deviation
- a series of at least 5 samples each having the same fixed weight in the range of 0.25-2 g and taken from the powder mixture to be analyzed varies with a relative standard deviation (RSD) below 2% with respect to the content of the one or more cannabinoids.
- RSS relative standard deviation
- the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:5. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:7.
- the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:10. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:7. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:5.
- the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:40 to 1:10. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:40 to 1:12. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:40 to 1:15. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:40 to 1:20.
- the one or more triglycerides is of vegetable origin. In some embodiments of the invention, the one or more triglycerides is free of triglycerides of animal origin.
- the one or more triglycerides is selected from one or more C4 to C14 triglycerides. In some embodiments of the invention, the one or more triglycerides is selected from one or more C4 to C12 triglycerides In some embodiments of the invention, the one or more triglycerides is selected from one or more C6 to C14 triglycerides. In some embodiments of the invention, the one or more triglycerides is selected from one or more C6 to C12 triglycerides.
- the one or more triglycerides is selected from one or more C6 to C10 triglycerides In some embodiments of the invention, the one or more triglycerides is selected from one or more C8 to C12 triglycerides. In some embodiments of the invention, the one or more triglycerides is selected from one or more C8 to C10 triglycerides.
- the one or more triglycerides comprises a partially hydrogenated vegetable oil. In some embodiments of the invention, the one or more triglycerides comprises a fully hydrogenated vegetable oil (HVO).
- HVO fully hydrogenated vegetable oil
- the one or more triglycerides is selected from triglycerides being liquid at or above 0 Degree Celsius.
- the one or more triglycerides is a blend of a number of triglycerides.
- the one or more triglycerides is heated to a temperature above ambient temperature before being added in the premixture.
- the one or more triglycerides is heated to a temperature of 50 to 80 Degree Celsius before being added in the premixture. In some embodiments of the invention, the one or more triglycerides is heated to a temperature of 50 to 70 Degree Celsius before being added in the premixture. In some embodiments of the invention, the one or more triglycerides is heated to a temperature of 50 to 60 Degree Celsius before being added in the premixture. In some embodiments of the invention, the one or more triglycerides is heated to a temperature of 60 to 70 Degree Celsius before being added in the premixture.
- the one or more triglycerides is heated to a temperature of 40 to 80 Degree Celsius before being added in the premixture. In some embodiments of the invention, the one or more triglycerides is heated to a temperature of 40 to 70 Degree Celsius before being added in the premixture.
- the one or more triglycerides is selected from triglycerides being liquid at or above 20 Degree Celsius. In some embodiments of the invention, the one or more triglycerides is selected from triglycerides being liquid at or above 25 Degree Celsius. In some embodiments of the invention, the one or more triglycerides is selected from triglycerides being liquid at or above 30 Degree Celsius. In some embodiments of the invention, the one or more triglycerides is selected from triglycerides being liquid at or above 40 Degree Celsius.
- the one or more triglycerides is selected from triglycerides with a melting temperature of 25 to 50 Degree Celsius. In some embodiments of the invention, the one or more triglycerides is selected from triglycerides with a melting temperature of 25 to 40 Degree Celsius. In some embodiments of the invention, the one or more triglycerides is selected from triglycerides with a melting temperature of 30 to 40 Degree Celsius. In some embodiments of the invention, the one or more triglycerides is selected from triglycerides with a melting temperature of 30 to 50 Degree Celsius.
- the one or more triglycerides comprises caprylic acid in an amount of 50 to 80% by weight. In some embodiments of the invention, the one or more triglycerides comprises caprylic acid in an amount of 50 to 70% by weight. In some embodiments of the invention, the one or more triglycerides comprises caprylic acid in an amount of 50 to 90% by weight. In some embodiments of the invention, the one or more triglycerides comprises caprylic acid in an amount of 60 to 90% by weight. In some embodiments of the invention, the one or more triglycerides comprises caprylic acid in an amount of 65 to 80% by weight.
- the one or more triglycerides comprises capric acid in an amount of 20 to 45% by weight. In some embodiments of the invention, the one or more triglycerides comprises capric acid in an amount of 20 to 50% by weight. In some embodiments of the invention, the one or more triglycerides comprises capric acid in an amount of 20 to 40% by weight. In some embodiments of the invention, the one or more triglycerides comprises capric acid in an amount of 20 to 35% by weight. In some embodiments of the invention, the one or more triglycerides comprises capric acid in an amount of 25 to 50% by weight.
- the one or more triglycerides comprises capric acid in an amount of 25 to 40% by weight. In some embodiments of the invention, the one or more triglycerides comprises capric acid in an amount of 30 to 50% by weight. In some embodiments of the invention, the one or more triglycerides comprises capric acid in an amount of 30 to 45% by weight. In some embodiments of the invention, the one or more triglycerides comprises capric acid in an amount of 20 to 30% by weight.
- the one or more triglycerides comprises caprylic acid in an amount of 65 to 80% by weight and capric acid in an amount of 20 to 35% by weight.
- the one or more triglycerides comprises caprylic acid in an amount of 50 to 65% by weight and capric acid in an amount of 30 to 45% by weight.
- the one or more triglycerides comprises coconut oil. In some embodiments of the invention, the one or more triglycerides is consisting essentially of coconut oil. In some embodiments of the invention, the one or more triglycerides is coconut oil.
- the one or more triglycerides is present in an amount of at least 1.5% by weight of the powder premixture.
- the one or more triglycerides is present in an amount of at least 2.0% by weight of the powder premixture.
- the one or more triglycerides is present in an amount of at least 2.5% by weight of the powder premixture.
- the one or more triglycerides is present in an amount of at least 3.0% by weight of the powder premixture.
- the one or more triglycerides is present in an amount of at least 4.0% by weight of the powder premixture.
- the one or more triglycerides is present in an amount of at least 5.0% by weight of the powder premixture. In some embodiments of the invention, the one or more triglycerides is present in an amount of at least 6.0% by weight of the powder premixture. In some embodiments of the invention, the one or more triglycerides is present in an amount of at least 7.0% by weight of the powder premixture. In some embodiments of the invention, the one or more triglycerides is present in an amount of at least 8.0% by weight of the powder premixture. In some embodiments of the invention, the one or more triglycerides is present in an amount of at least 9.0% by weight of the powder premixture. In some embodiments of the invention, the one or more triglycerides is present in an amount of at least 10.0% by weight of the powder premixture.
- the one or more sweeteners is present in an amount of at least 50% by weight of the powder premixture.
- the one or more sweeteners is present in an amount of at least 60% by weight of the powder premixture.
- the one or more sweeteners is present in an amount of at least 70% by weight of the powder premixture.
- the one or more sweeteners is present in an amount of at least 75% by weight of the powder premixture.
- the one or more sweeteners is present in an amount of at least 80% by weight of the powder premixture. In some embodiments of the invention, the one or more sweeteners is present in an amount of at least 90% by weight of the powder premixture. In some embodiments of the invention, the one or more sweeteners is present in an amount of at least 95% by weight of the powder premixture.
- the one or more sweeteners is selected from the group consisting of saccharide-containing components, such as sucrose, dextrose, maltose, saccharose, lactose, sorbose, dextrin, trehalose, D-tagatose, dried invert sugar, fructose, levulose, galactose, corn syrup solids, glucose syrup, and the like, alone or in combination.
- saccharide-containing components such as sucrose, dextrose, maltose, saccharose, lactose, sorbose, dextrin, trehalose, D-tagatose, dried invert sugar, fructose, levulose, galactose, corn syrup solids, glucose syrup, and the like, alone or in combination.
- sugar sweeteners may also be included as a humectant.
- the one or more sweeteners comprises dextrose. In some embodiments of the invention, the one or more sweeteners is dextrose.
- the one or more sweeteners comprises dextrin. In some embodiments of the invention, the one or more sweeteners is dextrin.
- the one or more sweeteners comprises sucrose. In some embodiments of the invention, the one or more sweeteners is sucrose.
- the one or more sweeteners comprises fructose. In some embodiments of the invention, the one or more sweeteners is fructose.
- the one or more sweeteners comprises one or more sugar alcohols.
- the one or more sugar alcohols is selected from the group consisting of sorbitol, xylitol, maltitol, isomalt, mannitol, erythritol, lactitol, and combinations thereof.
- the one or more sugar alcohols is selected from the group consisting of xylitol, erythritol, maltitol, mannitol, and combinations thereof.
- the one or more sugar alcohols comprises xylitol. In some embodiments of the invention, the one or more sugar alcohols is xylitol.
- the one or more sugar alcohols comprises erythritol. In some embodiments of the invention, the one or more sugar alcohols is erythritol.
- the one or more sugar alcohols comprises mannitol. In some embodiments of the invention, the one or more sugar alcohols is mannitol.
- the one or more sugar alcohols comprises maltitol. In some embodiments of the invention, the one or more sugar alcohols is maltitol.
- the one or more sugar alcohols comprises granulated sugar alcohol particles.
- the one or more sugar alcohols comprises non-directly (non-DC) sugar alcohol particles.
- the one or more sweeteners comprises one or more saccharides.
- the one or more sweeteners comprises at least two types of sweetener particles.
- the one or more sweeteners comprises sweetener particles having a particle size with more than 50% of the particles being below 250 microns. In some embodiments of the invention, the one or more sweeteners comprises sweetener particles having a particle size with more than 60% of the particles being below 250 microns. In some embodiments of the invention, the one or more sweeteners comprises sweetener particles having a particle size with more than 70% of the particles being below 250 microns. In some embodiments of the invention, the one or more sweeteners comprises sweetener particles having a particle size with more than 80% of the particles being below 250 microns.
- the one or more sweeteners comprises sweetener particles having a particle size with more than 20% of the particles being above 500 microns. In some embodiments of the invention, the one or more sweeteners comprises sweetener particles having a particle size with more than 30% of the particles being above 500 microns. In some embodiments of the invention, the one or more sweeteners comprises sweetener particles having a particle size with more than 50% of the particles being above 500 microns.
- the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:40 to 1:1. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:30 to 1:1. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:20 to 1:1. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:15 to 1:1.
- the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:10 to 1:1. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:10 to 1:2. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:8 to 1:2.
- the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:7 to 1:2. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:6 to 1:2. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:5 to 1:2.
- the one or more isolated cannabinoids is present in an amount of at least 5% by weight of the powder premixture. In some embodiments of the invention, the one or more isolated cannabinoids is present in an amount of at least 7% by weight of the powder premixture.
- the one or more isolated cannabinoids is present in an amount of at least 10% by weight of the powder premixture. In some embodiments of the invention, the one or more isolated cannabinoids is present in an amount of at least 15% by weight of the powder premixture.
- the one or more isolated cannabinoids is present in an amount of at least 20% by weight of the powder premixture. In some embodiments of the invention, the one or more isolated cannabinoids is present in an amount of at least 25% by weight of the powder premixture.
- the one or more isolated cannabinoids is present in an amount of at least 30% by weight of the powder premixture. In some embodiments of the invention, the one or more isolated cannabinoids is present in an amount of at least 35% by weight of the powder premixture. In some embodiments of the invention, the one or more isolated cannabinoids is present in an amount of at least 40% by weight of the powder premixture.
- the one or more isolated cannabinoids is present in the powder mixture in an amount of 0.1 to 400 mg. In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder mixture in an amount of 0.1 to 300 mg. In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder mixture in an amount of to 250 mg.
- the one or more isolated cannabinoids is present in the powder premixture in an amount of 1 to 200 mg. In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder premixture in an amount of 1 to 150 mg. In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder premixture in an amount of 1 to 100 mg.
- the one or more isolated cannabinoids is present in the powder premixture in an amount of 5 to 200 mg. In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder premixture in an amount of 5 to 100 mg.
- the one or more isolated cannabinoids is present in the powder premixture in an amount of 3 to 200 mg. In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder premixture in an amount of 3 to 100 mg.
- the one or more isolated cannabinoids is present in the powder premixture in an amount of 2 to 200 mg. In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder premixture in an amount of 2 to 100 mg.
- the one or more isolated cannabinoids is present in the powder premixture in an amount of 10 to 100 mg.
- the one or more isolated cannabinoids is selected from the group consisting of cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), and combinations thereof.
- the one or more isolated cannabinoids is selected from the group consisting of tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), and combinations thereof.
- THC tetrahydrocannabinol
- THCA tetrahydrocannabinolic acid
- THCV tetrahydrocannabivarin
- the one or more isolated cannabinoids comprise cannabigerol (CBG).
- the one or more cannabinoids comprise cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), salts and derivatives thereof.
- the one or more cannabinoids comprise tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), salts and derivatives thereof.
- THC tetrahydrocannabinol
- THCA tetrahydrocannabinolic acid
- THCV tetrahydrocannabivarin
- the one or more cannabinoids comprise cannabigerol (CBG), salts and derivatives thereof.
- the cannabinoid is selected from the group consisting of cannabidiol (CBD), cannabidiolic acid (CBDA), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), cannabielsoin (CBE), iso-tetrahydrocannabinol (iso-THC), cannabicyclol (CBL), cannabicitran (CBT), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), salts thereof, derivatives thereof and mixtures of cannabinoids.
- CBD cannabidiol
- CBDA canna
- the one or more cannabinoids comprise cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), salts and derivatives thereof.
- CBD cannabidiol
- CBDA cannabidiolic acid
- CBDV cannabidivarin
- salts and derivatives thereof comprising CBD, salts and derivatives thereof, including analogues and homologues.
- said one or more cannabinoids comprises CBD.
- said one or more cannabinoids is CBD.
- the one or more cannabinoids comprise tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), salts and derivatives thereof.
- said one or more cannabinoids comprises tetrahydrocannabinol (THC).
- THC is intended to mean (—)-trans- ⁇ 9 -tetrahydrocannabinol, i.e. (6aR,10aR)-delta-9-tetrahydrocannabinol).
- said one or more cannabinoids is THC.
- the one or more cannabinoids comprise at least two cannabinoids.
- said one or more cannabinoids comprises a combination of several cannabinoids, such as THC and CBD.
- said one or more cannabinoids is a combination of THC and CBD.
- the one or more isolated cannabinoids is present in a purity of at least 90% (w/w).
- the one or more isolated cannabinoids is present in a purity of at least 95% (w/w).
- the one or more isolated cannabinoids is present in a purity of at least 98% (w/w).
- the one or more isolated cannabinoids does not include cannabinoid distillates.
- the one or more isolated cannabinoids does not include cannabinoid extracts.
- the one or more isolated cannabinoids does not include one or more isolated cannabinoids in a purity of less than 90% (w/w).
- the one or more isolated cannabinoids is dissolved in the one or more triglycerides before admixture with the sweetener powder composition.
- the one or more isolated cannabinoids is added in the sweetener powder composition before admixture with the one or more triglycerides.
- the one or more triglycerides is added in the sweetener powder composition before admixture with the one or more isolated cannabinoids.
- premixture when it is mentioned that further ingredients are “added in the premixture” or similar wordings, the intended meaning is that these ingredients are added to the total mixture. Hence, the premixture could also be added to the further ingredients depending on the procedure and amounts involved. Usually, a “premix” or “premixture” are expressions used interchangeably. Further ingredients combined with the premixture is usually denoted a “powder blend” or similar wordings. The “powder blend” may comprise further ingredients.
- further ingredients are added in the premixture or in the powder blend selected from the group consisting of flavors, dry-binders, tableting aids, anti-caking agents, surfactants, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, further active ingredients, water-soluble indigestible polysaccharides, water-insoluble polysaccharides, and any combination thereof.
- one or more flavoring agents is added in the premixture or powder blend.
- a high intensity sweetener is added in the premixture or powder blend.
- the premixture is a ready-to-use premixture.
- the premixture is to be applied in an amount of 10-99.9% by weight in combination with further ingredients.
- a solid dosage form for oral administration of cannabinoids comprising a premixture according to the invention.
- the premixture is present in an amount of 10-100% by weight of the solid dosage form. In some embodiments of the invention, the premixture is present in an amount of about 100% by weight of the solid dosage form. In some embodiments of the invention, the premixture is present in an amount of substantially 100% by weight of the solid dosage form. In some embodiments of the invention, the premixture is present in an amount of 10-90% by weight of the solid dosage form.
- the premixture is present in an amount of 15-75% by weight of the solid dosage form. In some embodiments of the invention, the premixture is present in an amount of 20-70% by weight of the solid dosage form. In some embodiments of the invention, the premixture is present in an amount of 25-60% by weight of the solid dosage form. In some embodiments of the invention, the premixture is present in an amount of 30-50% by weight of the solid dosage form.
- a series of at least 10 solid dosage forms comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 5%.
- the method used for content uniformity of samples is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units.
- the acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance.
- An appropriate analytical method is selected for content uniformity.
- a series of at least 10 solid dosage forms comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 2%.
- a tablet for oral administration of cannabinoids comprising a premixture according to the invention.
- the premixture is present in an amount of 10-100% by weight of the tablet.
- the premixture is present in an amount of 15-75% by weight of the tablet.
- the tablet comprises one or more sugar alcohols in addition to the one or more sweeteners in the premixture selected from the group consisting of sorbitol, erythritol, maltitol, xylitol, isomalt, lactitol, mannitol, and combinations thereof.
- the tablet comprises one or more sweeteners in addition to the one or more sweeteners in the premixture in an amount of 20 to 80% by weight of the tablet.
- a series of at least 10 tablets comprise the one or more active pharmaceutical ingredients in an amount varying with a relative standard deviation (RSD) below 5%.
- RSS relative standard deviation
- the method used for content uniformity of tablets is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units.
- the acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance.
- An appropriate analytical method is selected for content uniformity.
- a series of at least 10 tablets comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 2%.
- the tablet comprises directly compressible (DC) sugar alcohol particles and non-directly compressible (non-DC) sugar alcohol particles.
- the tablet has a weight ratio between said non-DC sugar alcohol particles and said DC sugar alcohol particles, which is between 0.2 and 1.2.
- the tablet has a weight ratio between said non-DC sugar alcohol particles and said DC sugar alcohol particles, which is between 0.3 and 0.7.
- the tablet comprises one or more insoluble components selected from the group consisting of silica, microcrystalline cellulose, cellulose, silicified microcrystalline cellulose, clay, talc, starch, pregelatinized starch, calcium carbonate, dicalcium phosphate, magnesium carbonate, magnesium-alumino-metasilicates, hyper porous silica, and mixtures thereof.
- the tablet comprises one or more binders in an amount of 0.1 to 6% by weight of the tablet.
- the tablet comprises at least two modules, and wherein the premixture is comprised in at least one module of the tablet.
- the tablet comprises further ingredients selected from the group consisting of flavors, dry-binders, tableting aids, anti-caking agents, surfactants, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, further active ingredients, water-soluble indigestible polysaccharides, water-insoluble polysaccharides, and any combination thereof.
- a chewing gum for oral administration of cannabinoids comprising a premixture according to the invention.
- the premixture is present in an amount of 15-75% by weight of the chewing gum.
- a series of at least 10 chewing gums comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 5%.
- the method used for content uniformity of cannabinoids in chewing gums is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units.
- the acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance.
- An appropriate analytical method is selected for content uniformity.
- a series of at least 10 chewing gums comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 2%.
- the chewing gum comprises gum base in an amount of 20-40% by weight of the chewing gum, and wherein the chewing gum is designed to be masticated into a coherent residual containing water-insoluble components.
- the chewing gum comprises gum base, and wherein the gum base comprises an elastomer selected from the group consisting of styrene-butadiene rubber (SBR), butyl rubber, polyisobutylene (PIB), and combinations thereof.
- SBR styrene-butadiene rubber
- PIB polyisobutylene
- the chewing gum comprises gum base, and wherein the gum base comprises at least 5% by weight of elastomer.
- the chewing gum comprises gum base, and wherein the gum base comprises gum base resins selected from natural resins and/or synthetic resins.
- the chewing gum comprises gum base, and wherein the gum base comprises at least 5% by weight of gum base resins.
- the chewing gum comprises gum base, and wherein the gum base comprises gum base particles having an average particle size of between 400 ⁇ m and 1400 ⁇ m.
- the chewing gum comprises one or more sugar alcohols in addition to the one or more sweeteners in the premixture selected from the group consisting of sorbitol, erythritol, maltitol, xylitol, isomalt, lactitol, mannitol, and combinations thereof.
- the chewing gum comprises one or more sweeteners in addition to the one or more sweeteners in the premixture in an amount of 20 to 60% by weight of the chewing gum.
- a series of at least 10 compressed chewing gums comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 5%.
- the method used for content uniformity of cannabinoids in compressed chewing gums is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units.
- the acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance.
- An appropriate analytical method is selected for content uniformity.
- a series of at least 10 compressed chewing gums comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 2%.
- the chewing gum comprises at least two compressed modules, and wherein the premixture is comprised in at least one of the two compressed modules.
- the chewing gum comprises at least two compressed modules, and wherein the two modules are different in composition.
- the chewing gum comprises at least two compressed modules, and wherein at least one of the two compressed modules does not comprise gum base.
- the chewing gum comprises further ingredients selected from the group consisting of flavors, dry-binders, tableting aids, anti-caking agents, surfactants, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, further active ingredients, water-soluble indigestible polysaccharides, water-insoluble polysaccharides, and any combination thereof.
- a lozenge for oral administration of cannabinoids comprising a premixture according to the invention.
- the premixture is present in an amount of 10-100% by weight of the lozenge.
- the premixture is present in an amount of 15-75% by weight of the lozenge.
- a series of at least 10 lozenges comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 5%.
- the method used for content uniformity of lozenges is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units.
- the acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance.
- An appropriate analytical method is selected for content uniformity.
- a series of at least 10 lozenges comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 2%.
- the lozenge comprises one or more sugar alcohols in addition to the one or more sweeteners in the premixture selected from the group consisting of sorbitol, erythritol, maltitol, xylitol, isomalt, lactitol, mannitol, and combinations thereof.
- the lozenge comprises one or more sweeteners in addition to the one or more sweeteners in the premixture in an amount of 20 to 60% by weight of the lozenge.
- the lozenge comprises one or more insoluble components selected from the group consisting of silica, microcrystalline cellulose, cellulose, silicified microcrystalline cellulose, clay, talc, starch, pregelatinized starch, calcium carbonate, dicalcium phosphate, magnesium carbonate, magnesium-alumino-metasilicates, hyper porous silica, and mixtures thereof.
- the lozenge comprises one or more disintegrants operable to disintegrate the lozenge within a period of 1 minute or less in contact with oral saliva.
- the lozenge comprises one or more disintegrants selected from the group consisting of sodium croscarmellose, crospovidone, sodium starch glycolate, and combinations thereof.
- the lozenge comprises one or more disintegrants in an amount of 0.5 to 25% by weight of the lozenge.
- the lozenge comprises further ingredients selected from the group consisting of flavors, dry-binders, tableting aids, anti-caking agents, surfactants, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, further active ingredients, water-soluble indigestible polysaccharides, water-insoluble polysaccharides, and any combination thereof.
- a pouch for oral administration of cannabinoids comprising a premixture according to the invention.
- the premixture is present in an amount of 10-100% by weight of the pouch.
- the premixture is present in an amount of 15-75% by weight of the pouch.
- a series of at least 10 pouches comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 5%.
- the method used for content uniformity of pouches is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units.
- the acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance.
- An appropriate analytical method is selected for content uniformity.
- a series of at least 10 pouches comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 2%.
- the pouch comprises one or more insoluble components selected from the group consisting of silica, clay, talc, starch, pregelatinized starch, calcium carbonate, dicalcium phosphate, magnesium carbonate, magnesium-alumino-metasilicates, hyper porous silica and mixtures thereof.
- the pouch comprises one or more insoluble fibres.
- the pouch comprises one or more insoluble fibres selected from wheat fibers, pea fibers, rice fiber, maize fibers, oat fibers, tomato fibers, barley fibers, rye fibers, sugar beet fibers, buckwheat fibers, potato fibers, cellulose fibers, apple fibers, cocoa fibers, bran fibers, bamboo fibers, powdered cellulose, microcrystalline cellulose and combinations thereof.
- insoluble fibres selected from wheat fibers, pea fibers, rice fiber, maize fibers, oat fibers, tomato fibers, barley fibers, rye fibers, sugar beet fibers, buckwheat fibers, potato fibers, cellulose fibers, apple fibers, cocoa fibers, bran fibers, bamboo fibers, powdered cellulose, microcrystalline cellulose and combinations thereof.
- the pouch comprises one or more sugar alcohols in addition to the one or more sweeteners in the premixture selected from the group consisting of sorbitol, erythritol, maltitol, xylitol, isomalt, lactitol, mannitol, and combinations thereof.
- the pouch comprises one or more sweeteners in addition to the one or more sweeteners in the premixture in an amount of 20 to 60% by weight of the pouch.
- the pouch comprises further ingredients selected from the group consisting of flavors, dry-binders, anti-caking agents, surfactants, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, further active ingredients, water-soluble indigestible polysaccharides, water-insoluble polysaccharides, and any combination thereof.
- a method of preparing a powder premixture for oral administration of cannabinoids comprising the steps of:
- the one or more triglycerides is heated to a temperature above ambient temperature before being added in the premixture.
- a powder premixture for oral administration of cannabinoids comprising the steps of:
- the one or more triglycerides is heated to a temperature above ambient temperature before being added in the premixture.
- a powder premixture for oral administration of cannabinoids comprising the steps of:
- the one or more triglycerides is heated to a temperature above ambient temperature before being added in the premixture.
- the term “approximately” or “about” in reference to a number are generally taken to include numbers that fall within a range of 5%, 10%, 15%, or 20% in either direction (greater than or less than) of the number unless otherwise stated or otherwise evident from the context (except where such number would be less than 0% or exceed 100% of a possible value).
- particle size relates to the ability of the particles to move through or be retained by sieve holes of a specific size.
- particle size refers to the average particle size as determined according to European Pharmacopoeia 9.1 when using test method 2.9.38 particle size distribution estimation by analytical sieving, unless otherwise specifically is mentioned.
- particle or similar wording is intended to denote a single, discrete composition of solid matter, such as a granule or individual elements in powder, having a certain size that may deviate considerable.
- release refers to the released substance being liberated from the solid dosage form.
- the process of releasing a substance corresponds to the substance being dissolved in saliva.
- release in the present context is intended to mean tested under “in vivo” conditions, if not stated otherwise.
- in vivo conditions is intended to mean that a sample is masticated with a chewing frequency of 60 chews pr. minute for a certain period of time in a test panel of 8 test persons, if not stated otherwise. These test persons abstain from eating and drinking at least 30 minutes before initiation of any test.
- the test persons are healthy persons appointed on an objective basis according to specified requirements.
- sustained release or “extended release” is herein intended to mean prolonged release over time.
- rapid release or “quick release” or “high release” is herein intended to mean a higher content released for a given period of time.
- texture is meant a qualitative measure of the properties of the solid dosage form and of the overall mouth-feel experienced by the user during use.
- texture encompasses measurable quantities such as hardness as well as more subjective parameters related to the feel experienced by a user.
- sustained release or “extended release” is herein intended to mean prolonged release over time.
- rapid release or “quick release” or “high release” is herein intended to mean a higher content released for a given period of time.
- controlled release is intended to mean a release of a substance from a solid dosage form by the aid of active use of the solid dosage form in the oral cavity of the subject, whereby the active use is controlling the amount of substance released.
- a “self-emulsifying agent” is an agent which will form an emulsion when presented with an alternate phase with a minimum energy requirement.
- an emulsifying agent as opposed to a self-emulsifying agent, is one requiring additional energy to form an emulsion.
- lipid-based drug delivery systems and self-emulsifying systems have been developed.
- Lipid-based delivery systems and particularly self-emulsifying drug delivery systems (SEDDS) have been demonstrated to increase the solubility, dissolution and bioavailability of many insoluble active ingredients.
- SEDDS delivery systems are very limited by the amount of active ingredient loading that has to be dissolved in the vehicle composition. Higher concentration of active ingredients are obtained using co-solvents, which enable loads of up to 30% in specific cases.
- the formulation of the present invention may provide some clear benefits, both allowing a higher load of active ingredients and at the same time offer improved sensorics properties of the formulation during use. Other advantages are also present.
- the presence of SEDDS or at least a self-emulsifying agent was seen to act in synergy with increased saliva generation. While increased saliva generation was seen to distribute certain active ingredients and allocate a higher load of active ingredients to for instance mucosal surfaces, the presence of SEDDS or at least a self-emulsifying agent was seen to further increase the uptake of these active ingredients through oral surfaces. Accordingly, the synergy between the presence of SEDDS or at least a self-emulsifying agent and increased saliva generation according to the invention was a surprise to the inventors. In some embodiments, increased saliva generation may result in a higher exposure of the active ingredients to mucosal surfaces.
- SEDDS may work to increase the affinity of the active ingredients from this saliva to the mucosa.
- the potential of SEDDS to have a high load of active ingredients further contributes to the synergy of the solid dosage form according to the invention in combination with improved saliva generation.
- SEDDS is a solid or liquid dosage form comprising an oil phase, a surfactant and optionally a co-surfactant, characterized primarily in that said dosage form can form oil-in-water emulsion spontaneously in the oral cavity or at ambient temperature (referring generally to body temperature, namely 37° C.).
- a SEDDS enters the oral cavity, it is initially self-emulsified as emulsion droplets and rapidly dispersed throughout the oral cavity, and thus reducing the irritation caused by the direct contact of the active ingredient with the mucous membrane of the oral cavity, and hence helping on taste-masking active ingredients.
- the structure of the emulsion microparticulate will be changed or destroyed.
- the resulting microparticulate of micrometer or nanometer level can penetrate into the mucous membrane of for instance the oral cavity, and the absorbed oil droplets enter the blood circulation, thereby significantly improving the bioavailability of the active ingredient.
- the self-emulsifying system comprises one or more emulsifiers and one or more oil carriers.
- the self-emulsifying system comprises one or more emulsifiers, one or more oil carriers and one or more solubilizers.
- the self-emulsifying system comprises one or more emulsifiers, one or more oil carriers, one or more solubilizers and one or more solvents.
- the self-emulsifying system comprises one or more emulsifiers and one or more solvents.
- the self-emulsifying system comprises one or more emulsifiers that have both emulsifying and solubilizing properties.
- the self-emulsifying system comprises one or more emulsifiers that act as both an emulsifier and a carrier.
- the self-emulsifying system comprises one or more emulsifiers that act as both an emulsifier, a carrier and a solubilizer.
- the self-emulsifying system comprises one or more fatty acids, one or more glycerols, one or more waxes, one or more flavonoids and one or more terpenes.
- the self-emulsifying system comprises one or more emulsifiers that have an HLB-value of more than 6, preferably of 8-18.
- the one or more emulsifiers are selected from the group consisting of PEG-35 castor oil, PEG-6 oleoyl glycerides, PEG-6 linoleoyl glycerides, PEG-8 caprylic/capric glyceride, sorbitan monolaurate, sorbitan monooleate, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (60) sorbitan monostearate, polyoxyethylene (80) sorbitan monooleate, lauroylpoloxyl-32 glycerides, stearoyl polyoxyl-32 glycerides, polyoxyl-32 stearate, propylene glycol mono laurate, propylene glycol di laurate, and mixtures and combinations thereof.
- the one or more emulsifiers comprise PEG-35 castor oil.
- the oil carrier is selected from the group consisting of natural fatty acids; medium-chain triglycerides of caprylic (C8) and capric (C10) acids; propylene glycol esters of caprylic (C8) and capric (C10) acids; mono-, di- and triglycerides of mainly linoleic (C18:2) and oleic (C18:1) acids; fatty acid 18:1 cis-9; natural fatty acids; mono-, di- and triglycerides of oleic (C18:1) acid, and mixtures and combinations thereof.
- the one or more solvents are selected from the group consisting of polyglyceryl-3 dioleate, 1,2-propandiol, polyethylene glycol 300, polyethylene glycol 400, diethylene glycol monoethyl ether, and mixtures and combinations thereof.
- the oil carrier is selected from the group consisting of corn oil, Labrafac lipophile WL1349, Labrafac PG, Maisine CC, oleic acid, olive oil, Peceol, and mixtures and combinations thereof.
- the one or more solvents are selected from the group consisting of polyglyceryl-3 dioleate, 1,2-propandiol, polyethylene glycol 300, polyethylene glycol 400, diethylene glycol monoethyl ether, and mixtures and combinations thereof.
- the one or more solubilizers are selected from the group consisting of lauroylpoloxyl-32 glycerides; stearoyl polyoxyl-32 glycerides; Polyoxyl-32 stearate; synthetic copolymer of ethylene oxide (80) and propylene oxide (27); polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft co-polymer; alpha-, beta- or gamma cyclodextrins and derivatives thereof; pea proteins (globulins, albumins, glutelins proteins); and mixtures and combinations thereof.
- the formulation further comprises one or more lipids in addition to the lipid composition according to the invention.
- non-DC sugar alcohol particles refers to particles of non-directly compressible (non-DC) sugar alcohol. It is noted that the terms “non-DC sugar alcohol particles” and “non-DC particles” are used interchangeably.
- the non-DC sugar alcohol particles refer to particles which have not been preprocessed by granulation with e.g. other sugar alcohols or binders for the purpose of obtaining so-called direct compressible particles (DC).
- non-DC sugar alcohol particles include particles obtained by crystallization followed by milling which does not involve other sugar alcohols or binders. Thus, non-DC sugar alcohol particles are considered as particles consisting of non-DC sugar alcohol.
- DC sugar alcohol particles refers to particles of direct compressible (DC) sugar alcohol. It is noted that the terms “DC sugar alcohol particles” and “DC particles” are used interchangeably. DC sugar alcohol particles may be obtained e.g. as particles of sugar alcohols having DC grade by nature, e.g. sorbitol, or by granulating non-DC sugar alcohol with e.g. other sugar alcohols or binders for the purpose of obtaining so-called direct compressible particles (DC). Also, granulation of non-DC sugar alcohol with water as binder is considered to result in “DC sugar alcohol particles” in the present context.
- tablette or “tablet” or “compressed” is intended to mean that the tablet composition is pressed in a tableting apparatus and mainly being composed of particulate matter. Although the terms imply a method step, in the present context, the terms are intended to mean the resulting tablet obtained in tableting a portion of particles. It is noted that a tablet or tableted composition that is mentioned to comprise particles eventually is to be understood as particles that have been pressed together in a tableting step.
- the process of manufacture of the inventive tablet may be performed in a single tablet press, such as a rotary tablet press. But it may be a benefit under some circumstances to apply a separate tablet press.
- the upper punch is convex which gives the upper face of the pressed tablet a concave form.
- the shape of the punches may vary depending of the desired tablet shape.
- pressing of the tablets are performed at a force of 20 to 50 kN.
- the “tablet” is intended to mean a “fast disintegrating tablet” (“FDT”), or similar wording, such as “orally disintegrating tablet” (“ODT”).
- FDT fast disintegrating tablet
- ODT electronically disintegrating tablet
- the tablet according to the invention is made as one module, contrary to two or more modules, then the tablet is intended to be an FDT tablet.
- the tablet is made of more than one module, such as two modules, such additional module is intended to be a “lozenge” module, which provides a longer disintegration time compared to the FDT module according to the invention.
- the combination of an “FDT” module and a “lozenge” module contributes to another aspect of the invention.
- a “lozenge” module according to the invention may also comprise elements from the “FDT” modules but is generally different in composition, providing an extended disintegration time.
- the term “lozenge” is intended to cover that a “lozenge composition” has been “compressed” into a “lozenge module”.
- a “lozenge module” or similar wording is intended to mean that the module during use in the oral cavity is intended to be sucked or licked on.
- the term “lozenge” is given the ordinary meaning in the art of lozenges.
- the intention is that the lozenge module may not be chewed.
- the intention is also that the FDT module may not be chewed.
- the “lozenge module” of the present invention may disintegrate upon sucking or licked in minutes, contrary to seconds for orally disintegrating tablets (ODT) or fast disintegrating tablets (FDT) tablets.
- ODT orally disintegrating tablets
- FDT fast disintegrating tablets
- module is generally intended to be composed of a composition of matter with substantially the same characteristics throughout the module. Hence, if two module are present, then the two modules are different in composition and generally have two different characteristics throughout each module. In the present context, if only one module is present, then this module is considered an FDT tablet. On the other hand, if two modules are present, then the tablet is composed of an FDT tablet or FDT tablet module fused with a lozenge tablet or lozenge module. The term “fused” is intended to mean that the tablet is gathered together by means of compression force. Usually, if two modules are present, the lozenge module is made as the first module and the FDT module is made as the second module. The tablet may be composed of more than two module. The lozenge module may in certain embodiments be replaced by a gum base module. In the present context, the invention provides an attractive bi-phasic delivery of masking, even if the delivery of nicotine is “single-phased”.
- cannabinoid composition is intended to mean a volume of matter comprising one or more cannabinoids.
- the cannabinoid composition may contain other components than cannabinoids.
- the cannabinoid composition may constitute cannabinoids.
- the cannabinoid composition may constitute one type of cannabinoids.
- the cannabinoid composition may constitute two types of cannabinoids.
- the cannabinoid composition may constitute two or more types of cannabinoids.
- water-insoluble gum base or “gum base” or “gum base matrix” or similar wording is meant the mainly water-insoluble ingredients and hydrophobic gum base ingredients.
- the “gum base” may contain gum base polymers and plasticizers, waxes, emulsifiers, fats and/or fillers.
- natural resin means resinous compounds being either polyterpene derived from terpenes of natural origin or resinous compounds derived from gum rosin, wood rosin or tall-oil rosin.
- Elastomers provide the rubbery, elastomeric and bouncing nature to the gum, which varies depending on this ingredient's chemical structure and how it may be compounded with other ingredients.
- Elastomers suitable for use in the gum base and gum of the present invention may include natural or synthetic types.
- Polyvinyl acetate elastomer plasticizers are not considered elastomers according to the invention.
- Elastomers may be selected from the group consisting of styrene-butadiene copolymers, polyisobutylene, isobutylene-isoprene copolymers, polyethylene, polyurethane or any combination thereof.
- Preferred elastomers are styrene-butadiene copolymers (SBR), polyisobutylene and isobutylene-isoprene copolymers (BR).
- Styrene-butadiene type elastomers typically are copolymers of from about 20:80 to 60:40 styrenes:butadiene monomers. The ratio of these monomers affects the elasticity of the SBR as evaluated by mooney viscosity. As the styrene:butadiene ratio decreases, the mooney viscosity decreases.
- SBR typically consists of straight chain 1,3-butadiene copolymerized with phenylethylene (styrene).
- the average molecular weight of SBR is ⁇ 600,000 g/mole.
- Isobutylene-isoprene type elastomers or butyl as they may be called, have molar percent levels of isoprene ranging from 0.2 to 4.0. Similar to SBR, as the isoprene:isobutylene ratio decreases, so does the elasticity, measured by mooney viscosity.
- butyl rubber typically consists of branched 2-methyl-1,3-butadiene (isoprene) copolymerized with branched 2-methylpropene (isobutylene).
- the average molecular weight of BR is in the range from 150,000 g/mole to 1,000,000 g/mole.
- Polyisobutylene, or PIB as they may be called, type elastomers are polymers of 2-methylpropene.
- the low molecular weight elastomers provide soft chew characteristics to the gum base and still provide the elastic qualities as do the other elastomers.
- Average molecular weights may range from about 30,000 to 120,000 g/mole and the penetration may range from about 4 millimeters to 20 millimeters.
- the high molecular weight elastomers provide elasticity to the gum. Average molecular weight may range from 120,000 to 1,000,000 g/mole.
- Polybutene range in average molecular weight from about 5.000 g/mole to about 30,000 g/mole.
- Useful natural elastomers include natural rubber such as smoked or liquid latex and guayule, natural gums such as jelutong, lechi caspi, perillo, sorva, massaranduba balata, massaranduba chocolate, nispero, rosidinha, chicle, gutta percha, gutta kataiu, niger gutta, tunu, chilte, chiquibul, gutta hang kang. Natural elastomers may also be applied in aspects of the present invention.
- Elastomer plasticizers vary the firmness of the gum base. Their specificity on elastomer inter-molecular chain breaking (plasticizing) along with their varying softening points cause varying degrees of finished gum firmness and compatibility when used in base. Polyvinyl acetate elastomers plasticizers are examples of elastomer plasticizers of the present invention.
- Natural resins may be selected from ester gums including as examples glycerol esters of partially hydrogenated rosins, glycerol esters of polymerized rosins, glycerol esters of partially dimerized rosins, glycerol esters of tally oil rosins, pentaerythritol esters of partially hydrogenated rosins, methyl esters of rosins, partially hydrogenated methyl esters of rosins, pentaerythritol esters of rosins, synthetic resins such as terpene resins derived from alpha-pinene, beta-pinene, and/or d-limonene, and natural terpene resins.
- ester gums including as examples glycerol esters of partially hydrogenated rosins, glycerol esters of polymerized rosins, glycerol esters of partially dimerized rosins, glycerol esters of
- the solid dosage form comprises further ingredients selected from the group consisting of flavors, dry-binders, tableting aids, anti-caking agents, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, active ingredients, water-soluble indigestible polysaccharides, water-insoluble polysaccharides or any combination thereof.
- the solid dosage form according to the invention is manufactured by applying pressure to a content of particles by suitable compression means.
- the particles or powder is then pressed into a compact coherent tablet.
- the particles may for example comprise so-called primary particles or aggregated primary particles. When these are pressed, bonds are established between the particles or granules, thereby conferring a certain mechanical strength to the pressed tablet.
- powder, primary particles and aggregated primary particles may be somewhat misleading in the sense that the difference between primary particles and aggregated primary particles may very often be looked upon differently depending on the background of the user.
- sorbitol a sweetener
- aggregated primary particles refer to macro-particles comprising more or less preprocessed primary particles.
- conventional chewing gum may be manufactured by sequentially adding the various chewing gum ingredients to a commercially available mixer known in the art where the finished gum base is already present. After the initial ingredients have been thoroughly mixed, the gum mass is discharged from the mixer and shaped into the desired form such as by rolling into sheets and cutting into sticks, extruded into chunks or casting into pellets.
- the ingredients of conventional chewing gum may be mixed by first melting the gum base and adding it to the running mixer. Colors, active agents and/or emulsifiers may also be added at this time. A softener such as glycerin may also be added at this time, along with syrup and a portion of the bulking agent/sweetener.
- a flavoring agent is typically added with the final portion of the bulking agent/sweetener.
- a high-intensity sweetener is preferably added after the final portion of bulking agent and flavor have been added.
- the entire mixing procedure typically takes from thirty to forty minutes, but longer mixing times may sometimes be required.
- the solid dosage form does not include conventional chewing gum, i.e., so-called extruded chewing gum.
- the tableted solid dosage form according to the invention may comprise about 0.1 to about 75% by weight of an outer coating applied onto the solid dosage form centre.
- suitable coating types include hard coatings, film coatings and soft coatings of any composition including those currently used in coating of tableted solid dosage form.
- One presently preferred outer coating type is a hard coating, which term is used in the conventional meaning of that term including sugar coatings and sugar-free (or sugarless) coatings and combinations thereof.
- the object of hard coating is to obtain a sweet, crunchy layer, which is appreciated by the consumer and it may moreover protect the solid dosage form centres for various reasons.
- the solid dosage form centres are successively treated in suitable coating equipment with aqueous solutions of crystallisable sugar such as sucrose or dextrose, which, depending on the stage of coating reached, may contain other functional ingredients, e.g. fillers, binding agents, colours, etc.
- the sugar coating may contain further functional or active compounds including flavour compounds and/or active compounds.
- a suspension containing crystallisable sugar and/or polyol is applied onto the solid dosage form centres and the water it contains is evaporated off by blowing with air.
- the coating layer constitutes about 0.1 to about 75% by weight of the finished solid dosage form element, such as about 10 to about 60% by weight, including about 15 to about 50% by weight.
- the product is a pouch.
- the population of particles used for tableting may also be present in a pouch as a powder.
- this aspect of the invention includes the population of particles in a pouch without tableting, but as a powder or part of a powder with other powders or powder ingredients.
- DC directly compressible
- non-DC non-directly compressible
- Additional embodiments pertaining to the population of particles of the invention will also be applicable when included in a pouch.
- additional ingredients may be present in the pouch, such as water-soluble fibers or water-insoluble fibers, including microcrystalline cellulose.
- the pouch comprises a water-permeable membrane, such as a woven or non-woven fabric.
- the pouches according to the invention comprise openings, where the characteristic opening dimension is adapted to a characteristic dimension of the population of particles so as to retain the matrix composition inside the pouch before use and/or to retain a part of the content inside the pouch during use.
- the pouch forms a membrane allowing passage of saliva and prevents or inhibits passage of at least a part of the content.
- the membrane of the pouch may be of any suitable material e.g. woven or non-woven fabric (e.g. cotton, fleece etc.), heat sealable non-woven cellulose or other polymeric materials such as a synthetic, semi-synthetic or natural polymeric material.
- suitable pouch material is paper made of pulp and a small amount of wet strength agent.
- a material suitable for use must provide a semi-permeable membrane layer to prevent the powder or composition from leaving the bag or pouch during use. Suitable materials are also those that do not have a significant impact on the release of the active ingredients from the pouch.
- the powder is filled into pouches and is maintained in the pouch by a sealing.
- An ideal pouch is chemically and physically stable, it is pharmaceutically acceptable, it is insoluble in water, it is easy to fill with powder and seal, and it provides a semi-permeable membrane layer which prevent the powder from leaving the bag, but permit saliva and therein dissolved or sufficiently small suspended components from the powder in the pouch to pass through said pouch.
- the pouch may be placed in the oral cavity by the user. Saliva then enters into the pouch, and the active ingredient and other components, which are soluble in saliva, start to dissolve and are transported with the saliva out of the pouch into the oral cavity.
- the pouch may be masticated in a similar way as chewing a gum. This is particularly advantageous when the population of particles comprise gum base. Hence, the pouch may be masticated into a coherent residual containing water-insoluble components.
- flavors may be selected from the group consisting of coconut, coffee, chocolate, vanilla, grape fruit, orange, lime, menthol, liquorice, caramel aroma, honey aroma, peanut, walnut, cashew, hazelnut, almonds, pineapple, strawberry, raspberry, tropical fruits, cherries, cinnamon, peppermint, wintergreen, spearmint, eucalyptus , and mint, fruit essence such as from apple, pear, peach, strawberry, apricot, raspberry, cherry, pineapple, and plum essence.
- the essential oils include peppermint, spearmint, menthol, eucalyptus , clove oil, bay oil, anise, thyme, cedar leaf oil, nutmeg, and oils of the fruits mentioned above.
- Antioxidants suitable for use include butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), betacarotenes, tocopherols, acidulants such as Vitamin C (ascorbic acid or corresponding salts (ascorbates)), propyl gallate, catechins, green tea extract other synthetic and natural types or mixtures thereof.
- BHA butylated hydroxyanisole
- BHT butylated hydroxytoluene
- betacarotenes betacarotenes
- tocopherols acidulants
- acidulants such as Vitamin C (ascorbic acid or corresponding salts (ascorbates)), propyl gallate, catechins, green tea extract other synthetic and natural types or mixtures thereof.
- High intensity sweetening agents can also be used according to preferred embodiments of the invention.
- Preferred high intensity sweeteners include, but are not limited to sucralose, aspartame, salts of acesulfame, alitame, neotame, saccharin and its salts, cyclamic acid and its salts, glycyrrhizin, dihydrochalcones, thaumatin, monellin, monk fruit extract, advantame, stevioside and the like, alone or in combination.
- Encapsulation of sweetening agents can also be provided using another formulation component such as a resinous compound.
- usage level of the high-intensity sweetener will vary considerably and will depend on factors such as potency of the sweetener, rate of release, desired sweetness of the product, level and type of flavor used and cost considerations.
- the active level of artificial sweetener may vary from about 0.001 to about 8% by weight (preferably from about 0.02 to about 8% by weight).
- the usage level of the encapsulated high-intensity sweetener will be proportionately higher.
- the invention may include one or more fillers/texturizers including as examples, magnesium- and calcium carbonate, sodium sulphate, ground limestone, silicate compounds such as magnesium- and aluminum silicate, kaolin and clay, aluminum oxide, silicium oxide, talc, titanium oxide, mono-, di- and tri-calcium phosphates, cellulose polymers, such as wood, and combinations thereof.
- one preferred filler/texturizer is calcium carbonate.
- the one or more cannabinoids may be selected from various cannabinoids.
- “Cannabinoids” are a group of compounds including the endocannabinoids, the phytocannabinoids and those which are neither endocannabinoids or phytocannabinoids, hereinafter “syntho-cannabinoids”.
- Endocannabinoids are endogenous cannabinoids, which may have high affinity ligands of CB1 and CB2 receptors.
- phytocannabinoids are cannabinoids that originate in nature and can be found in the cannabis plant.
- the phytocannabinoids can be present in an extract including a botanical drug substance, isolated, or reproduced synthetically.
- “Syntho-cannabinoids” are those compounds capable of interacting with the cannabinoid receptors (CB1 and/or CB2) but are not found endogenously or in the cannabis plant. Examples include WIN 55212 and rimonabant.
- isolated phytocannabinoid or “isolated cannabinoid” is one which has been extracted from the cannabis plant and purified to such an extent that the additional components such as secondary and minor cannabinoids and the non-cannabinoid fraction have been substantially removed.
- a “synthetic cannabinoid” is one which has been produced by chemical synthesis. This term includes modifying an isolated phytocannabinoid, by, for example, forming a pharmaceutically acceptable salt thereof.
- a “substantially pure” cannabinoid is defined as a cannabinoid which is present at greater than 95% (w/w) pure. More preferably greater than 96% (w/w) through 97% (w/w) thorough 98% (w/w) to 99% % (w/w) and greater.
- a “highly purified” cannabinoid is defined as a cannabinoid that has been extracted from the cannabis plant and purified to the extent that other cannabinoids and non-cannabinoid components that are co-extracted with the cannabinoids have been substantially removed, such that the highly purified cannabinoid is greater than or equal to 95% (w/w) pure.
- Plant material is defined as a plant or plant part (e.g. bark, wood, leaves, stems, roots, flowers, fruits, seeds, berries or parts thereof) as well as exudates, and includes material falling within the definition of “botanical raw material” in the Guidance for Industry Botanical Drug Products Draft Guidance, August 2000, US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research.
- cannabinoid extract or “extract of cannabinoids”, which are used interchangeably, encompass “Botanical Drug Substances” derived from cannabis plant material.
- a Botanical Drug Substance is defined in the Guidance for Industry Botanical Drug Products Draft Guidance, August 2000, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research as: “A drug substance derived from one or more plants, algae, or macroscopic fungi. It is prepared from botanical raw materials by one or more of the following processes: pulverisation, decoction, expression, aqueous extraction, ethanolic extraction, or other similar processes.”
- a botanical drug substance does not include a highly purified or chemically modified substance derived from natural sources.
- “botanical drug substances” derived from cannabis plants do not include highly purified, Pharmacopoeial grade cannabinoids.
- Cannabis plant(s) encompasses wild type Cannabis sativa and also variants thereof, including cannabis chemovars which naturally contain different amounts of the individual cannabinoids, Cannabis sativa subspecies indica including the variants var. indica and var. kafiristanica, Cannabis indica, Cannabis ruderalis and also plants which are the result of genetic crosses, self-crosses or hybrids thereof.
- Cannabis plant material is to be interpreted accordingly as encompassing plant material derived from one or more cannabis plants. For the avoidance of doubt it is hereby stated that “ cannabis plant material” includes dried cannabis biomass.
- the one or more cannabinoids are selected from: cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCV A). More preferably the one or more cannabinoid is CBD or THC. This list is not exhaustive and merely details the cannabinoids which are identified in the present application for reference.
- Cannabinoids can be split into different groups as follows: Phytocannabinoids; Endocannabinoids; and Synthetic cannabinoids.
- Cannabinoid receptors can be activated by three major groups of agonist ligands, for the purposes of the present invention and whether or not explicitly denominated as such herein, lipophilic in nature and classed respectively as: endocannabinoids (produced endogenously by mammalian cells); phytocannabinoids (such as cannabidiol, produced by the cannabis plant); and, synthetic cannabinoids (such as HU-210).
- endocannabinoids produced endogenously by mammalian cells
- phytocannabinoids such as cannabidiol, produced by the cannabis plant
- synthetic cannabinoids such as HU-210
- Phytocannabinoids can be found as either the neutral carboxylic acid form or the decarboxylated form depending on the method used to extract the cannabinoids. For example, it is known that heating the carboxylic acid form will cause most of the carboxylic acid form to decarboxylate.
- Phytocannabinoids can also occur as either the pentyl (5 carbon atoms) or propyl (3 carbon atoms) variant.
- the phytocannabinoid THC is known to be a CB1 receptor agonist whereas the propyl variant THCV has been discovered to be a CB1 receptor antagonist meaning that it has almost opposite effects.
- examples of phytocannabinoids may be cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCV A). More preferably the one or more cannabinoid is CBD or THC.
- the formulation according to the present invention may also comprise at least one cannabinoid selected from those disclosed in A. Douglas Kinghom et al., Phytocannabinoids, Vol. 103, Chapter 1, pages 1-30.
- Examples of endocannabinoids are molecules that activate the cannabinoid receptors within the body. Examples include 2-arachidonyl glycerol (2AG), 2-arachidonyl glyceryl ether (2AGE), arachidonyl dopamine, and arachidonyl ethanolamide (anandamide). Structurally related endogenous molecules have been identified that share similar structural features, but that display weak or no activity towards the cannabinoid receptors but are also termed endocannabinoids.
- Examples of these endocannabinoid lipids include 2-acyl glycerols, alkyl or alkenyl glyceryl ethers, acyl dopamines and N-acylethanolamides that contain alternative fatty acid or alcohol moieties, as well as other fatty acid amides containing different head groups. These include N-acylserines as well as many other N-acylated amino acids. Examples of cannabinoid receptor agonists are neuromodulatory and affect short-term memory, appetite, stress response, anxiety, immune function and analgesia.
- the cannabinoid is palmitoylethanolamide (PEA) which is an endogenous fatty acid amide belonging to the class of nuclear factor agonists.
- PDA palmitoylethanolamide
- Synthetic cannabinoids encompass a variety of distinct chemical classes: the cannabinoids structurally related to THC, the cannabinoids not related to THC, such as (cannabimimetics) including the aminoalkylindoles, 1,5-diarylpyrazoles, quinolines, and arylsulfonamides, and eicosanoids related to the endocannabinoids. All or any of these cannabinoids can be used in the present invention.
- the formulation comprises one or two primary cannabinoids, which are preferably selected from the group consisting of, cannabidiol (CBD) or cannabidivarin (CBDV), tetrahydrocannabinol (THC), tetrahydrocannabivarin (THCV), tetrahydrocannabinolic acid (THCA), cannabigerol (CBG) and cannabidiolic acid (CBDA) or a combination thereof. It is preferred that the formulation comprises cannabidiol and/or tetrahydrocannabinol.
- the solid dosage form of the present invention may be used for the treatment or alleviation of pain, epilepsy, cancer, nausea, inflammation, congenital disorders, neurological disorders, oral infections, dental pain, sleep apnea, psychiatric disorders, gastrointestinal disorders, inflammatory bowel disease, appetite loss, diabetes and fibromyalgia.
- the oral cannabinoid formulation is suitable for use in the treatment of conditions requiring the administration of a neuroprotectant or anti-convulsive medication.
- the oral cannabinoid formulation may be for use in the treatment of seizures.
- the oral cannabinoid formulation may be for use in the treatment of Dravet syndrome, Lennox Gastaut syndrome, myoclonic seizures, juvenile myoclonic epilepsy, refractory epilepsy, schizophrenia, juvenile spasms, West syndrome, infantile spasms, refractory infantile spasms, tuberous sclerosis complex, brain tumours, neuropathic pain, cannabis use disorder, post-traumatic stress disorder, anxiety, early psychosis, Alzheimer's disease, and autism.
- CBD is used as an exemplary compound, but may also be another cannabinoid.
- Mannitol provided from Roquette in an amount of about 1780 g was added to a Lödige high shear mixer and heated to a temperature of about 55 Degree Celsius. Thereafter, a cannabinoid powder composition comprising CBD isolate from cannabis plant tissues (phytocannabinoid) with a 99% content of CBD provided by Medical Hemp (batch number MH B18592) in an amount of about 140 g was sieved through a 600 microns sieve and added to the sweetener powder composition. This mixture was mixed in the mixer at a speed of about 80 rpm for about 5 minutes.
- HVO provided from AAK under the tradename Akocrem NT 76-33 with a melting temperature of 30-35 Degree Celsius was melted at a temperature of about 55 Degree Celsius and added to the mixture in an amount of about 80 g.
- the temperature in the mixer was about 49 Degree Celsius, and the mixture was further mixed for about 10 minutes. After 10 minutes, the temperature of the final mixture was about 51 Degree Celsius.
- a total of 2 kg mixture powder premix was made in which the CBD content was about 70 mg/g.
- HVO Hydrogenated Vegetable Oil
- Sample 102 corresponds to the procedure above, the other samples are adjusted to the variation in contents.
- HVO Hydrogenated Vegetable Oil
- Sample 112 corresponds to the procedure above, the other samples are adjusted to the variation in contents.
- Powder Premix Number 110 111 112 113 114 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] [%] Mannitol 93.0 90.5 89.0 87.0 83.0 CBD isolate (purity 99%) 7.0 7.0 7.0 7.0 HVO 1.0 2.5 4.0 6.0 10.0 Total 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
- HVO Hydrogenated Vegetable Oil
- Sample 122 corresponds to the procedure above. Powder Premix Number 120 121 122 123 124 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] [%] Mannitol 89.0 Isomalt 89.0 Maltitol 89.0 Xylitol 89.0 Dextrose 89.0 CBD isolate (purity 99%) 7.0 7.0 7.0 7.0 7.0 HVO 4.0 4.0 4.0 4.0 4.0 4.0 4.0 Total 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
- Mannitol provided from Roquette in an amount of about 1780 g was added to a Lödige high shear mixer and heated to a temperature of about 55 Degree Celsius. Thereafter, a cannabinoid powder composition comprising CBD isolate from cannabis plant tissues (phytocannabinoid) with a 99% content of CBD provided by Medical Hemp (batch number MH B18592) in an amount of about 140 g was sieved through a 600 microns sieve and added to the sweetener powder composition. This mixture was mixed in the mixer at a speed of about 80 rpm for about 5 minutes.
- MCT Medium Chain Triglyceride
- Miglyol 812 provided from Sasol was added to the mixture during a period of about 3 minutes in an amount of about 80 g.
- the mixture was further mixed for about 10 minutes. After 10 minutes, the temperature of the final mixture was about 51 Degree Celsius.
- a total of 2 kg mixture powder premix was made in which the CBD content was about 70 mg/g.
- Miglyol having not been preheated unless specifically denoted. Variation in the type of Miglyol.
- Sample 222 corresponds to the procedure above.
- Miglyol 829 in Powder Premix Number 223 is heated to about 50° C. in order to work.
- Powder Premix Number 224 is a comparative powder.
- Raw material name [%] [%] [%] [%] [%] [%] Mannitol 89.0 89.0 89.0 89.0 89.0 CBD isolate (purity 99%) 7.0 7.0 7.0 7.0 7.0 Miglyol 812 4.0 Miglyol 810 4.0 Miglyol 818 4.0 Miglyol 829 4.0 Miglyol 840 4.0 Total 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
- Mannitol provided from Roquette in an amount of about 1220 g was added to a Lödige high shear mixer and heated to a temperature of about 55 Degree Celsius. Thereafter, a cannabinoid powder composition comprising CBD isolate from cannabis plant tissues (phytocannabinoid) with a 99% content of CBD provided by Medical Hemp (batch number MH B18592) in an amount of about 700 g was sieved through a 600 microns sieve and added to the sweetener powder composition. This mixture was mixed in the mixer at a speed of about 80 rpm for about 5 minutes.
- HVO provided from AAK under the tradename Akocrem NT 76-33 with a melting temperature of 30-35 Degree Celsius was melted at a temperature of about Degree Celsius and added to the mixture in an amount of about 80 g.
- the temperature in the mixer was about 49 Degree Celsius, and the mixture was further mixed for about 10 minutes. After 10 minutes, the temperature of the final mixture was about 51 Degree Celsius.
- a total of 2 kg mixture powder premix was made in which the CBD content was about 350 mg/g.
- HVO Hydrogenated Vegetable Oil having been preheated to a temperature of about 55 Degree Celsius. Variation in the content of HVO. Powder Premix Number 310 311 312 313 314 Content Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] [%] Mannitol 64.0 62.5 61.0 59.0 55.0 CBD isolate 35.0 35.0 35.0 35.0 (purity 99%) HVO 1.0 2.5 4.0 6.0 10.0 Total 100 100 100 100 100 100 100 100 100 100 100 100 100 Sample 312 corresponds to the procedure above, the other samples are adjusted to the variation in contents.
- HVO Hydrogenated Vegetable Oil
- Mannitol provided from Roquette in an amount of about 721 g was added to a Lödige high shear mixer and heated to a temperature of about 55 Degree Celsius. Thereafter, a cannabinoid powder composition comprising CBD isolate from cannabis plant tissues (phytocannabinoid) with a 99% content of CBD provided by Medical Hemp (batch number MH B18592) in an amount of about 91 g was mixed with HVO provided from AAK under the tradename Akocrem NT 76-33 with a melting temperature of 30-35 Degree Celsius in an amount of about 29 g. While stirring, the CBD-HVO mixture was heated to a temperature of about 60 Degree Celsius to form a liquid solution of CBD in HVO.
- cannabinoid powder composition comprising CBD isolate from cannabis plant tissues (phytocannabinoid) with a 99% content of CBD provided by Medical Hemp (batch number MH B18592) in an amount of about 91 g was mixed with HVO provided from AAK under the tradename Akocrem NT
- CBD and HVO corresponding to a ratio of about 75/25 (hereafter denoted 75% CBD mixture) was then added to the sweetener powder composition in an amount of about 79 g. After adding the lipid composition, the mixture was mixed for about 10 minutes. A total of 800 g mixture powder premix was made.
- Mannitol provided from Roquette in an amount of about 721 g was added to a Lödige high shear mixer and heated to a temperature of about 55 Degree Celsius. Thereafter, a cannabinoid powder composition comprising CBD isolate from cannabis plant tissues (phytocannabinoid) with a 99% content of CBD provided by Medical Hemp (batch number MH B18592) in an amount of about 91 g was mixed with Medium Chain Triglyceride (MCT), Miglyol 812, provided from Sasol in an amount of about 29 g. While stirring, the CBD-MCT mixture was heated to a temperature of about 70 Degree Celsius to form a liquid solution of CBD in MCT.
- MCT Medium Chain Triglyceride
- CBD and Miglyol 812 corresponding to a ratio of about 75/25 (hereafter denoted 75% CBD mixture) was then added to the sweetener powder composition in an amount of about 79 g. After adding the lipid composition, the mixture was mixed for about 10 minutes. A total of 800 g mixture powder premix was made.
- Mannitol provided from Roquette was added to a Lödige high shear mixer and heated to a temperature of about 55 Degree Celsius. Thereafter, a cannabinoid powder composition comprising CBD isolate from cannabis plant tissues (phytocannabinoid) with a purity about 99% of CBD provided by either Medical Hemp (batch number MH18592) or Valens (batch number BVA032013) was sieved through a 600 microns sieve and added to the sweetener powder composition. This mixture was mixed at a speed of about 80 rpm for about 10 minutes. No lipid composition was present.
- cannabinoid powder composition comprising CBD isolate from cannabis plant tissues (phytocannabinoid) with a purity about 99% of CBD provided by either Medical Hemp (batch number MH18592) or Valens (batch number BVA032013) was sieved through a 600 microns sieve and added to the sweetener powder composition. This mixture was mixed at a speed of about 80 rpm for about 10 minutes. No
- CBD isolate TABLE 19 Variation in the content of CBD isolate. Difference in CBD isolate source. Powder Premix Number 620 621 622 623 624 Content Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 90.0 85.0 80.0 75.0 70.0 CBD isolate 10.0 15.0 20.0 25.0 30.0 (BVA032013) Total 100 100 100 100 100 100 100 100 100
- Tablets were made based on the CBD containing powder mixtures of Examples 1-2 with each layer having a weight of about 50% of the total tablet.
- the total weight of the tablets were 1800 mg.
- the tablets were made with a standard tablet pressing machine (3090i, available from Fette GmbH) comprising dosing apparatus (P 3200 C, available from Fette GmbH, Germany). Punch used: 16.00 mm round punches. Rotor speed used was 11 rpm.
- a first layer (denoted layer 1) comprising the CBD containing powder mixture made in Examples 1-2 and additional ingredients was prepared and tableted before tableting the layer comprising gum base (denoted layer 2).
- Layer 1 with a weight of about 900 mg was compressed at a compression force of about 5 kN.
- layer 2 with a weight of about 900 mg and comprising gum base and additional ingredients was pressed on top of layer 1 at a compression force of 40 kN.
- the tablet machine was commissioned by adjusting the fill depth and compression force so the weight and hardness of tablets match the acceptance criteria. A pre-compression force could be included to avoid capping.
- Tablets were made based on the CBD containing powder mixtures of Example 3 with each layer having a weight of about 50% of the total tablet.
- the total weight of the tablets were 1800 mg.
- the tablets were made with a standard tablet pressing machine (3090i, available from Fette GmbH) comprising dosing apparatus (P 3200 C, available from Fette GmbH, Germany). Punch used: 16.00 mm round punches. Rotor speed used was 11 rpm.
- a first layer (denoted layer 1) comprising the CBD containing powder mixture made in Example 3 and additional ingredients was prepared and tableted before tableting the layer comprising gum base (denoted layer 2).
- Layer 1 was compressed at a compression force of about 5 kN.
- layer 2 comprising gum base and additional ingredients was pressed on top of layer 1 at a compression force of 40 kN.
- the tablet machine was commissioned by adjusting the fill depth and compression force so the weight and hardness of tablets match the acceptance criteria. A pre-compression force could be included to avoid capping.
- Tablets were made based on the CBD containing powder mixtures of Examples 4-5 with two layers where one layer having a weight of about 45% of the total tablet and another layer having a weight of about 55% (the layer without CBD).
- the total weight of the tablets were 1800 mg.
- the tablets were made with a standard tablet pressing machine (3090i, available from Fette GmbH) comprising dosing apparatus (P 3200 C, available from Fette GmbH, Germany). Punch used: 16.00 mm round punches. Rotor speed used was 11 rpm.
- a first layer (denoted layer 1) comprising the CBD containing powder mixture made in Examples 1-2 and additional ingredients was prepared and tableted before tableting the layer comprising gum base (denoted layer 2).
- Layer 1 was compressed at a compression force of about 5 kN.
- layer 2 comprising gum base and additional ingredients was pressed on top of layer 1 at a compression force of 40 kN.
- the tablet machine was commissioned by adjusting the fill depth and compression force so the weight and hardness of tablets match the acceptance criteria. A pre-compression force could be included to avoid capping.
- Tablets were made based on the CBD containing powder mixtures of Example 6 with two layers where one layer having a weight of about 45% of the total tablet and another layer having a weight of about 55% (the layer without CBD).
- the total weight of the tablets were 1800 mg.
- the tablets were made with a standard tablet pressing machine (3090i, available from Fette GmbH) comprising dosing apparatus (P 3200 C, available from Fette GmbH, Germany). Punch used: 16.00 mm round punches. Rotor speed used was 11 rpm.
- a first layer (denoted layer 1) comprising the CBD containing powder mixture made in Examples 1-2 and additional ingredients was prepared and tableted before tableting the layer comprising gum base (denoted layer 2).
- Layer 1 was compressed at a compression force of about 5 kN.
- layer 2 comprising gum base and additional ingredients was pressed on top of layer 1 at a compression force of 40 kN.
- the tablet machine was commissioned by adjusting the fill depth and compression force so the weight and hardness of tablets match the acceptance criteria. A pre-compression force could be included to avoid capping.
- CU Content Uniformity
- CU Content Uniformity
- At least 5 samples each having the same fixed weight in the range of 0.25-2 gram are taken from the powder mixture to be analyzed.
- the content of CBD active is analyzed by means of standard HPLC techniques. Content Uniformity is then calculated as the relative standard deviation (RSD) of the individual results.
- CU Content Uniformity
- At least 10 samples are taken from the solid dosage form, eg. tablets, to be analyzed.
- the content of CBD active is analyzed by means of standard HPLC techniques. Content Uniformity is then calculated as the relative standard deviation (RSD) of the individual results.
- a sample solid dosage form was tested in a test panel of 8 test persons. Test subjects abstain from eating and drinking at least 30 minutes before initiation of any test. The test person was a healthy person appointed on an objective basis according to specified requirements. After specific time intervals of use, eg. 0, 0.5, 1, 2, 3, 5 and minutes, the content of CBD was measured in the remaining solid dosage residue. The solid dosage form was subject to triple measurements for each of the 8 test persons, giving a total of 24 measurements for each sample. An average of the 24 measurements was calculated and the weight % release was calculated based on the original content of CBD in the sample. The content of CBD was measured in the remaining solid dosage form residue, if still present.
- the solid dosage form was weighted and placed in the mouth, and the test persons were instructed to place and use the solid dosage form as intended.
- the test persons were instructed to chew the sample at a frequency of 60 chews per minute.
- the test persons were instructed to place the sample between the tongue and the palate, and then the solid dosage form was sucked and turned every 0.5 minute.
- the desired test time was achieved (0.5, 1, 2, 3, 5 and min.)
- the solid dosage form was taken out and weighed directly into a measuring glass to be used for analysis of CBD content.
- An in vivo dissolution profile was obtained by analyzing the content of CBD in the solid dosage form at different dissolution times.
- a sample solid dosage form was tested. After specific time intervals of use, eg 0, 0.5, 1, 2, 3, 5 and 10 minutes, the content of CBD was measured in the remaining solid dosage residue.
- the solid dosage form was subject to triple measurements. An average of the measurements was calculated and the weight % release was calculated based on the original content of CBD in the sample. The content of CBD was measured in the remaining solid dosage form residue, if still present.
- the solid dosage form was weighted. Then 25 ml of phosphate buffer was added into a 50 ml measuring tube with screw cap. The solid dosage form was added to the tube. The tube was fixed horizontally on a shaking table. After shaking, the solid dosage form was analyzed for content of CBD. An in vitro profile was obtained by analyzing the content of the CBD in the solid dosage at different dissolution times.
- test panel of 8 test persons A sample was used as intended for 1 minute by a test panel of 8 test persons.
- the test person was a healthy person appointed on an objective basis according to specified requirements. Test subject abstains from eating and drinking at least 30 minutes before initiation of any test. The test person was not allowed to swallow during the procedure.
- the solid dosage form was weighted and placed in the mouth, and the test persons were instructed to place and use the solid dosage form as intended. For chewing gum, the test persons were instructed to chew the sample at a frequency of chews per minute. For lozenges the test persons were instructed to place the sample between the tongue and the palate, and then the solid dosage form was sucked and turned every 10 seconds. After one minute, saliva was obtained from the test person and collected in a vessel for later analysis.
- test set-up was composed of 8 test persons in a test panel. All of the test persons were healthy individuals appointed on an objective basis according to specified requirements. The sensory analysis was performed according to ISO 4121-2003 in testing conditions following ISO 8589. The result is an average of the results of the 8 individuals.
- test persons gave a rating from “+” to “+++++”, where “+” is poor and “+++++” is excellent, i.e. “+++++” means that the solid dosage form was excellent compared to the standard, “+++” means that the solid dosage form was comparable to the standard and “+” means that the solid dosage form was very far from comparable to the standard. “0” indicated that it was not tested.
- Textture the general impression of the solid dosage form when placed in the mouth with respect to elements such as hardness, roughness and a smoothness.
- “Friability” the impression of the solid dosage form when placed in the mouth and intended use is initiated. For instance, a very hard and viscous structure gave a very low rating and a very brittle structure also gave a very low rating.
- “Flavor” the overall impression of the solid dosage form during intended use with respect to flavor. For instance, a very low flavor experience gave a very low rating and a too high flavor experience that was not comparable to the standard also gave a very low rating.
- Off-notes the overall impression of the off-note from the one or more cannabinoids in the composition during intended use. For instance, if off-notes (grass, bitter notes, irritation in the throat) were experienced in the throat, a low rating was given and if other uncomfortable sensations was experienced, a low rating was also given.
- Example 11A The procedures of Example 11A was used for the powder premixes (Powder Premix Samples) above and the results are shown in the table below.
- the result of content uniformity for a sample is provided as a single value obtained as the relative standard deviation (RSD) of CBD content of multiple samples taken at the end of the premix preparation procedures.
- Example 11A The procedures of Example 11A was used for powder blends (Powder Blends) which are powder premixes (Powder Premix Samples) with additional ingredients as outlined in the formulations of the oral dosage forms. These powder blends were formed into the solid dosage forms.
- the procedure of Example 11B was used for the solid dosage forms. The results are shown in the tables below.
- the result of content uniformity (CU) for a sample is provided as a single value obtained as the relative standard deviation (RSD) of CBD content of multiple samples taken at the end of the preparation procedures. If individual samples have been collected at different stages of a tableting process (eg. start, middle, end) then content uniformity is determined by analysis of pooled samples from the different process stages.
- RSD relative standard deviation
- Example 11A The procedures of Example 11A was also made on further powder premixtures and powder blends used in different application forms. For instance, the powder provided in the examples above was applied in pouches, sachets, and flowpacks where similar good results for content uniformity were seen.
- Example 11B was also made on further solid dosage forms. Similar good results were seen for tablets without gum base, FDT tablets, chewing gums, and lozenges.
Abstract
Description
- The invention relates to the field of cannabinoids. In particular, the invention relates to a powder premixture for oral administration of cannabinoids.
- Cannabinoids are a group of chemicals found in Cannabis sativa, Cannabis indica, Cannabis ruderalis, Marijuana plant and related plant species. They are known to activate cannabinoid receptors (CB1 and CB2). These chemicals are also produced endogenously in humans and other animals. Cannabinoids are cyclic molecules exhibiting particular properties such as being lipophilic, have the ability to easily cross the blood-brain barrier, and having low toxicity.
- Cannabis sativa contains more than 400 chemicals and approximately 120 cannabinoids, the active constituents of cannabis, including tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), tetrahydrocannabivarin (THCV) and cannabigerol (CBG). Pharmacologically, the principal psychoactive constituent of cannabis is tetrahydrocannabinol (THC), which is used for treating a wide range of medical conditions, including glaucoma, AIDS wasting, neuropathic pain, treatment of spasticity associated with multiple sclerosis, fibromyalgia, and chemotherapy-induced nausea. THC is also effective in the treatment of allergies, inflammation, infection, depression, migraine, bipolar disorders, anxiety disorder, drug dependency and drug withdrawal syndromes.
- Oral administration of cannabinoids is a common route of administration. Cannabinoids are highly lipophilic, meaning that they are soluble in lipids and some organic solvents while being substantially insoluble or only sparsely soluble in water. Cannabinoids are soluble in highly non-polar solvents. Some of these solvents are pharmaceutically unacceptable, and the pharmaceutically acceptable solvents need to be used in high concentrations to produce solutions.
- Various solutions have been suggested in the prior art with respect to oral formulations for delivery of cannabinoids. Among these solutions, solid dosage forms, lozenges, chewing gums and pouches have been proposed. While these solutions may have certain benefits with respect to oral delivery of cannabinoids, such as CBD or THC, these solutions have been mainly focused on either release from the application forms or certain components that allow effective absorption of the cannabinoids in the mucosa.
- Generally, less attention have been given to accurate dosing of cannabinoids and reliability of formulating cannabinoids, such as CBD or THC, in oral formulations. For instance, homogeneous products would be beneficial but to some degree have been counteracted by the nature of the cannabinoids being highly lipophilic and thereby potentially interacting with remaining components of the oral formulations.
- It is a desire in the prior art with improved homogeneity but hitherto provided solutions have traditionally been considered less suitable also partly in view of the desire to provide fast releasing products. Already available means for providing improved homogeneity have shown to be associated with drawbacks while at the same time being required to provide fast release of the cannabinoids.
- In formulating solid dosage forms, various challenges are associated with obtaining a homogenous mixture where variations are avoided and a safe and convenient delivery may be obtained. Also, the general formulation of the tablets offering convenience to the user need not be compromised which is often the case if conventional delivery means are applied.
- Furthermore, it is preferable that a formulation is provided that may also help in obtaining improved sensorics properties of oral cannabinoid delivery. Here, important sensorics properties include friability, texture, flavor perception, sweetness perception and off-notes associated with cannabinoids. These properties are both relevant from a convenience perspective in solid dosage forms, but certainly also in order to support an appropriate delivery of cannabinoids from the tablets and avoid adverse side effects of cannabinoids.
- Another challenge is that cannabinoids tend to be associated with off-notes during administration due to the specific physiochemical properties of the compounds. The taste masking challenge is more profound when a higher release of cannabinoids are delivered. If off-notes are the predominant sensation during administration, convenience may be affected and even more critically, the delivery of cannabinoids may also be affected.
- Hence, there is a need in the prior art for powders and formulations that solve the above-referenced challenges and problems of the prior art. In particular, there is a need in the prior art for powders to be applied in various administration form, such as tablets, pouches, chewing gums and lozenges, that are both associated with a suitable uniformity of content of the cannabinoids and offer suitable sensorial properties. More particularly, it is a desire that these formulations are also acceptable or improved with respect to taste masking and give a desired release during administration.
- Accordingly, there is provided a powder premixture for oral administration of cannabinoids, comprising a cannabinoid powder composition comprising one or more isolated cannabinoids in an amount of at least 2% by weight of the powder premixture; a lipid composition comprising one or more triglycerides in an amount of at least 1.0% by weight of the powder premixture; and a sweetener powder composition comprising one or more sweeteners, wherein the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:4.
- In another aspect of the invention, there is provided oral administration forms where this powder is incorporated, such as partly or completely.
- In yet another aspect, there is provided methods for preparing powder premixtures for oral administration of cannabinoids.
- One of the advantages of the present invention is that accurate dosing of cannabinoids and reliability of formulating cannabinoids, such as CBD or THC, in oral formulations may be provided. For instance, homogeneous products would be beneficial but to some degree have been counteracted by the nature of the cannabinoids being highly lipophilic and thereby potentially interacting with remaining components of the oral formulations.
- Traditionally, hitherto provided solutions have been considered less suitable also partly in view of the desire to provide fast releasing products. Already available means for providing improved homogeneity have shown to be associated with drawbacks while at the same time being required to provide fast release of the cannabinoids.
- One prejudice in the prior art is that cannabinoids being highly lipophilic may not be properly formulated with other components in a powder or solid dosage form without compromising the other components and the interacting in the system.
- Another advantage is that the formulation according to the invention may also help in obtaining improved sensorics properties of oral cannabinoid delivery. Here, important sensorics properties include friability, texture, flavor perception, sweetness perception and off-notes associated with cannabinoids. These properties are both relevant from a convenience perspective in solid dosage forms, but certainly also in order to support an appropriate delivery of cannabinoids from the solid dosage forms and avoid adverse side effects of cannabinoids.
- Yet another advantage is that the invention may help addressing off-notes during administration. The taste masking challenge is more profound when a higher release of cannabinoids are delivered by such solid dosage forms. If off-notes are the predominant sensation during administration, convenience may be affected and even more critically, the delivery of cannabinoids may also be affected.
- In terms of improved content of uniformity, surprisingly results were seen. Generally, the method used for content uniformity of samples is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units. The acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance. An appropriate analytical method is selected for content uniformity, e.g. employing standard HPLC techniques.
- When attempting to obtain a high degree of even distribution, insufficient mixing may lead to uneven distribution, such as undesirable agglomeration of particles within certain parts of the solid dosage form. Also, even if mixing very thoroughly the ingredients, an undesirable handling of the mixture from the mixing to a tableting machine may lead to segregation. For example, smaller particles may typically segregate to the bottom part of a container, thereby leading to different particle distributions for different solid dosage forms. Particularly when the different ingredients have different particle sizes, segregation may lead to different contents in different solid dosage forms.
- Compared to powders where the lipid composition according to the invention was not applied in a formulation with a cannabinoid powder composition, content of uniformity was inferior. This was highly surprising to the inventors of the instant invention and was not expected in view of the prior art attempts to provide suitable solutions.
- In some embodiments of the invention, a series of at least 5 samples each having the same fixed weight in the range of 0.25-2 g and taken from the powder mixture to be analyzed varies with a relative standard deviation (RSD) below 10% with respect to the content of the one or more cannabinoids.
- In some embodiments of the invention, a series of at least 5 samples each having the same fixed weight in the range of 0.25-2 g and taken from the powder mixture to be analyzed varies with a relative standard deviation (RSD) below 5% with respect to the content of the one or more cannabinoids.
- In some embodiments of the invention, a series of at least 5 samples each having the same fixed weight in the range of 0.25-2 g and taken from the powder mixture to be analyzed varies with a relative standard deviation (RSD) below 2% with respect to the content of the one or more cannabinoids.
- In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:5. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:7.
- In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:10. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:7. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:5.
- In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:40 to 1:10. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:40 to 1:12. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:40 to 1:15. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:40 to 1:20.
- In some embodiments of the invention, the one or more triglycerides is of vegetable origin. In some embodiments of the invention, the one or more triglycerides is free of triglycerides of animal origin.
- In some embodiments of the invention, the one or more triglycerides is selected from one or more C4 to C14 triglycerides. In some embodiments of the invention, the one or more triglycerides is selected from one or more C4 to C12 triglycerides In some embodiments of the invention, the one or more triglycerides is selected from one or more C6 to C14 triglycerides. In some embodiments of the invention, the one or more triglycerides is selected from one or more C6 to C12 triglycerides. In some embodiments of the invention, the one or more triglycerides is selected from one or more C6 to C10 triglycerides In some embodiments of the invention, the one or more triglycerides is selected from one or more C8 to C12 triglycerides. In some embodiments of the invention, the one or more triglycerides is selected from one or more C8 to C10 triglycerides.
- In some embodiments of the invention, the one or more triglycerides comprises a partially hydrogenated vegetable oil. In some embodiments of the invention, the one or more triglycerides comprises a fully hydrogenated vegetable oil (HVO).
- In some embodiments of the invention, the one or more triglycerides is selected from triglycerides being liquid at or above 0 Degree Celsius.
- In some embodiments of the invention, the one or more triglycerides is a blend of a number of triglycerides.
- In some embodiments of the invention, the one or more triglycerides is heated to a temperature above ambient temperature before being added in the premixture.
- In some embodiments of the invention, the one or more triglycerides is heated to a temperature of 50 to 80 Degree Celsius before being added in the premixture. In some embodiments of the invention, the one or more triglycerides is heated to a temperature of 50 to 70 Degree Celsius before being added in the premixture. In some embodiments of the invention, the one or more triglycerides is heated to a temperature of 50 to 60 Degree Celsius before being added in the premixture. In some embodiments of the invention, the one or more triglycerides is heated to a temperature of 60 to 70 Degree Celsius before being added in the premixture. In some embodiments of the invention, the one or more triglycerides is heated to a temperature of 40 to 80 Degree Celsius before being added in the premixture. In some embodiments of the invention, the one or more triglycerides is heated to a temperature of 40 to 70 Degree Celsius before being added in the premixture.
- In some embodiments of the invention, the one or more triglycerides is selected from triglycerides being liquid at or above 20 Degree Celsius. In some embodiments of the invention, the one or more triglycerides is selected from triglycerides being liquid at or above 25 Degree Celsius. In some embodiments of the invention, the one or more triglycerides is selected from triglycerides being liquid at or above 30 Degree Celsius. In some embodiments of the invention, the one or more triglycerides is selected from triglycerides being liquid at or above 40 Degree Celsius.
- In some embodiments of the invention, the one or more triglycerides is selected from triglycerides with a melting temperature of 25 to 50 Degree Celsius. In some embodiments of the invention, the one or more triglycerides is selected from triglycerides with a melting temperature of 25 to 40 Degree Celsius. In some embodiments of the invention, the one or more triglycerides is selected from triglycerides with a melting temperature of 30 to 40 Degree Celsius. In some embodiments of the invention, the one or more triglycerides is selected from triglycerides with a melting temperature of 30 to 50 Degree Celsius.
- In some embodiments of the invention, the one or more triglycerides comprises caprylic acid in an amount of 50 to 80% by weight. In some embodiments of the invention, the one or more triglycerides comprises caprylic acid in an amount of 50 to 70% by weight. In some embodiments of the invention, the one or more triglycerides comprises caprylic acid in an amount of 50 to 90% by weight. In some embodiments of the invention, the one or more triglycerides comprises caprylic acid in an amount of 60 to 90% by weight. In some embodiments of the invention, the one or more triglycerides comprises caprylic acid in an amount of 65 to 80% by weight.
- In some embodiments of the invention, the one or more triglycerides comprises capric acid in an amount of 20 to 45% by weight. In some embodiments of the invention, the one or more triglycerides comprises capric acid in an amount of 20 to 50% by weight. In some embodiments of the invention, the one or more triglycerides comprises capric acid in an amount of 20 to 40% by weight. In some embodiments of the invention, the one or more triglycerides comprises capric acid in an amount of 20 to 35% by weight. In some embodiments of the invention, the one or more triglycerides comprises capric acid in an amount of 25 to 50% by weight. In some embodiments of the invention, the one or more triglycerides comprises capric acid in an amount of 25 to 40% by weight. In some embodiments of the invention, the one or more triglycerides comprises capric acid in an amount of 30 to 50% by weight. In some embodiments of the invention, the one or more triglycerides comprises capric acid in an amount of 30 to 45% by weight. In some embodiments of the invention, the one or more triglycerides comprises capric acid in an amount of 20 to 30% by weight.
- In some embodiments of the invention, the one or more triglycerides comprises caprylic acid in an amount of 65 to 80% by weight and capric acid in an amount of 20 to 35% by weight.
- In some embodiments of the invention, the one or more triglycerides comprises caprylic acid in an amount of 50 to 65% by weight and capric acid in an amount of 30 to 45% by weight.
- In some embodiments of the invention, the one or more triglycerides comprises coconut oil. In some embodiments of the invention, the one or more triglycerides is consisting essentially of coconut oil. In some embodiments of the invention, the one or more triglycerides is coconut oil.
- In some embodiments of the invention, the one or more triglycerides is present in an amount of at least 1.5% by weight of the powder premixture.
- In some embodiments of the invention, the one or more triglycerides is present in an amount of at least 2.0% by weight of the powder premixture.
- In some embodiments of the invention, the one or more triglycerides is present in an amount of at least 2.5% by weight of the powder premixture.
- In some embodiments of the invention, the one or more triglycerides is present in an amount of at least 3.0% by weight of the powder premixture.
- In some embodiments of the invention, the one or more triglycerides is present in an amount of at least 4.0% by weight of the powder premixture.
- In some embodiments of the invention, the one or more triglycerides is present in an amount of at least 5.0% by weight of the powder premixture. In some embodiments of the invention, the one or more triglycerides is present in an amount of at least 6.0% by weight of the powder premixture. In some embodiments of the invention, the one or more triglycerides is present in an amount of at least 7.0% by weight of the powder premixture. In some embodiments of the invention, the one or more triglycerides is present in an amount of at least 8.0% by weight of the powder premixture. In some embodiments of the invention, the one or more triglycerides is present in an amount of at least 9.0% by weight of the powder premixture. In some embodiments of the invention, the one or more triglycerides is present in an amount of at least 10.0% by weight of the powder premixture.
- In some embodiments of the invention, the one or more sweeteners is present in an amount of at least 50% by weight of the powder premixture.
- In some embodiments of the invention, the one or more sweeteners is present in an amount of at least 60% by weight of the powder premixture.
- In some embodiments of the invention, the one or more sweeteners is present in an amount of at least 70% by weight of the powder premixture.
- In some embodiments of the invention, the one or more sweeteners is present in an amount of at least 75% by weight of the powder premixture.
- In some embodiments of the invention, the one or more sweeteners is present in an amount of at least 80% by weight of the powder premixture. In some embodiments of the invention, the one or more sweeteners is present in an amount of at least 90% by weight of the powder premixture. In some embodiments of the invention, the one or more sweeteners is present in an amount of at least 95% by weight of the powder premixture.
- In some embodiments of the invention, the one or more sweeteners is selected from the group consisting of saccharide-containing components, such as sucrose, dextrose, maltose, saccharose, lactose, sorbose, dextrin, trehalose, D-tagatose, dried invert sugar, fructose, levulose, galactose, corn syrup solids, glucose syrup, and the like, alone or in combination. These sugar sweeteners may also be included as a humectant.
- In some embodiments of the invention, the one or more sweeteners comprises dextrose. In some embodiments of the invention, the one or more sweeteners is dextrose.
- In some embodiments of the invention, the one or more sweeteners comprises dextrin. In some embodiments of the invention, the one or more sweeteners is dextrin.
- In some embodiments of the invention, the one or more sweeteners comprises sucrose. In some embodiments of the invention, the one or more sweeteners is sucrose.
- In some embodiments of the invention, the one or more sweeteners comprises fructose. In some embodiments of the invention, the one or more sweeteners is fructose.
- In some embodiments of the invention, the one or more sweeteners comprises one or more sugar alcohols.
- In some embodiments of the invention, the one or more sugar alcohols is selected from the group consisting of sorbitol, xylitol, maltitol, isomalt, mannitol, erythritol, lactitol, and combinations thereof.
- In some embodiments of the invention, the one or more sugar alcohols is selected from the group consisting of xylitol, erythritol, maltitol, mannitol, and combinations thereof.
- In some embodiments of the invention, the one or more sugar alcohols comprises xylitol. In some embodiments of the invention, the one or more sugar alcohols is xylitol.
- In some embodiments of the invention, the one or more sugar alcohols comprises erythritol. In some embodiments of the invention, the one or more sugar alcohols is erythritol.
- In some embodiments of the invention, the one or more sugar alcohols comprises mannitol. In some embodiments of the invention, the one or more sugar alcohols is mannitol.
- In some embodiments of the invention, the one or more sugar alcohols comprises maltitol. In some embodiments of the invention, the one or more sugar alcohols is maltitol.
- In some embodiments of the invention, the one or more sugar alcohols comprises granulated sugar alcohol particles.
- In some embodiments of the invention, the one or more sugar alcohols comprises non-directly (non-DC) sugar alcohol particles.
- In some embodiments of the invention, the one or more sweeteners comprises one or more saccharides.
- In some embodiments of the invention, the one or more sweeteners comprises at least two types of sweetener particles.
- In some embodiments of the invention, the one or more sweeteners comprises sweetener particles having a particle size with more than 50% of the particles being below 250 microns. In some embodiments of the invention, the one or more sweeteners comprises sweetener particles having a particle size with more than 60% of the particles being below 250 microns. In some embodiments of the invention, the one or more sweeteners comprises sweetener particles having a particle size with more than 70% of the particles being below 250 microns. In some embodiments of the invention, the one or more sweeteners comprises sweetener particles having a particle size with more than 80% of the particles being below 250 microns.
- In some embodiments of the invention, the one or more sweeteners comprises sweetener particles having a particle size with more than 20% of the particles being above 500 microns. In some embodiments of the invention, the one or more sweeteners comprises sweetener particles having a particle size with more than 30% of the particles being above 500 microns. In some embodiments of the invention, the one or more sweeteners comprises sweetener particles having a particle size with more than 50% of the particles being above 500 microns.
- In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:40 to 1:1. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:30 to 1:1. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:20 to 1:1. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:15 to 1:1.
- In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:10 to 1:1. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:10 to 1:2. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:8 to 1:2.
- In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:7 to 1:2. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:6 to 1:2. In some embodiments of the invention, the weight ratio between the one or more triglycerides and the one or more isolated cannabinoids is in the range of 1:5 to 1:2.
- In some embodiments of the invention, the one or more isolated cannabinoids is present in an amount of at least 5% by weight of the powder premixture. In some embodiments of the invention, the one or more isolated cannabinoids is present in an amount of at least 7% by weight of the powder premixture.
- In some embodiments of the invention, the one or more isolated cannabinoids is present in an amount of at least 10% by weight of the powder premixture. In some embodiments of the invention, the one or more isolated cannabinoids is present in an amount of at least 15% by weight of the powder premixture.
- In some embodiments of the invention, the one or more isolated cannabinoids is present in an amount of at least 20% by weight of the powder premixture. In some embodiments of the invention, the one or more isolated cannabinoids is present in an amount of at least 25% by weight of the powder premixture.
- In some embodiments of the invention, the one or more isolated cannabinoids is present in an amount of at least 30% by weight of the powder premixture. In some embodiments of the invention, the one or more isolated cannabinoids is present in an amount of at least 35% by weight of the powder premixture. In some embodiments of the invention, the one or more isolated cannabinoids is present in an amount of at least 40% by weight of the powder premixture.
- In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder mixture in an amount of 0.1 to 400 mg. In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder mixture in an amount of 0.1 to 300 mg. In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder mixture in an amount of to 250 mg.
- In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder premixture in an amount of 1 to 200 mg. In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder premixture in an amount of 1 to 150 mg. In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder premixture in an amount of 1 to 100 mg.
- In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder premixture in an amount of 5 to 200 mg. In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder premixture in an amount of 5 to 100 mg.
- In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder premixture in an amount of 3 to 200 mg. In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder premixture in an amount of 3 to 100 mg.
- In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder premixture in an amount of 2 to 200 mg. In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder premixture in an amount of 2 to 100 mg.
- In some embodiments of the invention, the one or more isolated cannabinoids is present in the powder premixture in an amount of 10 to 100 mg.
- In some embodiments of the invention, the one or more isolated cannabinoids is selected from the group consisting of cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), and combinations thereof.
- In some embodiments of the invention, the one or more isolated cannabinoids is selected from the group consisting of tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), and combinations thereof.
- In some embodiments of the invention, the one or more isolated cannabinoids comprise cannabigerol (CBG).
- In an embodiment of the invention, the one or more cannabinoids comprise cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), salts and derivatives thereof.
- In an embodiment of the invention, the one or more cannabinoids comprise tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), salts and derivatives thereof.
- In an embodiment of the invention, the one or more cannabinoids comprise cannabigerol (CBG), salts and derivatives thereof.
- In some embodiments of the invention, the cannabinoid is selected from the group consisting of cannabidiol (CBD), cannabidiolic acid (CBDA), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), cannabielsoin (CBE), iso-tetrahydrocannabinol (iso-THC), cannabicyclol (CBL), cannabicitran (CBT), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), salts thereof, derivatives thereof and mixtures of cannabinoids.
- In an embodiment of the invention, the one or more cannabinoids comprise cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), salts and derivatives thereof. In an embodiment of the invention the one or more cannabinoids comprises CBD, salts and derivatives thereof, including analogues and homologues. In an embodiment of the invention said one or more cannabinoids comprises CBD. In an embodiment of the invention said one or more cannabinoids is CBD.
- In an embodiment of the invention, the one or more cannabinoids comprise tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), salts and derivatives thereof. In an embodiment of the invention said one or more cannabinoids comprises tetrahydrocannabinol (THC). Preferably THC is intended to mean (—)-trans-Δ9-tetrahydrocannabinol, i.e. (6aR,10aR)-delta-9-tetrahydrocannabinol). In an embodiment of the invention said one or more cannabinoids is THC.
- In an embodiment of the invention, wherein the one or more cannabinoids comprise at least two cannabinoids. In an embodiment of the invention said one or more cannabinoids comprises a combination of several cannabinoids, such as THC and CBD. In an embodiment of the invention said one or more cannabinoids is a combination of THC and CBD.
- In some embodiments of the invention, the one or more isolated cannabinoids is present in a purity of at least 90% (w/w).
- In some embodiments of the invention, the one or more isolated cannabinoids is present in a purity of at least 95% (w/w).
- In some embodiments of the invention, the one or more isolated cannabinoids is present in a purity of at least 98% (w/w).
- In some embodiments of the invention, the one or more isolated cannabinoids does not include cannabinoid distillates.
- In some embodiments of the invention, the one or more isolated cannabinoids does not include cannabinoid extracts.
- In some embodiments of the invention, the one or more isolated cannabinoids does not include one or more isolated cannabinoids in a purity of less than 90% (w/w).
- In some embodiments of the invention, the one or more isolated cannabinoids is dissolved in the one or more triglycerides before admixture with the sweetener powder composition.
- In some embodiments of the invention, the one or more isolated cannabinoids is added in the sweetener powder composition before admixture with the one or more triglycerides.
- In some embodiments of the invention, the one or more triglycerides is added in the sweetener powder composition before admixture with the one or more isolated cannabinoids.
- In some embodiments of the invention, further ingredients are added in the premixture.
- Generally, when it is mentioned that further ingredients are “added in the premixture” or similar wordings, the intended meaning is that these ingredients are added to the total mixture. Hence, the premixture could also be added to the further ingredients depending on the procedure and amounts involved. Usually, a “premix” or “premixture” are expressions used interchangeably. Further ingredients combined with the premixture is usually denoted a “powder blend” or similar wordings. The “powder blend” may comprise further ingredients.
- In some embodiments of the invention, further ingredients are added in the premixture or in the powder blend selected from the group consisting of flavors, dry-binders, tableting aids, anti-caking agents, surfactants, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, further active ingredients, water-soluble indigestible polysaccharides, water-insoluble polysaccharides, and any combination thereof.
- In some embodiments of the invention, one or more flavoring agents is added in the premixture or powder blend.
- In some embodiments of the invention, a high intensity sweetener is added in the premixture or powder blend.
- In some embodiments of the invention, the premixture is a ready-to-use premixture.
- In some embodiments of the invention, the premixture is to be applied in an amount of 10-99.9% by weight in combination with further ingredients.
- In an aspect of the invention, a solid dosage form for oral administration of cannabinoids is provided comprising a premixture according to the invention.
- In some embodiments of the invention, the premixture is present in an amount of 10-100% by weight of the solid dosage form. In some embodiments of the invention, the premixture is present in an amount of about 100% by weight of the solid dosage form. In some embodiments of the invention, the premixture is present in an amount of substantially 100% by weight of the solid dosage form. In some embodiments of the invention, the premixture is present in an amount of 10-90% by weight of the solid dosage form.
- In some embodiments of the invention, the premixture is present in an amount of 15-75% by weight of the solid dosage form. In some embodiments of the invention, the premixture is present in an amount of 20-70% by weight of the solid dosage form. In some embodiments of the invention, the premixture is present in an amount of 25-60% by weight of the solid dosage form. In some embodiments of the invention, the premixture is present in an amount of 30-50% by weight of the solid dosage form.
- In some embodiments of the invention, a series of at least 10 solid dosage forms comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 5%.
- Generally, the method used for content uniformity of samples is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units. The acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance. An appropriate analytical method is selected for content uniformity.
- In some embodiments of the invention, a series of at least 10 solid dosage forms comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 2%.
- In an aspect of the invention, a tablet for oral administration of cannabinoids is provided comprising a premixture according to the invention.
- In some embodiments of the invention, the premixture is present in an amount of 10-100% by weight of the tablet.
- In some embodiments of the invention, the premixture is present in an amount of 15-75% by weight of the tablet.
- In some embodiments of the invention, the tablet comprises one or more sugar alcohols in addition to the one or more sweeteners in the premixture selected from the group consisting of sorbitol, erythritol, maltitol, xylitol, isomalt, lactitol, mannitol, and combinations thereof.
- In some embodiments of the invention, the tablet comprises one or more sweeteners in addition to the one or more sweeteners in the premixture in an amount of 20 to 80% by weight of the tablet.
- In some embodiments of the invention, a series of at least 10 tablets comprise the one or more active pharmaceutical ingredients in an amount varying with a relative standard deviation (RSD) below 5%.
- Generally, the method used for content uniformity of tablets is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units. The acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance. An appropriate analytical method is selected for content uniformity.
- In some embodiments of the invention, a series of at least 10 tablets comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 2%.
- In some embodiments of the invention, the tablet comprises directly compressible (DC) sugar alcohol particles and non-directly compressible (non-DC) sugar alcohol particles.
- In some embodiments of the invention, the tablet has a weight ratio between said non-DC sugar alcohol particles and said DC sugar alcohol particles, which is between 0.2 and 1.2.
- In some embodiments of the invention, the tablet has a weight ratio between said non-DC sugar alcohol particles and said DC sugar alcohol particles, which is between 0.3 and 0.7.
- In some embodiments of the invention, the tablet comprises one or more insoluble components selected from the group consisting of silica, microcrystalline cellulose, cellulose, silicified microcrystalline cellulose, clay, talc, starch, pregelatinized starch, calcium carbonate, dicalcium phosphate, magnesium carbonate, magnesium-alumino-metasilicates, hyper porous silica, and mixtures thereof.
- In some embodiments of the invention, the tablet comprises one or more binders in an amount of 0.1 to 6% by weight of the tablet.
- In some embodiments of the invention, the tablet comprises at least two modules, and wherein the premixture is comprised in at least one module of the tablet.
- In some embodiments of the invention, the tablet comprises further ingredients selected from the group consisting of flavors, dry-binders, tableting aids, anti-caking agents, surfactants, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, further active ingredients, water-soluble indigestible polysaccharides, water-insoluble polysaccharides, and any combination thereof.
- In an aspect of the invention, a chewing gum for oral administration of cannabinoids is provided comprising a premixture according to the invention.
- In some embodiments of the invention, the premixture is present in an amount of 15-75% by weight of the chewing gum.
- In some embodiments of the invention, a series of at least 10 chewing gums comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 5%.
- Generally, the method used for content uniformity of cannabinoids in chewing gums is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units. The acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance. An appropriate analytical method is selected for content uniformity.
- In some embodiments of the invention, a series of at least 10 chewing gums comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 2%.
- In some embodiments of the invention, the chewing gum comprises gum base in an amount of 20-40% by weight of the chewing gum, and wherein the chewing gum is designed to be masticated into a coherent residual containing water-insoluble components.
- In some embodiments of the invention, the chewing gum comprises gum base, and wherein the gum base comprises an elastomer selected from the group consisting of styrene-butadiene rubber (SBR), butyl rubber, polyisobutylene (PIB), and combinations thereof.
- In some embodiments of the invention, the chewing gum comprises gum base, and wherein the gum base comprises at least 5% by weight of elastomer.
- In some embodiments of the invention, the chewing gum comprises gum base, and wherein the gum base comprises gum base resins selected from natural resins and/or synthetic resins.
- In some embodiments of the invention, the chewing gum comprises gum base, and wherein the gum base comprises at least 5% by weight of gum base resins.
- In some embodiments of the invention, the chewing gum comprises gum base, and wherein the gum base comprises gum base particles having an average particle size of between 400 μm and 1400 μm.
- In some embodiments of the invention, the chewing gum comprises one or more sugar alcohols in addition to the one or more sweeteners in the premixture selected from the group consisting of sorbitol, erythritol, maltitol, xylitol, isomalt, lactitol, mannitol, and combinations thereof.
- In some embodiments of the invention, the chewing gum comprises one or more sweeteners in addition to the one or more sweeteners in the premixture in an amount of 20 to 60% by weight of the chewing gum.
- In some embodiments of the invention, a series of at least 10 compressed chewing gums comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 5%.
- Generally, the method used for content uniformity of cannabinoids in compressed chewing gums is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units. The acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance. An appropriate analytical method is selected for content uniformity.
- In some embodiments of the invention, a series of at least 10 compressed chewing gums comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 2%.
- In some embodiments of the invention, the chewing gum comprises at least two compressed modules, and wherein the premixture is comprised in at least one of the two compressed modules.
- In some embodiments of the invention, the chewing gum comprises at least two compressed modules, and wherein the two modules are different in composition.
- In some embodiments of the invention, the chewing gum comprises at least two compressed modules, and wherein at least one of the two compressed modules does not comprise gum base.
- In some embodiments of the invention, the chewing gum comprises further ingredients selected from the group consisting of flavors, dry-binders, tableting aids, anti-caking agents, surfactants, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, further active ingredients, water-soluble indigestible polysaccharides, water-insoluble polysaccharides, and any combination thereof.
- In an aspect of the invention, a lozenge for oral administration of cannabinoids is provided comprising a premixture according to the invention.
- In some embodiments of the invention, the premixture is present in an amount of 10-100% by weight of the lozenge.
- In some embodiments of the invention, the premixture is present in an amount of 15-75% by weight of the lozenge.
- In some embodiments of the invention, a series of at least 10 lozenges comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 5%.
- Generally, the method used for content uniformity of lozenges is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units. The acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance. An appropriate analytical method is selected for content uniformity.
- In some embodiments of the invention, a series of at least 10 lozenges comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 2%.
- In some embodiments of the invention, the lozenge comprises one or more sugar alcohols in addition to the one or more sweeteners in the premixture selected from the group consisting of sorbitol, erythritol, maltitol, xylitol, isomalt, lactitol, mannitol, and combinations thereof.
- In some embodiments of the invention, the lozenge comprises one or more sweeteners in addition to the one or more sweeteners in the premixture in an amount of 20 to 60% by weight of the lozenge.
- In some embodiments of the invention, the lozenge comprises one or more insoluble components selected from the group consisting of silica, microcrystalline cellulose, cellulose, silicified microcrystalline cellulose, clay, talc, starch, pregelatinized starch, calcium carbonate, dicalcium phosphate, magnesium carbonate, magnesium-alumino-metasilicates, hyper porous silica, and mixtures thereof.
- In some embodiments of the invention, the lozenge comprises one or more disintegrants operable to disintegrate the lozenge within a period of 1 minute or less in contact with oral saliva.
- In some embodiments of the invention, the lozenge comprises one or more disintegrants selected from the group consisting of sodium croscarmellose, crospovidone, sodium starch glycolate, and combinations thereof.
- In some embodiments of the invention, the lozenge comprises one or more disintegrants in an amount of 0.5 to 25% by weight of the lozenge.
- In some embodiments of the invention, the lozenge comprises further ingredients selected from the group consisting of flavors, dry-binders, tableting aids, anti-caking agents, surfactants, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, further active ingredients, water-soluble indigestible polysaccharides, water-insoluble polysaccharides, and any combination thereof.
- In an aspect of the invention, a pouch for oral administration of cannabinoids is provided comprising a premixture according to the invention.
- In some embodiments of the invention, the premixture is present in an amount of 10-100% by weight of the pouch.
- In some embodiments of the invention, the premixture is present in an amount of 15-75% by weight of the pouch.
- In some embodiments of the invention, a series of at least 10 pouches comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 5%.
- Generally, the method used for content uniformity of pouches is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units. The acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance. An appropriate analytical method is selected for content uniformity.
- In some embodiments of the invention, a series of at least 10 pouches comprise the one or more cannabinoids in an amount varying with a relative standard deviation (RSD) below 2%.
- In some embodiments of the invention, the pouch comprises one or more insoluble components selected from the group consisting of silica, clay, talc, starch, pregelatinized starch, calcium carbonate, dicalcium phosphate, magnesium carbonate, magnesium-alumino-metasilicates, hyper porous silica and mixtures thereof.
- In some embodiments of the invention, the pouch comprises one or more insoluble fibres.
- In some embodiments of the invention, the pouch comprises one or more insoluble fibres selected from wheat fibers, pea fibers, rice fiber, maize fibers, oat fibers, tomato fibers, barley fibers, rye fibers, sugar beet fibers, buckwheat fibers, potato fibers, cellulose fibers, apple fibers, cocoa fibers, bran fibers, bamboo fibers, powdered cellulose, microcrystalline cellulose and combinations thereof.
- In some embodiments of the invention, the pouch comprises one or more sugar alcohols in addition to the one or more sweeteners in the premixture selected from the group consisting of sorbitol, erythritol, maltitol, xylitol, isomalt, lactitol, mannitol, and combinations thereof.
- In some embodiments of the invention, the pouch comprises one or more sweeteners in addition to the one or more sweeteners in the premixture in an amount of 20 to 60% by weight of the pouch.
- In some embodiments of the invention, the pouch comprises further ingredients selected from the group consisting of flavors, dry-binders, anti-caking agents, surfactants, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, further active ingredients, water-soluble indigestible polysaccharides, water-insoluble polysaccharides, and any combination thereof.
- In an aspect of the invention, there is provided a method of preparing a powder premixture for oral administration of cannabinoids, comprising the steps of:
-
- i) dissolving or dispersing a cannabinoid powder composition comprising one or more isolated cannabinoids in a lipid composition comprising one or more triglycerides followed by
- ii) mixing a sweetener powder composition comprising one or more sweeteners with the mixture obtained in i) to obtain a powder premixture,
- wherein the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:4.
- In some embodiments of the invention, the one or more triglycerides is heated to a temperature above ambient temperature before being added in the premixture.
- In an aspect of the invention, there is provided a powder premixture for oral administration of cannabinoids, comprising the steps of:
-
- i) mixing a sweetener powder composition comprising one or more sweeteners with a cannabinoid powder composition comprising one or more isolated cannabinoids followed by
- ii) mixing a lipid composition comprising one or more triglycerides with the mixture obtained in i) to obtain a powder premixture,
- wherein the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:4.
- In some embodiments of the invention, the one or more triglycerides is heated to a temperature above ambient temperature before being added in the premixture.
- In an aspect of the invention, there is provided a powder premixture for oral administration of cannabinoids, comprising the steps of:
-
- i) mixing a sweetener powder composition comprising one or more sweeteners with a lipid composition comprising one or more triglycerides followed by
- ii) mixing a cannabinoid powder composition comprising one or more isolated cannabinoids with the mixture obtained in i) to obtain a powder premixture,
- wherein the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:4.
- In some embodiments of the invention, the one or more triglycerides is heated to a temperature above ambient temperature before being added in the premixture.
- The verb “to comprise” as is used in this description and in the claims and its conjugations are used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition, reference to an element by the indefinite article “a” or “an” does not exclude the possibility that more than one of the elements are present, unless the context clearly requires that there is one and only one of the elements. The indefinite article “a” or “an” thus usually means “at least one”. Additionally, the words “a” and “an” when used in the present document in connection with the word comprising or containing denote “one or more.” The expression “one or more” is intended to mean one, two, three or more.
- As used herein, the term “approximately” or “about” in reference to a number are generally taken to include numbers that fall within a range of 5%, 10%, 15%, or 20% in either direction (greater than or less than) of the number unless otherwise stated or otherwise evident from the context (except where such number would be less than 0% or exceed 100% of a possible value).
- As used herein, the term “%” and “percent” refers to percent by weight, unless otherwise is stated.
- The term “particle size” relates to the ability of the particles to move through or be retained by sieve holes of a specific size. As used herein, the term “particle size” refers to the average particle size as determined according to European Pharmacopoeia 9.1 when using test method 2.9.38 particle size distribution estimation by analytical sieving, unless otherwise specifically is mentioned.
- The term “particle” or similar wording is intended to denote a single, discrete composition of solid matter, such as a granule or individual elements in powder, having a certain size that may deviate considerable.
- In the present context the term “release” refers to the released substance being liberated from the solid dosage form. In some embodiments, the process of releasing a substance corresponds to the substance being dissolved in saliva. The term “release” in the present context is intended to mean tested under “in vivo” conditions, if not stated otherwise. In the present context, when the solid dosage form is masticated, “in vivo” conditions is intended to mean that a sample is masticated with a chewing frequency of 60 chews pr. minute for a certain period of time in a test panel of 8 test persons, if not stated otherwise. These test persons abstain from eating and drinking at least 30 minutes before initiation of any test. The test persons are healthy persons appointed on an objective basis according to specified requirements.
- The term “sustained release” or “extended release” is herein intended to mean prolonged release over time. The term “rapid release” or “quick release” or “high release” is herein intended to mean a higher content released for a given period of time.
- By the phrase “texture” is meant a qualitative measure of the properties of the solid dosage form and of the overall mouth-feel experienced by the user during use. Thus, the term “texture” encompasses measurable quantities such as hardness as well as more subjective parameters related to the feel experienced by a user.
- The term “sustained release” or “extended release” is herein intended to mean prolonged release over time. The term “rapid release” or “quick release” or “high release” is herein intended to mean a higher content released for a given period of time. The term “controlled release” is intended to mean a release of a substance from a solid dosage form by the aid of active use of the solid dosage form in the oral cavity of the subject, whereby the active use is controlling the amount of substance released.
- A “self-emulsifying agent” is an agent which will form an emulsion when presented with an alternate phase with a minimum energy requirement. In contrast, an emulsifying agent, as opposed to a self-emulsifying agent, is one requiring additional energy to form an emulsion.
- Due to the poor solubility of certain active ingredients in physiological fluids, it is an unmet need to solubilize cannabinoids upon mixture with the body physiological fluids to facilitate bio-absorption. To overcome low oral bioavailability, various lipid-based drug delivery systems and self-emulsifying systems have been developed. Lipid-based delivery systems and particularly self-emulsifying drug delivery systems (SEDDS) have been demonstrated to increase the solubility, dissolution and bioavailability of many insoluble active ingredients. However, lipid-based and SEDDS delivery systems are very limited by the amount of active ingredient loading that has to be dissolved in the vehicle composition. Higher concentration of active ingredients are obtained using co-solvents, which enable loads of up to 30% in specific cases.
- Particular challenges are considered to arise in formulating solid dosage forms with SEDDS. For instance, challenges may arise with obtaining a homogenous mixture where variations are avoided and a safe and convenient delivery may be obtained. Also, the general formulation of the solid dosage forms offering convenience to the user need not be compromised which is often the case if precaution is not taken, such as in cases where a high load of active ingredients is needed.
- Particularly with respect to SEDDS, the formulation of the present invention may provide some clear benefits, both allowing a higher load of active ingredients and at the same time offer improved sensorics properties of the formulation during use. Other advantages are also present.
- Importantly, the presence of SEDDS or at least a self-emulsifying agent was seen to act in synergy with increased saliva generation. While increased saliva generation was seen to distribute certain active ingredients and allocate a higher load of active ingredients to for instance mucosal surfaces, the presence of SEDDS or at least a self-emulsifying agent was seen to further increase the uptake of these active ingredients through oral surfaces. Accordingly, the synergy between the presence of SEDDS or at least a self-emulsifying agent and increased saliva generation according to the invention was a surprise to the inventors. In some embodiments, increased saliva generation may result in a higher exposure of the active ingredients to mucosal surfaces. The presence of SEDDS may work to increase the affinity of the active ingredients from this saliva to the mucosa. Particularly, the potential of SEDDS to have a high load of active ingredients further contributes to the synergy of the solid dosage form according to the invention in combination with improved saliva generation.
- In the present context, SEDDS is a solid or liquid dosage form comprising an oil phase, a surfactant and optionally a co-surfactant, characterized primarily in that said dosage form can form oil-in-water emulsion spontaneously in the oral cavity or at ambient temperature (referring generally to body temperature, namely 37° C.). When a SEDDS enters the oral cavity, it is initially self-emulsified as emulsion droplets and rapidly dispersed throughout the oral cavity, and thus reducing the irritation caused by the direct contact of the active ingredient with the mucous membrane of the oral cavity, and hence helping on taste-masking active ingredients. In the oral cavity, the structure of the emulsion microparticulate will be changed or destroyed. The resulting microparticulate of micrometer or nanometer level can penetrate into the mucous membrane of for instance the oral cavity, and the absorbed oil droplets enter the blood circulation, thereby significantly improving the bioavailability of the active ingredient.
- In an embodiment of the invention, the self-emulsifying system comprises one or more emulsifiers and one or more oil carriers.
- In an embodiment of the invention, the self-emulsifying system comprises one or more emulsifiers, one or more oil carriers and one or more solubilizers.
- In an embodiment of the invention, the self-emulsifying system comprises one or more emulsifiers, one or more oil carriers, one or more solubilizers and one or more solvents.
- In an embodiment of the invention, the self-emulsifying system comprises one or more emulsifiers and one or more solvents.
- In an embodiment of the invention, the self-emulsifying system comprises one or more emulsifiers that have both emulsifying and solubilizing properties.
- In an embodiment of the invention, the self-emulsifying system comprises one or more emulsifiers that act as both an emulsifier and a carrier.
- In an embodiment of the invention, the self-emulsifying system comprises one or more emulsifiers that act as both an emulsifier, a carrier and a solubilizer.
- In an embodiment of the invention, the self-emulsifying system comprises one or more fatty acids, one or more glycerols, one or more waxes, one or more flavonoids and one or more terpenes.
- In an embodiment of the invention, the self-emulsifying system comprises one or more emulsifiers that have an HLB-value of more than 6, preferably of 8-18.
- In an embodiment of the invention, the one or more emulsifiers are selected from the group consisting of PEG-35 castor oil, PEG-6 oleoyl glycerides, PEG-6 linoleoyl glycerides, PEG-8 caprylic/capric glyceride, sorbitan monolaurate, sorbitan monooleate, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (60) sorbitan monostearate, polyoxyethylene (80) sorbitan monooleate, lauroylpoloxyl-32 glycerides, stearoyl polyoxyl-32 glycerides, polyoxyl-32 stearate, propylene glycol mono laurate, propylene glycol di laurate, and mixtures and combinations thereof.
- In an embodiment of the invention, the one or more emulsifiers comprise PEG-35 castor oil.
- In an embodiment of the invention, the oil carrier is selected from the group consisting of natural fatty acids; medium-chain triglycerides of caprylic (C8) and capric (C10) acids; propylene glycol esters of caprylic (C8) and capric (C10) acids; mono-, di- and triglycerides of mainly linoleic (C18:2) and oleic (C18:1) acids; fatty acid 18:1 cis-9; natural fatty acids; mono-, di- and triglycerides of oleic (C18:1) acid, and mixtures and combinations thereof.
- In an embodiment of the invention, the one or more solvents are selected from the group consisting of polyglyceryl-3 dioleate, 1,2-propandiol, polyethylene glycol 300, polyethylene glycol 400, diethylene glycol monoethyl ether, and mixtures and combinations thereof.
- In an embodiment of the invention, the oil carrier is selected from the group consisting of corn oil, Labrafac lipophile WL1349, Labrafac PG, Maisine CC, oleic acid, olive oil, Peceol, and mixtures and combinations thereof.
- In an embodiment of the invention, the one or more solvents are selected from the group consisting of polyglyceryl-3 dioleate, 1,2-propandiol, polyethylene glycol 300, polyethylene glycol 400, diethylene glycol monoethyl ether, and mixtures and combinations thereof.
- In an embodiment of the invention, the one or more solubilizers are selected from the group consisting of lauroylpoloxyl-32 glycerides; stearoyl polyoxyl-32 glycerides; Polyoxyl-32 stearate; synthetic copolymer of ethylene oxide (80) and propylene oxide (27); polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft co-polymer; alpha-, beta- or gamma cyclodextrins and derivatives thereof; pea proteins (globulins, albumins, glutelins proteins); and mixtures and combinations thereof.
- In an embodiment of the invention, the formulation further comprises one or more lipids in addition to the lipid composition according to the invention.
- The term “non-DC sugar alcohol particles” refers to particles of non-directly compressible (non-DC) sugar alcohol. It is noted that the terms “non-DC sugar alcohol particles” and “non-DC particles” are used interchangeably. In the present context, the non-DC sugar alcohol particles refer to particles which have not been preprocessed by granulation with e.g. other sugar alcohols or binders for the purpose of obtaining so-called direct compressible particles (DC). In the present context, non-DC sugar alcohol particles include particles obtained by crystallization followed by milling which does not involve other sugar alcohols or binders. Thus, non-DC sugar alcohol particles are considered as particles consisting of non-DC sugar alcohol.
- The term “DC sugar alcohol particles” refers to particles of direct compressible (DC) sugar alcohol. It is noted that the terms “DC sugar alcohol particles” and “DC particles” are used interchangeably. DC sugar alcohol particles may be obtained e.g. as particles of sugar alcohols having DC grade by nature, e.g. sorbitol, or by granulating non-DC sugar alcohol with e.g. other sugar alcohols or binders for the purpose of obtaining so-called direct compressible particles (DC). Also, granulation of non-DC sugar alcohol with water as binder is considered to result in “DC sugar alcohol particles” in the present context.
- The term “tableted” or “tablet” or “compressed” is intended to mean that the tablet composition is pressed in a tableting apparatus and mainly being composed of particulate matter. Although the terms imply a method step, in the present context, the terms are intended to mean the resulting tablet obtained in tableting a portion of particles. It is noted that a tablet or tableted composition that is mentioned to comprise particles eventually is to be understood as particles that have been pressed together in a tableting step.
- The following description outlines explanations of how the tablet of the invention may be produced and further details of what may be added to the inventive composition.
- Typically, the process of manufacture of the inventive tablet may be performed in a single tablet press, such as a rotary tablet press. But it may be a benefit under some circumstances to apply a separate tablet press.
- Preferably, the upper punch is convex which gives the upper face of the pressed tablet a concave form.
- It should of course be noted that the shape of the punches may vary depending of the desired tablet shape.
- In some embodiments of the invention, pressing of the tablets are performed at a force of 20 to 50 kN.
- In one aspect of the invention, the “tablet” is intended to mean a “fast disintegrating tablet” (“FDT”), or similar wording, such as “orally disintegrating tablet” (“ODT”). If not stated otherwise, if the tablet according to the invention is made as one module, contrary to two or more modules, then the tablet is intended to be an FDT tablet. If on the other hand, the tablet is made of more than one module, such as two modules, such additional module is intended to be a “lozenge” module, which provides a longer disintegration time compared to the FDT module according to the invention. The combination of an “FDT” module and a “lozenge” module contributes to another aspect of the invention. A “lozenge” module according to the invention may also comprise elements from the “FDT” modules but is generally different in composition, providing an extended disintegration time.
- The term “lozenge” is intended to cover that a “lozenge composition” has been “compressed” into a “lozenge module”. In the present context, a “lozenge module” or similar wording is intended to mean that the module during use in the oral cavity is intended to be sucked or licked on. The term “lozenge” is given the ordinary meaning in the art of lozenges. The intention is that the lozenge module may not be chewed. The intention is also that the FDT module may not be chewed. Generally, the “lozenge module” of the present invention may disintegrate upon sucking or licked in minutes, contrary to seconds for orally disintegrating tablets (ODT) or fast disintegrating tablets (FDT) tablets. Hence, the intention is that the “lozenge module” is to deliver the one or more cannabinoids over a longer period of time than the FDT module, if the tablet is made as a combination of the two modules.
- The term “module” is generally intended to be composed of a composition of matter with substantially the same characteristics throughout the module. Hence, if two module are present, then the two modules are different in composition and generally have two different characteristics throughout each module. In the present context, if only one module is present, then this module is considered an FDT tablet. On the other hand, if two modules are present, then the tablet is composed of an FDT tablet or FDT tablet module fused with a lozenge tablet or lozenge module. The term “fused” is intended to mean that the tablet is gathered together by means of compression force. Usually, if two modules are present, the lozenge module is made as the first module and the FDT module is made as the second module. The tablet may be composed of more than two module. The lozenge module may in certain embodiments be replaced by a gum base module. In the present context, the invention provides an attractive bi-phasic delivery of masking, even if the delivery of nicotine is “single-phased”.
- The term “cannabinoid composition” is intended to mean a volume of matter comprising one or more cannabinoids. The cannabinoid composition may contain other components than cannabinoids. The cannabinoid composition may constitute cannabinoids. The cannabinoid composition may constitute one type of cannabinoids. The cannabinoid composition may constitute two types of cannabinoids. The cannabinoid composition may constitute two or more types of cannabinoids.
- By the terms “water-insoluble gum base” or “gum base” or “gum base matrix” or similar wording is meant the mainly water-insoluble ingredients and hydrophobic gum base ingredients. The “gum base” may contain gum base polymers and plasticizers, waxes, emulsifiers, fats and/or fillers.
- The term “natural resin”, as used herein, means resinous compounds being either polyterpene derived from terpenes of natural origin or resinous compounds derived from gum rosin, wood rosin or tall-oil rosin.
- Elastomers provide the rubbery, elastomeric and bouncing nature to the gum, which varies depending on this ingredient's chemical structure and how it may be compounded with other ingredients. Elastomers suitable for use in the gum base and gum of the present invention may include natural or synthetic types. Polyvinyl acetate elastomer plasticizers are not considered elastomers according to the invention.
- Elastomers may be selected from the group consisting of styrene-butadiene copolymers, polyisobutylene, isobutylene-isoprene copolymers, polyethylene, polyurethane or any combination thereof. Preferred elastomers are styrene-butadiene copolymers (SBR), polyisobutylene and isobutylene-isoprene copolymers (BR).
- Styrene-butadiene type elastomers, or SBR as they may be called, typically are copolymers of from about 20:80 to 60:40 styrenes:butadiene monomers. The ratio of these monomers affects the elasticity of the SBR as evaluated by mooney viscosity. As the styrene:butadiene ratio decreases, the mooney viscosity decreases.
- The structure of SBR typically consists of straight chain 1,3-butadiene copolymerized with phenylethylene (styrene). The average molecular weight of SBR is <600,000 g/mole.
- Isobutylene-isoprene type elastomers, or butyl as they may be called, have molar percent levels of isoprene ranging from 0.2 to 4.0. Similar to SBR, as the isoprene:isobutylene ratio decreases, so does the elasticity, measured by mooney viscosity.
- The structure of butyl rubber typically consists of branched 2-methyl-1,3-butadiene (isoprene) copolymerized with branched 2-methylpropene (isobutylene). The average molecular weight of BR is in the range from 150,000 g/mole to 1,000,000 g/mole.
- Polyisobutylene, or PIB as they may be called, type elastomers are polymers of 2-methylpropene. The low molecular weight elastomers provide soft chew characteristics to the gum base and still provide the elastic qualities as do the other elastomers. Average molecular weights may range from about 30,000 to 120,000 g/mole and the penetration may range from about 4 millimeters to 20 millimeters.
- The higher the penetration, the softer the PIB. Similar to the SBR and butyl, the high molecular weight elastomers provide elasticity to the gum. Average molecular weight may range from 120,000 to 1,000,000 g/mole.
- Polybutene range in average molecular weight from about 5.000 g/mole to about 30,000 g/mole.
- Useful natural elastomers include natural rubber such as smoked or liquid latex and guayule, natural gums such as jelutong, lechi caspi, perillo, sorva, massaranduba balata, massaranduba chocolate, nispero, rosidinha, chicle, gutta percha, gutta kataiu, niger gutta, tunu, chilte, chiquibul, gutta hang kang. Natural elastomers may also be applied in aspects of the present invention.
- Elastomer plasticizers vary the firmness of the gum base. Their specificity on elastomer inter-molecular chain breaking (plasticizing) along with their varying softening points cause varying degrees of finished gum firmness and compatibility when used in base. Polyvinyl acetate elastomers plasticizers are examples of elastomer plasticizers of the present invention.
- Natural resins may be selected from ester gums including as examples glycerol esters of partially hydrogenated rosins, glycerol esters of polymerized rosins, glycerol esters of partially dimerized rosins, glycerol esters of tally oil rosins, pentaerythritol esters of partially hydrogenated rosins, methyl esters of rosins, partially hydrogenated methyl esters of rosins, pentaerythritol esters of rosins, synthetic resins such as terpene resins derived from alpha-pinene, beta-pinene, and/or d-limonene, and natural terpene resins.
- In an embodiment of the invention, the solid dosage form comprises further ingredients selected from the group consisting of flavors, dry-binders, tableting aids, anti-caking agents, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, active ingredients, water-soluble indigestible polysaccharides, water-insoluble polysaccharides or any combination thereof.
- The solid dosage form according to the invention is manufactured by applying pressure to a content of particles by suitable compression means. The particles or powder is then pressed into a compact coherent tablet. The particles may for example comprise so-called primary particles or aggregated primary particles. When these are pressed, bonds are established between the particles or granules, thereby conferring a certain mechanical strength to the pressed tablet.
- It should be noted that the above-introduced terms: powder, primary particles and aggregated primary particles may be somewhat misleading in the sense that the difference between primary particles and aggregated primary particles may very often be looked upon differently depending on the background of the user. Some may for instance regard a sweetener, such as sorbitol, as a primary particle in spite of the fact that sorbitol due to the typically preprocessing performed on sorbitol when delivered to the customer should rather be regarded as some sort of aggregated primary particles. The definition adopted in the description of this invention is that aggregated primary particles refer to macro-particles comprising more or less preprocessed primary particles.
- When pressure is applied to the particles, the bulk volume is reduced, and the amount of air is decreased. During this process energy is consumed. As the particles come into closer proximity to each other during the volume reduction process, bonds may be established between the particles or granules. The formation of bonds is associated with a reduction in the energy of the system as energy is released. Volume reduction takes place by various mechanisms and different types of bonds may be established between the particles or granules depending on the pressure applied and the properties of the particles or granules. The first thing that happens when a powder is pressed is that the particles are rearranged under low compaction pressures to form a closer packing structure. Particles with a regular shape appear to undergo rearrangement more easily than those of irregular shape. As the pressure increases, further rearrangement is prevented, and subsequent volume reduction is obtained by plastic and elastic deformation and/or fragmentation of the tablet particles. Brittle particles are likely to undergo fragmentation, i.e. breakage of the original particles into smaller units. Plastic deformation is an irreversible process resulting in a permanent change of particle shape, whereas the particles resume their original shape after elastic deformation. Evidently, both plastic and elastic deformation may occur, when compressing an solid dosage form.
- Several studies of the bond types in pressed tablets have been made over the years, typically in the context of pharmaceuticals and several techniques of obtaining pressed tablets on the basis of available powders has been provided. Such studies have been quite focused on what happens when the volume reduction is performed and how the end-product may be optimized for the given purpose. Several refinements with respect to pressed tablets has for instance been made in the addition of for example binders in the tablet raw materials for the purpose of obtaining a sufficient strength to the final pressed tablet while maintaining acceptable properties, e.g. with respect to release.
- Contrary to tableted chewing gum, conventional chewing gum may be manufactured by sequentially adding the various chewing gum ingredients to a commercially available mixer known in the art where the finished gum base is already present. After the initial ingredients have been thoroughly mixed, the gum mass is discharged from the mixer and shaped into the desired form such as by rolling into sheets and cutting into sticks, extruded into chunks or casting into pellets. Generally, the ingredients of conventional chewing gum may be mixed by first melting the gum base and adding it to the running mixer. Colors, active agents and/or emulsifiers may also be added at this time. A softener such as glycerin may also be added at this time, along with syrup and a portion of the bulking agent/sweetener. Further portions of the bulking agent/sweetener may then be added to the mixer. A flavoring agent is typically added with the final portion of the bulking agent/sweetener. A high-intensity sweetener is preferably added after the final portion of bulking agent and flavor have been added. The entire mixing procedure typically takes from thirty to forty minutes, but longer mixing times may sometimes be required. Those skilled in the art will recognize that many variations of the above described procedure may be followed.
- In some embodiments of the invention, the solid dosage form does not include conventional chewing gum, i.e., so-called extruded chewing gum.
- In accordance with the invention, the tableted solid dosage form according to the invention may comprise about 0.1 to about 75% by weight of an outer coating applied onto the solid dosage form centre. Thus, suitable coating types include hard coatings, film coatings and soft coatings of any composition including those currently used in coating of tableted solid dosage form.
- One presently preferred outer coating type is a hard coating, which term is used in the conventional meaning of that term including sugar coatings and sugar-free (or sugarless) coatings and combinations thereof. The object of hard coating is to obtain a sweet, crunchy layer, which is appreciated by the consumer and it may moreover protect the solid dosage form centres for various reasons. In a typical process of providing the solid dosage form centres with a protective sugar coating, the solid dosage form centres are successively treated in suitable coating equipment with aqueous solutions of crystallisable sugar such as sucrose or dextrose, which, depending on the stage of coating reached, may contain other functional ingredients, e.g. fillers, binding agents, colours, etc. In the present context, the sugar coating may contain further functional or active compounds including flavour compounds and/or active compounds.
- In a typical hard coating process as it will be described in detail in the following, a suspension containing crystallisable sugar and/or polyol is applied onto the solid dosage form centres and the water it contains is evaporated off by blowing with air.
- This cycle must be repeated several times, typically 3 to 80 times, in order to reach the swelling required. The term “swelling” refers to the increase in weight or thickness of the products, as considered at the end of the coating operation by comparison with the beginning, and in relation to the final weight or thickness of the coated products. In accordance with the present invention, the coating layer constitutes about 0.1 to about 75% by weight of the finished solid dosage form element, such as about 10 to about 60% by weight, including about 15 to about 50% by weight.
- In an embodiment of the invention, the product is a pouch.
- In one aspect of the invention, the population of particles used for tableting may also be present in a pouch as a powder. Hence, this aspect of the invention includes the population of particles in a pouch without tableting, but as a powder or part of a powder with other powders or powder ingredients. It follows that the directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles of the invention may be included in the pouch according to the invention. Additional embodiments pertaining to the population of particles of the invention will also be applicable when included in a pouch. It is noted that additional ingredients may be present in the pouch, such as water-soluble fibers or water-insoluble fibers, including microcrystalline cellulose.
- According to an advantageous embodiment of the invention the pouch comprises a water-permeable membrane, such as a woven or non-woven fabric.
- The pouches according to the invention comprise openings, where the characteristic opening dimension is adapted to a characteristic dimension of the population of particles so as to retain the matrix composition inside the pouch before use and/or to retain a part of the content inside the pouch during use.
- In other words, according to the various embodiments, the pouch forms a membrane allowing passage of saliva and prevents or inhibits passage of at least a part of the content. The membrane of the pouch may be of any suitable material e.g. woven or non-woven fabric (e.g. cotton, fleece etc.), heat sealable non-woven cellulose or other polymeric materials such as a synthetic, semi-synthetic or natural polymeric material. An example of suitable pouch material is paper made of pulp and a small amount of wet strength agent. A material suitable for use must provide a semi-permeable membrane layer to prevent the powder or composition from leaving the bag or pouch during use. Suitable materials are also those that do not have a significant impact on the release of the active ingredients from the pouch.
- The powder is filled into pouches and is maintained in the pouch by a sealing. An ideal pouch is chemically and physically stable, it is pharmaceutically acceptable, it is insoluble in water, it is easy to fill with powder and seal, and it provides a semi-permeable membrane layer which prevent the powder from leaving the bag, but permit saliva and therein dissolved or sufficiently small suspended components from the powder in the pouch to pass through said pouch.
- The pouch may be placed in the oral cavity by the user. Saliva then enters into the pouch, and the active ingredient and other components, which are soluble in saliva, start to dissolve and are transported with the saliva out of the pouch into the oral cavity. In some embodiments of the invention, the pouch may be masticated in a similar way as chewing a gum. This is particularly advantageous when the population of particles comprise gum base. Hence, the pouch may be masticated into a coherent residual containing water-insoluble components.
- According to embodiments of the invention, flavors may be selected from the group consisting of coconut, coffee, chocolate, vanilla, grape fruit, orange, lime, menthol, liquorice, caramel aroma, honey aroma, peanut, walnut, cashew, hazelnut, almonds, pineapple, strawberry, raspberry, tropical fruits, cherries, cinnamon, peppermint, wintergreen, spearmint, eucalyptus, and mint, fruit essence such as from apple, pear, peach, strawberry, apricot, raspberry, cherry, pineapple, and plum essence. The essential oils include peppermint, spearmint, menthol, eucalyptus, clove oil, bay oil, anise, thyme, cedar leaf oil, nutmeg, and oils of the fruits mentioned above.
- Antioxidants suitable for use include butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), betacarotenes, tocopherols, acidulants such as Vitamin C (ascorbic acid or corresponding salts (ascorbates)), propyl gallate, catechins, green tea extract other synthetic and natural types or mixtures thereof.
- High intensity sweetening agents can also be used according to preferred embodiments of the invention. Preferred high intensity sweeteners include, but are not limited to sucralose, aspartame, salts of acesulfame, alitame, neotame, saccharin and its salts, cyclamic acid and its salts, glycyrrhizin, dihydrochalcones, thaumatin, monellin, monk fruit extract, advantame, stevioside and the like, alone or in combination.
- In order to provide longer lasting sweetness and flavor perception, it may be desirable to encapsulate or otherwise control the release of at least a portion of the high intensity sweeteners.
- Techniques such as wet granulation, wax granulation, spray drying, spray chilling, fluid bed coating, conservation, encapsulation in yeast cells and fiber extrusion may be used to achieve desired release characteristics. Encapsulation of sweetening agents can also be provided using another formulation component such as a resinous compound.
- Usage level of the high-intensity sweetener will vary considerably and will depend on factors such as potency of the sweetener, rate of release, desired sweetness of the product, level and type of flavor used and cost considerations. Thus, the active level of artificial sweetener may vary from about 0.001 to about 8% by weight (preferably from about 0.02 to about 8% by weight). When carriers used for encapsulation are included, the usage level of the encapsulated high-intensity sweetener will be proportionately higher.
- The invention, if desired, may include one or more fillers/texturizers including as examples, magnesium- and calcium carbonate, sodium sulphate, ground limestone, silicate compounds such as magnesium- and aluminum silicate, kaolin and clay, aluminum oxide, silicium oxide, talc, titanium oxide, mono-, di- and tri-calcium phosphates, cellulose polymers, such as wood, and combinations thereof. According to an embodiment of the invention, one preferred filler/texturizer is calcium carbonate.
- According to the invention, the one or more cannabinoids may be selected from various cannabinoids.
- “Cannabinoids” are a group of compounds including the endocannabinoids, the phytocannabinoids and those which are neither endocannabinoids or phytocannabinoids, hereinafter “syntho-cannabinoids”.
- “Endocannabinoids” are endogenous cannabinoids, which may have high affinity ligands of CB1 and CB2 receptors.
- “Phytocannabinoids” are cannabinoids that originate in nature and can be found in the cannabis plant. The phytocannabinoids can be present in an extract including a botanical drug substance, isolated, or reproduced synthetically.
- “Syntho-cannabinoids” are those compounds capable of interacting with the cannabinoid receptors (CB1 and/or CB2) but are not found endogenously or in the cannabis plant. Examples include WIN 55212 and rimonabant.
- An “isolated phytocannabinoid” or “isolated cannabinoid” is one which has been extracted from the cannabis plant and purified to such an extent that the additional components such as secondary and minor cannabinoids and the non-cannabinoid fraction have been substantially removed.
- A “synthetic cannabinoid” is one which has been produced by chemical synthesis. This term includes modifying an isolated phytocannabinoid, by, for example, forming a pharmaceutically acceptable salt thereof.
- A “substantially pure” cannabinoid is defined as a cannabinoid which is present at greater than 95% (w/w) pure. More preferably greater than 96% (w/w) through 97% (w/w) thorough 98% (w/w) to 99% % (w/w) and greater.
- A “highly purified” cannabinoid is defined as a cannabinoid that has been extracted from the cannabis plant and purified to the extent that other cannabinoids and non-cannabinoid components that are co-extracted with the cannabinoids have been substantially removed, such that the highly purified cannabinoid is greater than or equal to 95% (w/w) pure.
- “Plant material” is defined as a plant or plant part (e.g. bark, wood, leaves, stems, roots, flowers, fruits, seeds, berries or parts thereof) as well as exudates, and includes material falling within the definition of “botanical raw material” in the Guidance for Industry Botanical Drug Products Draft Guidance, August 2000, US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research.
- In the context of this application the terms “cannabinoid extract” or “extract of cannabinoids”, which are used interchangeably, encompass “Botanical Drug Substances” derived from cannabis plant material. A Botanical Drug Substance is defined in the Guidance for Industry Botanical Drug Products Draft Guidance, August 2000, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research as: “A drug substance derived from one or more plants, algae, or macroscopic fungi. It is prepared from botanical raw materials by one or more of the following processes: pulverisation, decoction, expression, aqueous extraction, ethanolic extraction, or other similar processes.” A botanical drug substance does not include a highly purified or chemically modified substance derived from natural sources. Thus, in the case of cannabis, “botanical drug substances” derived from cannabis plants do not include highly purified, Pharmacopoeial grade cannabinoids.
- The term “Cannabis plant(s)” encompasses wild type Cannabis sativa and also variants thereof, including cannabis chemovars which naturally contain different amounts of the individual cannabinoids, Cannabis sativa subspecies indica including the variants var. indica and var. kafiristanica, Cannabis indica, Cannabis ruderalis and also plants which are the result of genetic crosses, self-crosses or hybrids thereof. The term “Cannabis plant material” is to be interpreted accordingly as encompassing plant material derived from one or more cannabis plants. For the avoidance of doubt it is hereby stated that “cannabis plant material” includes dried cannabis biomass.
- Preferably the one or more cannabinoids are selected from: cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCV A). More preferably the one or more cannabinoid is CBD or THC. This list is not exhaustive and merely details the cannabinoids which are identified in the present application for reference.
- So far, more than 120 different phytocannabinoids have been identified which are within the scope of the present invention.
- Cannabinoids can be split into different groups as follows: Phytocannabinoids; Endocannabinoids; and Synthetic cannabinoids.
- Cannabinoid receptors can be activated by three major groups of agonist ligands, for the purposes of the present invention and whether or not explicitly denominated as such herein, lipophilic in nature and classed respectively as: endocannabinoids (produced endogenously by mammalian cells); phytocannabinoids (such as cannabidiol, produced by the cannabis plant); and, synthetic cannabinoids (such as HU-210).
- Phytocannabinoids can be found as either the neutral carboxylic acid form or the decarboxylated form depending on the method used to extract the cannabinoids. For example, it is known that heating the carboxylic acid form will cause most of the carboxylic acid form to decarboxylate.
- Phytocannabinoids can also occur as either the pentyl (5 carbon atoms) or propyl (3 carbon atoms) variant. For example, the phytocannabinoid THC is known to be a CB1 receptor agonist whereas the propyl variant THCV has been discovered to be a CB1 receptor antagonist meaning that it has almost opposite effects.
- According to the invention, examples of phytocannabinoids may be cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCV A). More preferably the one or more cannabinoid is CBD or THC.
- The formulation according to the present invention may also comprise at least one cannabinoid selected from those disclosed in A. Douglas Kinghom et al., Phytocannabinoids, Vol. 103, Chapter 1, pages 1-30.
- Examples of endocannabinoids are molecules that activate the cannabinoid receptors within the body. Examples include 2-arachidonyl glycerol (2AG), 2-arachidonyl glyceryl ether (2AGE), arachidonyl dopamine, and arachidonyl ethanolamide (anandamide). Structurally related endogenous molecules have been identified that share similar structural features, but that display weak or no activity towards the cannabinoid receptors but are also termed endocannabinoids. Examples of these endocannabinoid lipids include 2-acyl glycerols, alkyl or alkenyl glyceryl ethers, acyl dopamines and N-acylethanolamides that contain alternative fatty acid or alcohol moieties, as well as other fatty acid amides containing different head groups. These include N-acylserines as well as many other N-acylated amino acids. Examples of cannabinoid receptor agonists are neuromodulatory and affect short-term memory, appetite, stress response, anxiety, immune function and analgesia.
- In one embodiment the cannabinoid is palmitoylethanolamide (PEA) which is an endogenous fatty acid amide belonging to the class of nuclear factor agonists.
- Synthetic cannabinoids encompass a variety of distinct chemical classes: the cannabinoids structurally related to THC, the cannabinoids not related to THC, such as (cannabimimetics) including the aminoalkylindoles, 1,5-diarylpyrazoles, quinolines, and arylsulfonamides, and eicosanoids related to the endocannabinoids. All or any of these cannabinoids can be used in the present invention.
- It is preferred that the formulation comprises one or two primary cannabinoids, which are preferably selected from the group consisting of, cannabidiol (CBD) or cannabidivarin (CBDV), tetrahydrocannabinol (THC), tetrahydrocannabivarin (THCV), tetrahydrocannabinolic acid (THCA), cannabigerol (CBG) and cannabidiolic acid (CBDA) or a combination thereof. It is preferred that the formulation comprises cannabidiol and/or tetrahydrocannabinol.
- Preferably, the solid dosage form of the present invention may be used for the treatment or alleviation of pain, epilepsy, cancer, nausea, inflammation, congenital disorders, neurological disorders, oral infections, dental pain, sleep apnea, psychiatric disorders, gastrointestinal disorders, inflammatory bowel disease, appetite loss, diabetes and fibromyalgia.
- In a further aspect of the present invention, the oral cannabinoid formulation is suitable for use in the treatment of conditions requiring the administration of a neuroprotectant or anti-convulsive medication.
- The oral cannabinoid formulation may be for use in the treatment of seizures.
- The oral cannabinoid formulation may be for use in the treatment of Dravet syndrome, Lennox Gastaut syndrome, myoclonic seizures, juvenile myoclonic epilepsy, refractory epilepsy, schizophrenia, juvenile spasms, West syndrome, infantile spasms, refractory infantile spasms, tuberous sclerosis complex, brain tumours, neuropathic pain, cannabis use disorder, post-traumatic stress disorder, anxiety, early psychosis, Alzheimer's disease, and autism.
- The following non-limiting examples illustrate different variations of the present invention. The examples are meant for indicating the inventive concept; hence the mentioned examples should not be understood as exhaustive for the present. In particular, CBD is used as an exemplary compound, but may also be another cannabinoid.
- Mannitol (Pearlitol 150SD) provided from Roquette in an amount of about 1780 g was added to a Lödige high shear mixer and heated to a temperature of about 55 Degree Celsius. Thereafter, a cannabinoid powder composition comprising CBD isolate from cannabis plant tissues (phytocannabinoid) with a 99% content of CBD provided by Medical Hemp (batch number MH B18592) in an amount of about 140 g was sieved through a 600 microns sieve and added to the sweetener powder composition. This mixture was mixed in the mixer at a speed of about 80 rpm for about 5 minutes. After activation of the chopper (about 600 rpm) of the Lödige mixer, HVO provided from AAK under the tradename Akocrem NT 76-33 with a melting temperature of 30-35 Degree Celsius was melted at a temperature of about 55 Degree Celsius and added to the mixture in an amount of about 80 g. After adding the lipid composition, the temperature in the mixer was about 49 Degree Celsius, and the mixture was further mixed for about 10 minutes. After 10 minutes, the temperature of the final mixture was about 51 Degree Celsius. A total of 2 kg mixture powder premix was made in which the CBD content was about 70 mg/g.
-
TABLE 1 Hydrogenated Vegetable Oil (HVO) having been preheated to a temperature of about 55 Degree Celsius. Variation in the content of CBD isolate (purity 99%). Sample 102 corresponds to the procedure above, the other samples are adjusted to the variation in contents. Powder Premix Number 100 101 102 103 104 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 94.0 91.0 89.0 87.0 84.0 CBD isolate (purity 99%) 2.0 5.0 7.0 9.0 12.0 HVO 4.0 4.0 4.0 4.0 4.0 Total 100 100 100 100 100 -
TABLE 2 Hydrogenated Vegetable Oil (HVO) having been preheated to a temperature of about 55 Degree Celsius. Variation in the content of HVO. Sample 112 corresponds to the procedure above, the other samples are adjusted to the variation in contents. Powder Premix Number 110 111 112 113 114 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 93.0 90.5 89.0 87.0 83.0 CBD isolate (purity 99%) 7.0 7.0 7.0 7.0 7.0 HVO 1.0 2.5 4.0 6.0 10.0 Total 100 100 100 100 100 -
TABLE 3 Hydrogenated Vegetable Oil (HVO) having been preheated to a temperature of about 55 Degree Celsius. Variation in the type of sweetener. Here mannitol was replaced by other sweeteners. Sample 122 corresponds to the procedure above. Powder Premix Number 120 121 122 123 124 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 89.0 Isomalt 89.0 Maltitol 89.0 Xylitol 89.0 Dextrose 89.0 CBD isolate (purity 99%) 7.0 7.0 7.0 7.0 7.0 HVO 4.0 4.0 4.0 4.0 4.0 Total 100 100 100 100 100 - Mannitol (Pearlitol 150SD) provided from Roquette in an amount of about 1780 g was added to a Lödige high shear mixer and heated to a temperature of about 55 Degree Celsius. Thereafter, a cannabinoid powder composition comprising CBD isolate from cannabis plant tissues (phytocannabinoid) with a 99% content of CBD provided by Medical Hemp (batch number MH B18592) in an amount of about 140 g was sieved through a 600 microns sieve and added to the sweetener powder composition. This mixture was mixed in the mixer at a speed of about 80 rpm for about 5 minutes. After activation of the chopper (about 600 rpm) of the Lödige mixer, Medium Chain Triglyceride (MCT), Miglyol 812, provided from Sasol was added to the mixture during a period of about 3 minutes in an amount of about 80 g. After adding the Miglyol 812, the mixture was further mixed for about 10 minutes. After 10 minutes, the temperature of the final mixture was about 51 Degree Celsius. A total of 2 kg mixture powder premix was made in which the CBD content was about 70 mg/g.
-
TABLE 4 Miglyol 812 having not been preheated. Variation in the content of CBD isolate (purity 99%). Sample 202 corresponds to the procedure above, the other samples are adjusted to the variation in contents. Powder Premix Number 200 201 202 203 204 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 94.0 91.0 89.0 87.0 84.0 CBD isolate (purity 99%) 2.0 5.0 7.0 9.0 12.0 Miglyol 812 4.0 4.0 4.0 4.0 4.0 Total 100 100 100 100 100 -
TABLE 5 Miglyol 812 having not been preheated. Variation in the content of Miglyol 812. Sample 212 corresponds to the procedure above, the other samples are adjusted to the variation in contents. Powder Premix Number 210 211 212 213 214 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 93.0 90.5 89.0 87.0 83.0 CBD isolate (purity 99%) 7.0 7.0 7.0 7.0 7.0 Miglyol 812 1.0 2.5 4.0 6.0 10.0 Total 100 100 100 100 100 -
TABLE 6 Miglyol having not been preheated unless specifically denoted. Variation in the type of Miglyol. Sample 222 corresponds to the procedure above. Miglyol 829 in Powder Premix Number 223 is heated to about 50° C. in order to work. Powder Premix Number 224 is a comparative powder. Powder Premix Number 220 221 222 223 224 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 89.0 89.0 89.0 89.0 89.0 CBD isolate (purity 99%) 7.0 7.0 7.0 7.0 7.0 Miglyol 812 4.0 Miglyol 810 4.0 Miglyol 818 4.0 Miglyol 829 4.0 Miglyol 840 4.0 Total 100 100 100 100 100 -
TABLE 7 Miglyol 812 having not been preheated. Variation in the type of sweetener. Here mannitol was replaced by other sweeteners. Sample 232 corresponds to the procedure above. Powder Premix Number 230 231 232 233 234 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 89.0 Isomalt 89.0 Maltitol 89.0 Xylitol 89.0 Dextrose 89.0 CBD isolate (purity 99%) 7.0 7.0 7.0 7.0 7.0 Miglyol 812 4.0 4.0 4.0 4.0 4.0 Total 100 100 100 100 100 - Mannitol (Pearlitol 150SD) provided from Roquette in an amount of about 1220 g was added to a Lödige high shear mixer and heated to a temperature of about 55 Degree Celsius. Thereafter, a cannabinoid powder composition comprising CBD isolate from cannabis plant tissues (phytocannabinoid) with a 99% content of CBD provided by Medical Hemp (batch number MH B18592) in an amount of about 700 g was sieved through a 600 microns sieve and added to the sweetener powder composition. This mixture was mixed in the mixer at a speed of about 80 rpm for about 5 minutes. After activation of the chopper (about 600 rpm) of the Lödige mixer, HVO provided from AAK under the tradename Akocrem NT 76-33 with a melting temperature of 30-35 Degree Celsius was melted at a temperature of about Degree Celsius and added to the mixture in an amount of about 80 g. After adding the lipid composition, the temperature in the mixer was about 49 Degree Celsius, and the mixture was further mixed for about 10 minutes. After 10 minutes, the temperature of the final mixture was about 51 Degree Celsius. A total of 2 kg mixture powder premix was made in which the CBD content was about 350 mg/g.
-
TABLE 8 Hydrogenated Vegetable Oil (HVO) having been preheated to a temperature of about 55 Degree Celsius. Variation in the content of CBD isolate (purity 99%). Sample 302 corresponds to the procedure above, the other samples are adjusted to the variation in contents. Powder Premix Number 300 301 302 303 304 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 71.0 66.0 61.0 56.0 51.0 CBD isolate (purity 99%) 25.0 30.0 35.0 40.0 45.0 HVO 4.0 4.0 4.0 4.0 4.0 Total 100 100 100 100 100 -
TABLE 9 Hydrogenated Vegetable Oil (HVO) having been preheated to a temperature of about 55 Degree Celsius. Variation in the content of HVO. Powder Premix Number 310 311 312 313 314 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 64.0 62.5 61.0 59.0 55.0 CBD isolate 35.0 35.0 35.0 35.0 35.0 (purity 99%) HVO 1.0 2.5 4.0 6.0 10.0 Total 100 100 100 100 100 Sample 312 corresponds to the procedure above, the other samples are adjusted to the variation in contents. -
TABLE 10 Hydrogenated Vegetable Oil (HVO) having been preheated to a temperature of about 55 Degree Celsius. Variation in the type of sweetener. Here mannitol was replaced by other sweeteners. Powder Premix Number 320 321 322 323 324 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 61.0 Isomalt 61.0 Maltitol 61.0 Xylitol 61.0 Dextrose 61.0 CBD isolate 35.0 35.0 35.0 35.0 35.0 (purity 99%) HVO 4.0 4.0 4.0 4.0 4.0 Total 100 100 100 100 100 Sample 322 corresponds to the procedure above. - Premix: Hydrogenated Vegetable Oil (HVO) Mixture with Isolated CBD Added to Sweetener
- Mannitol (Pearlitol 150SD) provided from Roquette in an amount of about 721 g was added to a Lödige high shear mixer and heated to a temperature of about 55 Degree Celsius. Thereafter, a cannabinoid powder composition comprising CBD isolate from cannabis plant tissues (phytocannabinoid) with a 99% content of CBD provided by Medical Hemp (batch number MH B18592) in an amount of about 91 g was mixed with HVO provided from AAK under the tradename Akocrem NT 76-33 with a melting temperature of 30-35 Degree Celsius in an amount of about 29 g. While stirring, the CBD-HVO mixture was heated to a temperature of about 60 Degree Celsius to form a liquid solution of CBD in HVO. The mixture of CBD and HVO corresponding to a ratio of about 75/25 (hereafter denoted 75% CBD mixture) was then added to the sweetener powder composition in an amount of about 79 g. After adding the lipid composition, the mixture was mixed for about 10 minutes. A total of 800 g mixture powder premix was made.
-
TABLE 11 Hydrogenated Vegetable Oil (HVO) having been heated to a temperature of about 60 Degree Celsius after mixing with 99% purity CBD (75% CBD mixture). Variation in the content of CBD (75% CBD mixture). Powder Premix Number 400 401 402 403 404 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 94.1 92.0 90.1 88.1 85.1 CBD isolate 5.9 7.9 9.9 11.9 14.9 (75% CBD mixture) Total 100 100 100 100 100 Sample 402 corresponds to the procedure above, the other samples are adjusted to the variation in contents. -
TABLE 12 Hydrogenated Vegetable Oil (HVO) having been heated to a temperature of about 60 Degree Celsius after mixing with 99% purity CBD (X % CBD mixture). Variation in the content of CBD in mixture with HVO. Powder Premix Number 410 411 412 413 414 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 90.1 90.1 90.1 90.1 90.1 CBD isolate 9.9 9.9 9.9 9.9 9.9 (X % CBD mixture) (50%)* (60%)* (75%)* (80%)* (90%)* Total 100 100 100 100 100 *denotes the percentage X of CBD in “X % CBD mixture”. Sample 412 corresponds to the procedure above, the other samples are adjusted to the variation in contents. -
TABLE 13 Hydrogenated Vegetable Oil (HVO) having been heated to a temperature of about 60 Degree Celsius after mixing with 99% CBD (75% CBD mixture). Variation in the type of sweetener. Here mannitol was replaced by other sweeteners. Powder Premix Number 420 421 422 423 424 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 90.1 Isomalt 90.1 Maltitol 90.1 Xylitol 90.1 Dextrose 90.1 CBD isolate 9.9 9.9 9.9 9.9 9.9 (75% CBD mixture) Total 100 100 100 100 100 Sample 422 corresponds to the procedure above. - Premix: Miglyol Mixture with Isolated CBD Added to Sweetener
- Mannitol (Pearlitol 150SD) provided from Roquette in an amount of about 721 g was added to a Lödige high shear mixer and heated to a temperature of about 55 Degree Celsius. Thereafter, a cannabinoid powder composition comprising CBD isolate from cannabis plant tissues (phytocannabinoid) with a 99% content of CBD provided by Medical Hemp (batch number MH B18592) in an amount of about 91 g was mixed with Medium Chain Triglyceride (MCT), Miglyol 812, provided from Sasol in an amount of about 29 g. While stirring, the CBD-MCT mixture was heated to a temperature of about 70 Degree Celsius to form a liquid solution of CBD in MCT. The mixture of CBD and Miglyol 812 corresponding to a ratio of about 75/25 (hereafter denoted 75% CBD mixture) was then added to the sweetener powder composition in an amount of about 79 g. After adding the lipid composition, the mixture was mixed for about 10 minutes. A total of 800 g mixture powder premix was made.
-
TABLE 14 Miglyol 812 mixed with 99% purity CBD followed by heating (75% CBD mixture). Variation in the content of CBD (75% CBD mixture). Powder Premix Number 500 501 502 503 504 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 94.1 92.0 90.1 88.1 85.1 CBD isolate 5.9 7.9 9.9 11.9 14.9 (75% CBD mixture) Total 100 100 100 100 100 Sample 502 corresponds to the procedure above, the other samples are adjusted to the variation in contents. -
TABLE 15 Miglyol 812 mixed with 99% CBD followed by heating (X % CBD mixture). Variation in the content of CBD in mixture with Miglyol 812. Powder Premix Number 510 511 512 513 514 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 90.1 90.1 90.1 90.1 90.1 CBD isolate 9.9 9.9 9.9 9.9 9.9 (X % CBD mixture) (50%)* (60%)* (75%)* (80%)* (90%)* Total 100 100 100 100 100 *denotes the percentage X of CBD in “X % CBD mixture”. Sample 512 corresponds to the procedure above, the other samples are adjusted to the variation in contents. -
TABLE 16 Miglyol 812 mixed with 99% CBD followed by heating (75% CBD mixture). Variation in the type of sweetener. Here mannitol was replaced by other sweeteners. Powder Premix Number 520 521 522 523 524 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 90.1 Isomalt 90.1 Maltitol 90.1 Xylitol 90.1 Dextrose 90.1 CBD isolate 9.9 9.9 9.9 9.9 9.9 (75% CBD mixture) Total 100 100 100 100 100 Sample 522 corresponds to the procedure above. - Premix: Comparative Samples—without Triglyceride Lipids
- Mannitol (Pearlitol 150SD) provided from Roquette was added to a Lödige high shear mixer and heated to a temperature of about 55 Degree Celsius. Thereafter, a cannabinoid powder composition comprising CBD isolate from cannabis plant tissues (phytocannabinoid) with a purity about 99% of CBD provided by either Medical Hemp (batch number MH18592) or Valens (batch number BVA032013) was sieved through a 600 microns sieve and added to the sweetener powder composition. This mixture was mixed at a speed of about 80 rpm for about 10 minutes. No lipid composition was present.
-
TABLE 17 Variation in the content of CBD isolate. Powder Premix Number 600 601 602 603 604 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 90.0 85.0 80.0 75.0 70.0 CBD isolate 10.0 15.0 20.0 25.0 30.0 (MH18592) Total 100 100 100 100 100 -
TABLE 18 Variation in the content of CBD isolate. Powder Premix Number 610 611 612 613 614 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 92.0 94.0 96.0 97.0 98.0 CBD isolate 8.0 6.0 4.0 3.0 2.0 (MH18592) Total 100 100 100 100 100 -
TABLE 19 Variation in the content of CBD isolate. Difference in CBD isolate source. Powder Premix Number 620 621 622 623 624 Content Content Content Content Content Raw material name [%] [%] [%] [%] [%] Mannitol 90.0 85.0 80.0 75.0 70.0 CBD isolate 10.0 15.0 20.0 25.0 30.0 (BVA032013) Total 100 100 100 100 100 - Preparation of Tablet with Two Layers
- Tablets were made based on the CBD containing powder mixtures of Examples 1-2 with each layer having a weight of about 50% of the total tablet. The total weight of the tablets were 1800 mg. The tablets were made with a standard tablet pressing machine (3090i, available from Fette GmbH) comprising dosing apparatus (P 3200 C, available from Fette GmbH, Germany). Punch used: 16.00 mm round punches. Rotor speed used was 11 rpm.
- A first layer (denoted layer 1) comprising the CBD containing powder mixture made in Examples 1-2 and additional ingredients was prepared and tableted before tableting the layer comprising gum base (denoted layer 2). Layer 1 with a weight of about 900 mg was compressed at a compression force of about 5 kN. Hereafter, layer 2 with a weight of about 900 mg and comprising gum base and additional ingredients was pressed on top of layer 1 at a compression force of 40 kN. The tablet machine was commissioned by adjusting the fill depth and compression force so the weight and hardness of tablets match the acceptance criteria. A pre-compression force could be included to avoid capping.
-
TABLE 20 In all of the tablet examples, the amount of the various ingredients is given as % by weight of the tablet. Content [%] Content [%] Raw material name Layer 1-900 mg Layer 2-900 mg Powder Premix Sample from 16.1 Example 1 Flavors 1.2 1.8 High-intensity sweeteners 0.1 0.3 Lubricant 3.0 3.0 Mannitol 29.6 Xylitol DC 12.7 Gum base 31.5 Other components 0.7 Total 50 50 -
TABLE 21 In all of the tablet examples, the amount of the various ingredients is given as % by weight of the tablet. Content [%] Content [%] Raw material name Layer 1-900 mg Layer 2-900 mg Powder Premix Sample from 16.1 Example 2 Flavors 1.2 1.8 High-intensity sweeteners 0.1 0.3 Lubricant 3.0 3.0 Mannitol 29.6 Xylitol DC 12.7 Gum base 31.5 Other components 0.7 Total 50 50 -
TABLE 22 In all of the tablet examples, the amount of the various ingredients is given as % by weight of the tablet. Content [%] Content [%] Raw material name Layer 1-900 mg Layer 2-900 mg Powder Premix Sample from 16.1 Example 2 Flavors 1.2 1.8 High-intensity sweeteners 0.1 0.3 Silicon dioxide * 0.3 Lubricant 3.0 3.0 Mannitol 29.3 Xylitol DC 12.7 Gum base 31.5 Other components 0.7 Total 50 50 * Silicon dioxide may optionally be added at the stage of preparing the mixture in Example 2 - Preparation of Tablet with Two Layers
- Tablets were made based on the CBD containing powder mixtures of Example 3 with each layer having a weight of about 50% of the total tablet. The total weight of the tablets were 1800 mg. The tablets were made with a standard tablet pressing machine (3090i, available from Fette GmbH) comprising dosing apparatus (P 3200 C, available from Fette GmbH, Germany). Punch used: 16.00 mm round punches. Rotor speed used was 11 rpm.
- A first layer (denoted layer 1) comprising the CBD containing powder mixture made in Example 3 and additional ingredients was prepared and tableted before tableting the layer comprising gum base (denoted layer 2). Layer 1 was compressed at a compression force of about 5 kN. Hereafter, layer 2 comprising gum base and additional ingredients was pressed on top of layer 1 at a compression force of 40 kN. The tablet machine was commissioned by adjusting the fill depth and compression force so the weight and hardness of tablets match the acceptance criteria. A pre-compression force could be included to avoid capping.
-
TABLE 23 In all of the tablet examples, the amount of the various ingredients is given as % by weight of the tablet. Content [%] Content [%] Raw material name Layer 1-900 mg Layer 2-900 mg Powder Premix Sample from 7.9 Example 3 Flavors 1.2 1.8 High-intensity sweeteners 0.1 0.3 Silicon dioxide * 0.3 Lubricant 3.0 3.0 Mannitol 37.5 Xylitol DC 12.7 Gum base 31.5 Other components 0.7 Total 50 50 * Silicon dioxide may optionally be added at the stage of preparing the mixture in Example 3 -
TABLE 24 In all of the tablet examples, the amount of the various ingredients is given as % by weight of the tablet. Content [%] Content [%] Raw material name Layer 1-900 mg Layer 2-900 mg Powder Premix Sample from 15.8 Example 3 Flavors 1.2 1.8 High-intensity sweeteners 0.1 0.3 Silicon dioxide * 0.3 Lubricant 3.0 3.0 Mannitol 29.6 Xylitol DC 12.7 Gum base 31.5 Other components 0.7 Total 50 50 * Silicon dioxide may optionally be added at the stage of preparing the mixture in Example 3 - Preparation of Tablet with Two Layers
- Tablets were made based on the CBD containing powder mixtures of Examples 4-5 with two layers where one layer having a weight of about 45% of the total tablet and another layer having a weight of about 55% (the layer without CBD). The total weight of the tablets were 1800 mg. The tablets were made with a standard tablet pressing machine (3090i, available from Fette GmbH) comprising dosing apparatus (P 3200 C, available from Fette GmbH, Germany). Punch used: 16.00 mm round punches. Rotor speed used was 11 rpm.
- A first layer (denoted layer 1) comprising the CBD containing powder mixture made in Examples 1-2 and additional ingredients was prepared and tableted before tableting the layer comprising gum base (denoted layer 2). Layer 1 was compressed at a compression force of about 5 kN. Hereafter, layer 2 comprising gum base and additional ingredients was pressed on top of layer 1 at a compression force of 40 kN. The tablet machine was commissioned by adjusting the fill depth and compression force so the weight and hardness of tablets match the acceptance criteria. A pre-compression force could be included to avoid capping.
-
TABLE 25 In all of the tablet examples, the amount of the various ingredients is given as % by weight of the tablet. Content [%] Content [%] Raw material name Layer 1-810 mg Layer 2-990 mg Powder Premix Sample from 15.0 Example 4 Flavors 1.0 2.4 High-intensity sweeteners 0.1 0.1 Lubricant 2.5 3.2 Mannitol 26.4 Xylitol DC 15.6 Gum base 33 Other components 0.7 Total 45 55 -
TABLE 26 In all of the tablet examples, the amount of the various ingredients is given as % by weight of the tablet. Content [%] Content [%] Raw material name Layer 1-810 mg Layer 2-990 mg Powder Premix Sample from 15.0 Example 5 Flavors 1.0 2.4 High-intensity sweeteners 0.1 0.1 Lubricant 2.5 3.2 Mannitol 26.4 Xylitol DC 15.6 Gum base 33 Other components 0.7 Total 45 55 - Comparative Tablets with Two Layers
- Tablets were made based on the CBD containing powder mixtures of Example 6 with two layers where one layer having a weight of about 45% of the total tablet and another layer having a weight of about 55% (the layer without CBD). The total weight of the tablets were 1800 mg. The tablets were made with a standard tablet pressing machine (3090i, available from Fette GmbH) comprising dosing apparatus (P 3200 C, available from Fette GmbH, Germany). Punch used: 16.00 mm round punches. Rotor speed used was 11 rpm.
- A first layer (denoted layer 1) comprising the CBD containing powder mixture made in Examples 1-2 and additional ingredients was prepared and tableted before tableting the layer comprising gum base (denoted layer 2). Layer 1 was compressed at a compression force of about 5 kN. Hereafter, layer 2 comprising gum base and additional ingredients was pressed on top of layer 1 at a compression force of 40 kN. The tablet machine was commissioned by adjusting the fill depth and compression force so the weight and hardness of tablets match the acceptance criteria. A pre-compression force could be included to avoid capping.
-
TABLE 27 In all of the tablet examples, the amount of the various ingredients is given as % by weight of the tablet. Content [%] Content [%] Raw material name Layer 1-810 mg Layer 2-990 mg Powder Premix Sample from 5.6 Example 6 Flavors 1.0 2.4 High-intensity sweeteners 0.1 0.1 Lubricant 2.5 3.2 Mannitol 35.8 6.4 Xylitol DC 9.2 Gum base 33 Other components 0.7 Total 45 55 -
TABLE 28 In all of the tablet examples, the amount of the various ingredients is given as % by weight of the tablet. Content [%] Content [%] Raw material name Layer 1-810 mg Layer 2-990 mg Powder Premix Sample from 14.1 Example 6 Flavors 1.0 2.4 High-intensity sweeteners 0.1 0.1 Lubricant 2.5 3.2 Mannitol 27.3 6.4 Xylitol DC 9.2 Gum base 33 Other components 0.7 Total 45 55 -
TABLE 29 In all of the tablet examples, the amount of the various ingredients is given as % by weight of the tablet. Content [%] Content [%] Raw material name Layer 1-810 mg Layer 2-990 mg Powder Premix Sample from 2.8 Example 6 Flavors 1.0 2.4 High-intensity sweeteners 0.1 0.1 Lubricant 2.5 3.2 Mannitol 38.6 6.4 Xylitol DC 9.2 Gum base 33 Other components 0.7 Total 45 55 - Content Uniformity (CU), ie. homogeneity of the CBD active substance in powder premixtures (Powder Premix Samples) as well as powder blends which are mixtures with additional ingredients to be processed into the oral dosage form (Powder Blends), is determined according to European Pharmacopoeia 10.8 using test method 2.9.40 Uniformity of dosage units.
- At least 5 samples each having the same fixed weight in the range of 0.25-2 gram are taken from the powder mixture to be analyzed. For each sample, the content of CBD active is analyzed by means of standard HPLC techniques. Content Uniformity is then calculated as the relative standard deviation (RSD) of the individual results.
- Content Uniformity (CU), ie. homogeneity of the CBD active substance in solid dosage forms, is determined according to European Pharmacopoeia 10.8 using test method 2.9.40 Uniformity of dosage units.
- At least 10 samples are taken from the solid dosage form, eg. tablets, to be analyzed. For each sample, the content of CBD active is analyzed by means of standard HPLC techniques. Content Uniformity is then calculated as the relative standard deviation (RSD) of the individual results.
- A sample solid dosage form was tested in a test panel of 8 test persons. Test subjects abstain from eating and drinking at least 30 minutes before initiation of any test. The test person was a healthy person appointed on an objective basis according to specified requirements. After specific time intervals of use, eg. 0, 0.5, 1, 2, 3, 5 and minutes, the content of CBD was measured in the remaining solid dosage residue. The solid dosage form was subject to triple measurements for each of the 8 test persons, giving a total of 24 measurements for each sample. An average of the 24 measurements was calculated and the weight % release was calculated based on the original content of CBD in the sample. The content of CBD was measured in the remaining solid dosage form residue, if still present.
- The solid dosage form was weighted and placed in the mouth, and the test persons were instructed to place and use the solid dosage form as intended. For chewing gum, the test persons were instructed to chew the sample at a frequency of 60 chews per minute. For lozenges the test persons were instructed to place the sample between the tongue and the palate, and then the solid dosage form was sucked and turned every 0.5 minute. Once the desired test time was achieved (0.5, 1, 2, 3, 5 and min.), the solid dosage form was taken out and weighed directly into a measuring glass to be used for analysis of CBD content. An in vivo dissolution profile was obtained by analyzing the content of CBD in the solid dosage form at different dissolution times.
- This test was made to tablets, chewing gums, and lozenges. Also, this test was made to other cannabinoids, including THC.
- A sample solid dosage form was tested. After specific time intervals of use, eg 0, 0.5, 1, 2, 3, 5 and 10 minutes, the content of CBD was measured in the remaining solid dosage residue. The solid dosage form was subject to triple measurements. An average of the measurements was calculated and the weight % release was calculated based on the original content of CBD in the sample. The content of CBD was measured in the remaining solid dosage form residue, if still present.
- The solid dosage form was weighted. Then 25 ml of phosphate buffer was added into a 50 ml measuring tube with screw cap. The solid dosage form was added to the tube. The tube was fixed horizontally on a shaking table. After shaking, the solid dosage form was analyzed for content of CBD. An in vitro profile was obtained by analyzing the content of the CBD in the solid dosage at different dissolution times.
- This test was made to tablets, chewing gum, and lozenges. Also, this test was made to other cannabinoids, including THC.
- CBD Delivered to the Oral Mucosa from Solid Dosage Forms
- A sample was used as intended for 1 minute by a test panel of 8 test persons. The test person was a healthy person appointed on an objective basis according to specified requirements. Test subject abstains from eating and drinking at least 30 minutes before initiation of any test. The test person was not allowed to swallow during the procedure. The solid dosage form was weighted and placed in the mouth, and the test persons were instructed to place and use the solid dosage form as intended. For chewing gum, the test persons were instructed to chew the sample at a frequency of chews per minute. For lozenges the test persons were instructed to place the sample between the tongue and the palate, and then the solid dosage form was sucked and turned every 10 seconds. After one minute, saliva was obtained from the test person and collected in a vessel for later analysis. In tests for 2 minutes release, the same procedure was followed until 2 minutes where the last saliva sample was collected and added to the same vessel for aggregated analysis. The aggregated saliva sample was collected after 2 minutes, and the content of CBD was measured in the saliva. The content of CBD was also measured in the remaining residue. The residue, if still present, was positioned in a flask, weighted, and analyzed. The residue, if still present, and saliva were subject to 3 triple measurements for each of the 8 test persons, giving a total of 24 measurement for each sample. An average of the 24 measurements was then calculated. By comparing the amount of CBD in the residue and the amount of CBD in the saliva with the amount of CBD in the solid dosage form before use, the amount of CBD delivered to the oral mucosa could be estimated.
- This test was made to tablets, chewing gum, and lozenges. Also, this test was made to other cannabinoids, including THC.
- In addition to release measurements, either in vivo or in vitro, sensoric tests were performed to reveal very important characteristics and properties of the solid dosage form. These sensoric parameters are important as indicators of the structure of the solid dosage form composition. The structure is the underlying guidance as to how the solid dosage form resembles the structure of a comparative solid dosage form, which is set as the standard in the test series, i.e. the solid dosage forms are compared to each other in the test series of preferably 5 samples. The test set-up was composed of 8 test persons in a test panel. All of the test persons were healthy individuals appointed on an objective basis according to specified requirements. The sensory analysis was performed according to ISO 4121-2003 in testing conditions following ISO 8589. The result is an average of the results of the 8 individuals.
- The test persons gave a rating from “+” to “+++++”, where “+” is poor and “+++++” is excellent, i.e. “+++++” means that the solid dosage form was excellent compared to the standard, “+++” means that the solid dosage form was comparable to the standard and “+” means that the solid dosage form was very far from comparable to the standard. “0” indicated that it was not tested.
- Four different parameters were tested in a test panel:
-
Friability Flavor Sweetness Off-notes - “Texture”—the general impression of the solid dosage form when placed in the mouth with respect to elements such as hardness, roughness and a smoothness.
- “Friability”—the impression of the solid dosage form when placed in the mouth and intended use is initiated. For instance, a very hard and viscous structure gave a very low rating and a very brittle structure also gave a very low rating.
- “Flavor”—the overall impression of the solid dosage form during intended use with respect to flavor. For instance, a very low flavor experience gave a very low rating and a too high flavor experience that was not comparable to the standard also gave a very low rating.
- “Sweetness”—the overall impression of the taste of the solid dosage form during intended use with respect to sweetness. For instance, if the sweetness was decreasing rapidly, a very low rating was given and if the sweetness was too high giving an uncomfortable feeling, a very low rating was also given.
- “Off-notes”—the overall impression of the off-note from the one or more cannabinoids in the composition during intended use. For instance, if off-notes (grass, bitter notes, irritation in the throat) were experienced in the throat, a low rating was given and if other uncomfortable sensations was experienced, a low rating was also given.
- The procedures of Example 11A was used for the powder premixes (Powder Premix Samples) above and the results are shown in the table below. The result of content uniformity for a sample is provided as a single value obtained as the relative standard deviation (RSD) of CBD content of multiple samples taken at the end of the premix preparation procedures.
-
TABLE 30 Content uniformity of powder premixtures with Hydrogenated Vegetable Oil (HVO)-HVO added to isolated CBD and sweetener. Powder Premix Content uniformity Sample no. Example (RSD) 100 Example 1 1.1% 101 Example 1 1.2% 102 Example 1 1.2% 103 Example 1 1.5% 104 Example 1 1.7% -
TABLE 31 Content uniformity of powder premixtures with Hydrogenated Vegetable Oil (HVO)-HVO added to isolated CBD and sweetener. Powder Premix Content uniformity Sample no. Example (RSD) 110 Example 1 1.3% 111 Example 1 1.3% 112 Example 1 1.2% 113 Example 1 1.2% 114 Example 1 1.1% -
TABLE 32 Content uniformity of powder premixtures with Hydrogenated Vegetable Oil (HVO) (preheated)- HVO added to isolated CBD and sweetener. Powder Premix Content uniformity Sample no. Example (RSD) 120 Example 1 1.3% 121 Example 1 1.1% 122 Example 1 1.2% 123 Example 1 0.9% 124 Example 1 1.2% -
TABLE 33 Content uniformity of powder premixtures with Miglyol- Miglyol added to isolated CBD and sweetener. Powder Premix Content uniformity Sample no. Example (RSD) 200 Example 2 1.1% 201 Example 2 1.2% 202 Example 2 1.1% 203 Example 2 1.3% 204 Example 2 1.5% -
TABLE 34 Content uniformity of powder premixtures with Miglyol- Miglyol added to isolated CBD and sweetener. Powder Premix Content uniformity Sample no. Example (RSD) 210 Example 2 1.1% 211 Example 2 1.1% 212 Example 2 1.1% 213 Example 2 1.0% 214 Example 2 1.0% -
TABLE 35 Content uniformity of powder premixtures with Miglyol- Miglyol added to isolated CBD and sweetener. Powder Premix Content uniformity Sample no. Example (RSD) 220 Example 2 1.1% 221 Example 2 1.2% 222 Example 2 1.1% 223 Example 2 1.0% -
TABLE 35 Content uniformity of powder premixtures with Miglyol- Miglyol added to isolated CBD and sweetener. Powder Premix Content uniformity Sample no Example (RSD) 230 Example 2 1.2% 231 Example 2 1.1% 232 Example 2 1.1% 233 Example 2 1.2% 234 Example 2 1.1% -
TABLE 36 Content uniformity of powder premixtures with Hydrogenated Vegetable Oil (HVO)-HVO added to isolated CBD in high load and sweetener. Powder Premix Content uniformity Sample no. Example (RSD) 300 Example 3 2.2% 301 Example 3 2.6% 302 Example 3 2.8% 303 Example 3 3.0% 304 Example 3 3.3% -
TABLE 37 Content uniformity of powder premixtures with Hydrogenated Vegetable Oil (HVO) - HVO added to isolated CBD in high load and sweetener. Powder Premix Content uniformity Sample no. Example (RSD) 310 Example 3 2.9% 311 Example 3 2.9% 312 Example 3 2.8% 313 Example 3 2.6% 314 Example 3 2.6% -
TABLE 38 Content uniformity of powder premixtures with Hydrogenated Vegetable Oil (HVO) - HVO added to isolated CBD in high load and sweetener. Powder Premix Content uniformity Sample no. Example (RSD) 320 Example 3 2.8% 321 Example 3 2.7% 322 Example 3 2.8% 323 Example 3 2.6% 324 Example 3 2.9% -
TABLE 39 Content uniformity of powder premixtures with Hydrogenated Vegetable Oil (HVO) - CBD/HVO mixture added to sweetener. Powder Premix Content uniformity Sample no. Example (RSD) 400 Example 4 2.6% 401 Example 4 2.7% 402 Example 4 2.7% 403 Example 4 2.8% 404 Example 4 2.8% -
TABLE 40 Content uniformity of powder premixtures with Hydrogenated Vegetable Oil (HVO) - CBD/HVO mixture added to sweetener. Powder Premix Content uniformity Sample no. Example (RSD) 410 Example 4 2.7% 411 Example 4 2.8% 412 Example 4 2.7% 413 Example 4 2.5% 414 Example 4 2.6% -
TABLE 41 Content uniformity of powder premixtures with Hydrogenated Vegetable Oil (HVO) - CBD/HVO mixture added to sweetener. Powder Premix Content uniformity Sample no. Example (RSD) 420 Example 4 2.6% 421 Example 4 2.8% 422 Example 4 2.7% 423 Example 4 2.5% 424 Example 4 2.7% -
TABLE 42 Content uniformity of powder premixtures with Miglyol - CBD/Miglyol mixture added to sweetener. Powder Premix Content uniformity Sample no. Example (RSD) 500 Example 5 2.5% 501 Example 5 2.6% 502 Example 5 2.6% 503 Example 5 2.7% 504 Example 5 2.9% -
TABLE 43 Content uniformity of powder premixtures with Miglyol - CBD/Miglyol mixture added to sweetener. Powder Premix Content uniformity Sample no. Example (RSD) 510 Example 5 2.7% 511 Example 5 2.8% 512 Example 5 2.6% 513 Example 5 2.6% 514 Example 5 2.6% -
TABLE 44 Content uniformity of powder premixtures with Miglyol - CBD/Miglyol mixture added to sweetener. Powder Premix Content uniformity Sample no. Example (RSD) 520 Example 5 2.7% 521 Example 5 2.7% 522 Example 5 2.6% 523 Example 5 2.5% 524 Example 5 2.6% -
TABLE 45 Content uniformity of comparative samples - without triglycerides lipids. Powder Premix Content uniformity Sample no. Example (RSD) 600 Example 6 4.2% 601 Example 6 4.2% 602 Example 6 4.3% 603 Example 6 4.3% 604 Example 6 4.5% -
TABLE 46 Content uniformity of powder premixtures with Miglyol (not preheated) - mixture added to sweetener. Powder Premix Content uniformity Sample no. Example (RSD) 610 Example 6 4.1% 611 Example 6 4.0% 612 Example 6 4.0% 613 Example 6 3.9% 614 Example 6 3.9% -
TABLE 47 Content uniformity of powder premixtures with Miglyol (not preheated) - mixture added to sweetener. Powder Premix Content uniformity Sample no. Example (RSD) 620 Example 6 4.2% 621 Example 6 4.1% 622 Example 6 4.3% 623 Example 6 4.4% 624 Example 6 4.4% - The procedures of Example 11A was used for powder blends (Powder Blends) which are powder premixes (Powder Premix Samples) with additional ingredients as outlined in the formulations of the oral dosage forms. These powder blends were formed into the solid dosage forms. The procedure of Example 11B was used for the solid dosage forms. The results are shown in the tables below.
- The result of content uniformity (CU) for a sample is provided as a single value obtained as the relative standard deviation (RSD) of CBD content of multiple samples taken at the end of the preparation procedures. If individual samples have been collected at different stages of a tableting process (eg. start, middle, end) then content uniformity is determined by analysis of pooled samples from the different process stages.
-
TABLE 48 Based on the procedure in Example 11B Solid dosage Powder Premix Solid dosage Powder Blend form CU Sample No form CU (RSD) (RSD) 102 Example 7 2.3% 1.5% (Table 20) 202 Example 7 2.1% 1.6% (Table 21) -
TABLE 49 Based on the procedure in Example 11B Solid dosage Powder Premix Solid dosage Powder Blend form CU Sample No form CU (RSD) (RSD) 312 Example 8 1.7% 1.4% (Table 23) 322 Example 8 1.6% 1.0% (Table 24) -
TABLE 50 Based on the procedure in Example 11B Solid dosage Powder Premix Solid dosage Powder Blend form CU Sample No form CU (RSD) (RSD) 422 Example 9 2.8% 1.0% (Table 25) 502 Example 9 3.0% 1.2% (Table 26) -
TABLE 51 Based on the procedure in Example 11B Solid dosage Powder Premix Solid dosage Powder Blend form CU Sample No form CU (RSD) (RSD) 602 Example 10 4.8% 6.4% (Table 27) 610 Example 10 5.7% 6.1% (Table 28) 622 Example 10 7.7% 6.5% (Table 29) - The procedures of Example 11A was also made on further powder premixtures and powder blends used in different application forms. For instance, the powder provided in the examples above was applied in pouches, sachets, and flowpacks where similar good results for content uniformity were seen.
- The procedures of Example 11B was also made on further solid dosage forms. Similar good results were seen for tablets without gum base, FDT tablets, chewing gums, and lozenges.
Claims (25)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/857,937 US20240008514A1 (en) | 2022-07-05 | 2022-07-05 | Cannabinoid Lipid Premixture |
PCT/DK2023/050179 WO2024008261A1 (en) | 2022-07-05 | 2023-07-05 | Cannabinoid lipid premixture |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/857,937 US20240008514A1 (en) | 2022-07-05 | 2022-07-05 | Cannabinoid Lipid Premixture |
Publications (1)
Publication Number | Publication Date |
---|---|
US20240008514A1 true US20240008514A1 (en) | 2024-01-11 |
Family
ID=89432294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/857,937 Pending US20240008514A1 (en) | 2022-07-05 | 2022-07-05 | Cannabinoid Lipid Premixture |
Country Status (1)
Country | Link |
---|---|
US (1) | US20240008514A1 (en) |
-
2022
- 2022-07-05 US US17/857,937 patent/US20240008514A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11903919B2 (en) | Oral cannabinoid tablet | |
CA3040513C (en) | An oral cannabinoid tablet | |
EP3920890B1 (en) | An oral cannabinoid tablet | |
US20240065973A1 (en) | Tableted Cannabinoid Chewing Gum With Tableted Modules | |
US10933017B2 (en) | Tableted cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers | |
US11471405B2 (en) | Tableted chewing gum with enhanced delivery of cannabinoids | |
US20230218512A1 (en) | Fast Disintegrating Cannabinoid Tablets | |
AU2020258631B2 (en) | Fast disintegrating cannabinoid tablets | |
US11241413B2 (en) | Cannabinoid lozenge formulation | |
US11253473B2 (en) | Method of producing tableted cannabinoid chewing gum | |
CA3065042A1 (en) | Fast disintegrating cannabinoid tablets | |
US20240008514A1 (en) | Cannabinoid Lipid Premixture | |
CN113423279A (en) | Tabletted cannabinoid chewing gum with layered structure | |
CA3166745A1 (en) | Cannabinoid lipid premixture | |
CA3035390C (en) | Tableted chewing gum with enhanced delivery of cannabinoids | |
US20200276118A1 (en) | Tableted cannabinoid chewing gum with improved release | |
WO2024008261A1 (en) | Cannabinoid lipid premixture | |
EP3930696A1 (en) | Tableted chewing gum with enhanced delivery of cannabinoids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NORDICCAN A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FERTIN PHARMA A/S;REEL/FRAME:061359/0155 Effective date: 20220823 Owner name: FERTIN PHARMA A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOESEN, DORTHE SCHACKINGER;LAURSEN, SIMON LYKKE ROEST;JENSEN, SANNE SKOV;REEL/FRAME:061358/0892 Effective date: 20220818 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: FERTIN PHARMA A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NORDICCAN A/S;REEL/FRAME:065224/0214 Effective date: 20231009 |